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Abstract 
 The unique structure, outstanding reactivity and essential biochemical functions of 
vitamin B12 have spanned a century of groundbreaking chemical, biological and medical 
research. The central cobalt ion of B12 is the most reactive site of the nutrient. Thus, the 
aim of this thesis is the replacement of cobalt by other metals, leading to a new class of 
B12-related derivatives: metbalamins. These metal-modified B12 derivatives keep the 
cobalamin framework intact but are expected to have altered physicochemical and 
catalytic properties. Therefore metbalamins are promising antivitamin B12 candidates 
for the development of antiproliferative or antimicrobial agents. 
 
Although metbalamins can be obtained by complex 
biosynthetic procedures, their total and partial 
synthesis has not been reported yet. Indeed, all 
attemps to demetallate the intact corrin macrocycle 
led to destruction of the B12 scaffold. Hence, efforts 
during this work focused on the demetallation and 
corrin reconstitution of ring-opened secocorrinoids, 
leading to novel metbalamin derivatives.  
 
Demetallation and corrin reconstitution experiments 
were applied on two classes of compounds: 5,6- and 
7,8-seco-corrinoids. First, the opened B-ring of 7,8-
seco-corrinoids was reconstituted in a rapid, stereospecific and quantitative reaction. 
This reaction was triggered by cobaltocene (CoCp2), introduced as a new one-electron 
reducing agent for the formation of C-C bonds (C7-C8). Due to the presence of a redox 
sensitive Co
III
 ion, cyanide was used as a metal-ion protecting group to achieve      
ligand-centered chemoselectivity. Subsequently, B12 was reconstituted in three steps, 
completing the first reversible route for the synthesis of ring-opened “complete” 
secocorrins. The structure of the reconstituted vitamin was determined by X-ray 
crystallography and the biological function of reconstituted B12 and other route 
intermediates was evaluated with microbiologically using L. Leichmannii. Importantly 
one of the new B12 derivatives showed promising antivitamin B12 activity. 
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The second route focused on the demetallation and ring reconstitution of 5,6-seco-
corrinoids. Herein, a straightforward method to simultaneously reconnect the opened 
macrocycle and remove the cobalt from the corrin cavity is presented. In this reaction 
and in contrast to the former strategy, CoCp2 was used as both metal and ligand 
reducing agent. Thus, Co
III 
was reduced to Co
II
 and a C-C bond between a ketone (C5) 
and a lactam (C6) was formed. Subsequently, cyanide was employed as decomplexating 
agent for the extraction of the labile Co
II
 ion from the corrin cavity, obtaining a metal-
free ring-closed B12 derivative. Metal ions like Ni
II
 were inserted in the corrin 
macrocycle, accessing a new family of B12 derivatives: 5,6-diolmetbalamins. These 
unprecedented metal-modified B12 derivatives were fully characterized by UV-Vis, HR-
MS and extensive 1D and 2D NMR studies. 
 
 
 
In summary, this thesis presents a chemical route for the synthesis of metal-modified 
B12 derivatives from secocorrins. The demetallation of 5,6-seco-corrinoids was achieved 
by reducing the inert Co
III
 to a more labile Co
II
 center with CoCp2 and using cyanide as 
decomplexating agent Importantly, CoCp2 was employed as a new versatile one-
electron reducing agent for the formation of C-C bonds in the reconstitution of ring-
opened 5,6- and 7,8-seco-corrinoids.  
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Zusammenfassung 
 
Die einzigartige Struktur, Reaktivität und biochemische Funktion von Vitamin B12 
inspiriert Naturwissenschaftler seit über einem Jahrhundert zu bahnbrechender 
chemischer, biologischer und medizinischer Forschung. Die Reaktivität von B12 hängt 
entscheidend vom zentral komplexierten Kobaltion ab. Daraus ergibt sich die 
Zielsetzung dieser Doktorarbeit: der Austausch besagten Kobalts durch ein anderes 
Metall, was zu einer neuen Klasse von B12-Derivaten führt: Metbalaminen. Von diesen 
wird erwartet, dass sie trotz intaktem molekularen Gerüst veränderte physicochemische 
und katalytische Eigenschaften besitzen. Aus diesem Grund sind Metbalamine 
vielversprechende Kandidaten sogenannter Antivitamin B12 Verbindungen für die 
Entwicklung antiproliferativer oder antimikrobialer Reagenzien.  
 
Metbalamine können auf äusserst komplexem 
biosynthetischem Wege hergestellt werden. Ihre 
chemische Synthese jedoch stellt ein über 
Jahrzehnte verfolgtes, aber bislang unerreichtes 
Ziel dar. Sämtliche Versuche, den intakten 
Corrinring zu demetallieren, führten bislang zur 
Degradierung der molekularen Struktur. 
Folglich fokussiert sich die vorliegende Arbeit 
auf die Demetallierung und Rekonstituierung 
von Corrin-geöffneten Secocorrinoiden, mit 
dem Ziel der Herstellung neuartiger 
Metbalaminderivative. 
 
Demetallierungs- und Rekonstituierungsexperimente wurden auf zwei Klassen von B12-
Ausgangsverbindungen angewandt: 5,6- und 7,8-seco-Corrinoiden. Zunächst wurde das 
B-Ring-geöffnete 7,8-seco-Corrinoid mittels einer schnellen, stereospezifischen und 
quantitativen Reaktion rekonstituiert. Diese Reaktion wurde durch Cobaltocen (CoCp2) 
initiiert, welches als ein-Elektron-Reduktionsmittel zur C7-C8-Bindungsbildung agierte. 
Um die ligand-zentrierte Chemoselektivität in Gegenwart des redox-sensitiven         
Co
III
-Ions zu gewährleisten, wurde Cyanid als Schutzgruppe eingesetzt. Anschliessend 
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wurde B12 in drei Stufen rekonstituiert, was die erste reversible Methode zur Synthese  
von Ring-geöffneten «vollständigen» Secocorrinoiden darstellt. Die Struktur des 
rekonstituierten B12 wurde durch Röntgenstrukturanalyse nachgewiesen. Die 
biologische Funktion sowohl des rekonstituierten B12 wie auch dessen 
Zwischenprodukte wurde in mikrobiologischen Tests mit L. Leichmannii getestet. 
Hierbei offenbarte ein neues B12 Derivat vielvesprechende Antivitamin-Aktivität.  
 
 
 
Die zweite Syntheseroute konzentrierte sich auf die Demetallierung und Rekonstitution 
von 5,6-seco-Corrinoiden. Von besonderem Interesse ist hierbei die entwickelte 
Methode, sowohl den bislang unerreichten Ringschluss des geöffneten Makrozyklus, als 
auch die Entfernung des Kobaltions simultan durchzuführen. Im Gegensatz zur früheren 
Strategie, wurde Cobaltocen als Metall- und Ligandenreduktionsmittel eingesetzt, was 
sowohl zur Reduktion von Co
III
 zu Co
II
, als auch zur C-C-Bindungsbildung zwischen 
dem Keton-C5 und dem Lactam-C6 führte. Anschliessende Dekomplexierung des nun 
labilen Co
II
 und Remetallierung durch Metallionen wie Ni
II
 führte zu einer 
präzedenzlosen Klasse von B12-Derivaten: 5,6-Diolmetbalaminen. Letztere wurden 
mittels UV-Vis, HR-MS, sowie ausführlichen 1D- und 2D NMR Untersuchungen 
umfänglich charakterisiert. 
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Die vorliegende Arbeit präsentiert eine chemische Methode zur Synthese einer neuen 
Klasse von Metall-modifizierten B12-Derivaten aus Secocorrinoiden. Die 
Demetallierung von 5,6-seco-Corrinoiden wurde durch die Reduktion von inertem Co
III
 
zu labilerem Co
II
 mittels Cobaltocen und anschliessender Dekomplexierung durch 
Cyanid erreicht. Die vielfältige Anwendbarkeit von Cobaltocen als Reduktionsmittel 
wurde des weiteren in der C-C-Bindungsbildung in der Rekonstitution sowohl von 5,6- 
als auch 7,8-seco-Corrinoiden nachgewiesen.  
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d  doublet 
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dTMP  deoxythymidine monophosphate  
EDC
.
HCl N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
equiv  equivalent 
ESI-MS electron spray ionization mass spectrometry 
HR-ESI-MS high resolution electron spray ionization mass spectrometry 
FH4  tetrahydrofolate 
HCl  hydrochloric acid 
HC  haptocorrin 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HPLC  high performance liquid chromatography  
HSQC  heteronuclear single-quantum correlation spectroscopy  
IF  intrinsic factor 
IR   infrared spectroscopy 
H2SO4  sulfuric acid 
m  multiplet 
MCM  methyl malonyl coenzyme A mutase  
MB  methylene blue 
MeOH  methanol 
MetH  methionine synthase  
MS  mass spectrometry  
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NMR  nuclear magnetic resonance 
Py  Pyridine   
RNR  ribonucleotide reductase 
ROESY rotating frame overhauser effect spectroscopy 
s  singlet 
SAM  S-adenosylmethionine 
t   triplet  
tR  retention time  
TC  transcobalamin 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TEMPO 2,2,6,6-tetramethylpiperidinoyloxyl 
TLC   thin layer chromatography 
TRIS  tris(hydroxymethyl)aminomethane  
UPLC  ultra performance liquid chromatography 
UV-Vis ultraviolet-visible spectroscopy   
W  watt 
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1. Introduction  
 
1.1. A century of vitamin B12: a revolutionary molecule    
In a world adapting to a new post Great War era, the Professor of Sanitary Engineering 
George C. Whipple was not aware that the experiments he was carrying out were laying 
the foundation for the discovery of one of the most complex and intriguing molecules in 
Nature.
1-3
 His pioneering studies on the therapeutic effects of a liver diet on anemic 
dogs marked the start of a century of intensive research around the active component 
present in liver that could heal anemia. Indeed, during the Roaring Twenties pernicious 
anemia was still a fatal disease and the urge to find an effective treatment against it led 
George R. Minot and William P. Murphy to apply Whipple’s advances on human 
patients. They demonstrated that the daily ingestion of large amounts of cooked calf or 
beef liver (between 120 and 240 g) guaranteed a prompt and long-lasting remission of 
their patients’ anemia.4,5 Thanks to “their discoveries concerning liver therapy in cases 
of anemia”; Whipple, Minot and Murphy were awarded the Nobel Prize in Physiology 
and Medicine in 1934. 
Despite the successful clinical use of liver for treating pernicious anemia, the active 
substance responsible for the therapeutic effect remained a mystery for decades after 
Whipple’s first efforts. It was not until 1948 that Folkers at Merck and Smith at Glaxo 
simultaneously isolated red crystalline needles of the anti-pernicious anemia factor, 
which they called vitamin B12.
6-10
 Attracted by the extraordinary properties of this 
substance, numerous chemists and crystallographers started working on the structural 
elucidation of vitamin B12. Soon the community realized about the structural complexity 
of this molecule and only after years of work, Dorothy C. Hodgkin solved the structure 
of vitamin B12 in 1956.
11
 Her “determinations by X-ray techniques of the structures of 
important biochemical substances” were worth the Noble Prize in Chemistry in 1964. 
The unprecedented structure of vitamin B12 earned the attention of brilliant chemists. 
Establishing a bold collaboration during the 1960s, Albert Eschenmoser and Robert B. 
Woodward accomplished the total synthesis of vitamin B12 in almost 11 years of work 
and employing more than 100 coworkers on the project.
12-14
  The ambitious enterprise 
remains as one of the classics of total synthesis and in 1965; Woodward was also 
awarded the Nobel Prize in Chemistry “for his outstanding achievements in the art of 
organic synthesis”.  
12 
 
Being a millestone in organic chemistry, the total synthesis of vitamin B12 involves 
more than 70 synthetic steps and is therefore not a realistic method for the high scale 
production of the nutrient. In this regard, microbiologists played a crucial role 
establishing methods for the industrial production of vitamin B12 from bacterial 
fermentation.
15,16
 Early microbiological studies discovered that vitamin B12 belongs to a 
family of structurally related naturally-occuring compounds called corrinoids.
17
  
Importantly, in 1958 Barker and coworkers isolated a corrinoid containing an 
organometallic Co-C bond with coenzyme activity in the bacterium Clostridium 
tetanomorphum.
18
  
Having found the first organometallic coenzyme, enzymologists joined the vitamin B12 
fever. Soon it was realized that the biological role of vitamin B12 as an enzymatic 
cofactor was widespread and present in almost all forms of life.
19-21
 Additionally, the 
reactivity of coenzyme B12 is dominated by its structure as a coordination compound 
and involves elegant ligand exchange reactions with varying mechanisms in the 
different enzymes where vitamin B12 is involved.
22
 In this context, vitamin B12 became 
a pivotal point for the development of bioinorganic chemistry since the second half of 
the 20
th
 century.
23,24
   
Almost 100 years after Whipple’s experiments, the chemistry and biochemistry of 
vitamin B12 are well explored.
22-26
 However, recent fundamental discoveries on the 
enzymatic activity of B12 together with the potential medicinal, sensing and catalytic 
B12-based applications keep the thrill around this natural product.
27-32
 Its beautiful 
complexity and unique properties guarantee that vitamin B12 will hold a special place in 
scientific research also in the 21
st
 century.  
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1.2. Structure and electronic properties   
B12 turned to be a substance of frightening complexity (Lord Todd). 
 
Vitamin B12, B12 or Cbl (Figure 1) possesses one of the most sophisticated structures of 
all monomeric natural products.
11
 The core of this octahedral complex is occupied by a 
Co
III
 ion, coordinated by four nitrogen atoms in all the equatorial positions that belong 
to a tetrapyrrolic macrocycle called corrin. This unique macrocycle belongs to the 
family of porphyrinoids and has two important particularites: a) the pyrrol subunits A 
and D are directly connected over a C-C bond and b) corrinoids have a chromophore 
with 14 delocalized π-electrons over 13 carbon atoms.33 The corrin macrocycle is 
completed with eight peripheral methyl groups (two at the meso positions C5 and C15 
and six connected to the pyrrol rings) and seven amide side chains. One of this amide 
side chains contains a propan-2-ol, a phosphate, a ribose and a dimethylbenzimidazole 
base (Dmbz). These three subunits form the so-called “loop”, a molecular switch that 
can reversibly coordinate the Co
III
 ion through its lower  axial position.34 Thus, two 
possible configurations (base-on/base-off) are established, a fundamental equilibrium 
for the transport, cellular uptake and reactivity of the vitamin within enzymes.
35
 On the 
upper  axial position, several ligands can coordinate the metal center depending on the 
biological role of vitamin B12.
23
   
 
 
Figure 1. Structure of vitamin B12.  
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Natural porphyrinoids have been named “pigments of life” due to their intense 
coloration.
36
 Vitamin B12 is indeed an intensely red crystalline compound mostly due to 
the presence of 14 π-delocalized electrons in the corrin macrocycle. In fact, the π-π* 
corrin electronic transitions dominate the absorption spectra of Cbls. In general, three 
main distinctive bands are found: the  and  bands (between 600 and 450 nm) and the 
 band (350-370 nm) (Figure 2).22 Additionally, the aromatic system of the Dmbz ligand 
gives raise to absorption bands between 275-290 nm. The energy and intensity of all π-
π* bands (, Dmbz) are influenced by the CoIII center and the presence of different 
base-on/base-off configuration) and  axial ligands (e.g. 1, 1-OH2, 1-CH3, 1-Ado).
37
 
Therefore, UV-Vis spectroscopy is a valuable source of information regarding structural 
features of vitamin B12 derivatives such as the π–system and the axially coordinating 
ligands.  
200 300 400 500 600 700
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Figure 2. UV-Vis spectrum of cyanocobalamin (1). 
 
B12 is the only vitamin containing a metal center and its presence is not arbitrary. Indeed 
the redox reactivity of this coordination compound within biological systems is 
normally metal-centered.
22
 Cobalt can undergo oxidation and reduction reactions that 
influence the geometry of the whole complex (Scheme 1).
23,38
 Thus, when the 
octahedral d
6
 Co
III
 from B12 is reduced; d
7
 Co
II 
square-pyramidal or d
8 
Co
I
 square-planar 
complexes are formed.    
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Scheme 1. Redox chemistry, electronic configurations and coordination geometries of 
Cbls. Charges are omitted for clarity.  
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1.3. Transport  
The presence of B12 cofactors is essential for the metabolism of microorganisms and 
animals.
22
 However, Cbls can only be synthesized by certain bacteria and therefore, 
animals need to take up this nutrient from their diet and subsequently transport it to their 
cells.
39,40
 In humans, the recommended daily intake of vitamin B12 is 2-3 g.
41
  These 
minute amounts of B12 are delivered to our cells using a complex uptake pathway that 
involves transporting proteins with excellent selectivity, affinity and binding properties 
towards B12 in its base-on configuration (Kon = 10
7
-10
8
 M
-1
s
-1
, Kd = 10
-15
 M) (Figure 
3).
35,41
 These proteins are haptocorrin (HC, saliva and gastric fluids), intrinsic factor (IF, 
gastric fluid) and transcobalamin (TC, vascular endothelium).
35,40,42
 Once cobalamin is 
released in human cells, the nutrient is metabolized to one of the two biologically active 
forms of B12: adenosylcobalamin (1-Ado) or methylcobalamin (1-CH3). The formation 
of the two organometallic cofactors is completed by the enzyme CblC, which catalyzes 
the dissociation of the single bond between cobalt and the corresponding upper axial 
ligand i.e. cyanide.
43
 A homolytic cleavage of the  axial ligand to form cob(II)alamin 
followed by alkylation with adenosyltriphosphate (ATP) achieves the synthesis of        
1-Ado. Conversely, a cob(I)alamin is required for the formation of 1-CH3. Indeed, the 
Co
I
 supernucleophile can bind a methyl group from S-adenosylmethionine (SAM).
44
 
Both 1-Ado and 1-CH3 fulfill different roles within human metabolism and unravel 
different types of reactivity that demonstrate the versatility of Cbls within enzymes.  
 
 
 
Figure 3. Human uptake pathway of vitamin B12.
35,39-41
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1.4. Enzymology  
Cbls participate in many metabolic reactions amongst different forms of life. The main 
classes of enzymes that profit from corrinoid cofactors are dehalogenases, methyl 
transferases, dehydratases, mutases, a deaminase and a ribonucleotide reductase.
35
 
Within these enzymes, different biologically active corrinoids are used, mostly 
methylcobalamin (1-CH3) or adenosylcobalamin (1-Ado).
45,46
 The chemistry of B12 
within enzymes is so diverse that this molecule has been called “nature’s most beautiful 
cofactor”.47 Indeed, a single molecule can act as a nucleophile, electrophile or 
participate in radical reactions due to the powerful redox chemistry at the cobalt center 
that normally involves the exchange of the axial ligand.22,48  In these enzymatic 
processes, the lower  axial position anchors the coenzyme to the corresponding 
enzymatic binding pocket. Thus, once base-on cobalamins have been transported into 
cells, they can adopt two different configurations within enzymes: either they stay in a 
base-on form or they switch to a base-off / histidine-on configuration (Figure 4). In the 
latter, the cobalt center is coordinated to a histidine residue of the corresponding 
enzyme.
46
  
 
 
Figure 4.  Configurations of vitamin B12 within enzymes.
46
  
 
Two B12-dependent enzymes are necessary for human metabolism: methylmalonyl 
coenzyme A mutase (MCM) and methionine synthase (MetH). In both enzymes, 
cobalamins adopt a base-off / histidine-on configuration.
45,46
 However, the chemistry of 
both B12 cofactors largely differs.  
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1.4.1.  Methyl malonyl coenzyme A mutase (MCM) 
 
The main goal of this enzyme located in human mitochondria is to metabolize methyl 
malonyl coenzyme A into citric acid cycle intermediates. In this catalytic process, 
adenosylcobalamin (1-Ado) acts as a cofactor in the reversible transformation of (2R)-
methylmalonyl-CoA to succinyl-CoA.
22
  The interconversion follows a radical 
mechanism involving 1-Ado.
45
 First, the organometallic bond of coenzyme B12 is 
homolitically cleaved, leading to a pentacoordinate Co
II
-containing Cbl and a 5’-
deoxyadenosyl radical (Scheme 2, A). Subsequently, this radical abstracts one H from 
(2R)-methylmalonyl-CoA (Scheme 2, B, left), leading to 5’-deoxyadenosyl and a 
radical species that undergoes an intramolecular 1,2-rearrangement. Upon regeneration 
of the 5’-deoxyadenosyl radical, succinyl-CoA is formed (Scheme 2, B, right).   
 
 
 
Scheme 2. 1-Ado mediated isomerization of (2R)-methylmalonyl-CoA to succinyl-CoA 
within MCM.  
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1.4.2.  Methionine synthase (MetH) 
 
This enzyme is a cytosolic methyl transferase that catalyses the conversion of 
homocysteine into methionine using methylcobalamin (1-CH3) as cofactor (Scheme 
3).
22,46
 To achieve the synthesis of methionine, the peripheral thiolate of homocysteine 
attacks the  axial methyl ligand of 1-CH3 following an SN2 mechanism. This reaction 
leads to methionine and a square planar cob(I)alamin, the latter being a 
supernucleophile that, in a subsequent reaction, withdraws a methyl group from 
methyltetrahydrofolate (CH3-H4-FH4) to regenerate the Cbl cofactor.  
 
 
 
Scheme 3. 1-CH3 mediated enzymatic methylation of homocysteine to methionine 
within MetH.  
 
This single catalytic reaction is the link between several metabolic processes, since four 
essential biomolecules (vitamin B12, homocysteine, methionine and folate) are involved 
in the enzyme. The interruption of this reaction originates a metabolic blockage with 
serious implications for human health (methylfolate trap).
49,50
 The two most common 
causes for such a blockage are a) mutations affecting methionine synthase enzymatic 
activity, b) vitamin B12 deficiency.
51
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1.5. Clinical significance 
As mentioned in section 1.1., vitamin B12 turned out to be an essential nutrient to avoid 
pernicious anemia. Knowing that this natural product was involved in the production of 
red-blood cells, it was not until its enzymatic roles were discovered and several clinical 
studies were performed that the importance of vitamin B12 was fully understood. 
Indeed, vitamin B12 deficiency leads to deteriorated neurophyschiatric and 
hematological conditions.
52-54
 
The metabolic reactions where vitamin B12 is involved show the importance of this 
cofactor.
22,25
 Taking methionine synthase as an example (see section 1.4.2., Scheme 3), 
the regeneration of methylcobalamin within this enzyme involves the synthesis of 
tetrahydrofolate, a necessary precursor for the synthesis of dTMP. Thus, vitamin B12 is 
indirectly involved in the synthesis of DNA nucleobases and is therefore essential for 
cell replication.
55
 While the correlation of vitamin B12 with cell growth demonstrates 
why the deficiency of this nutrient causes serious medical conditions, this close 
relationship also explains why fast-proliferating cells (like those in tumors or sites of 
bacterial proliferation) increase their B12 consumption to fuel their uncommon 
growth.
39,56
 This fact reveals a dangerous downside to this nutrient: while essential for 
healthy individuals, under certain clinical conditions B12 can turn into a threat. 
 
 
1.6.  Medicinal applications  
The extraordinary chemistry and enzymology of vitamin B12 has attracted the attention 
of scientists over decades. Research in this field includes not only the characterization 
of the natural product and its biochemical functions, but also the potential use of 
(modified) Cbls as diagnostic or therapeutic agents.
28,29,49,57,58
 In this regard, the unique 
chemistry of vitamin B12 offers attractive possibilities to develop new versatile drugs 
with novel modes of action.  
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1.6.1. Trojan horse/ biovector  
 
A widely explored approach includes the use of vitamin B12 as a biovector to transport a 
given drug specifically to its target.
29,56,59
 The introduction of a bulky foreign group in 
vitamin B12 needs to be carefully adressed, since its uptake pathway is specifically 
designed for the unique structure of this nutrient. Indeed, B12 transporting proteins 
tightly enclose the vitamin, leaving only two positions of the cobalamin scaffold 
unprotected: the upper axial ligand and the 5’-OH group of the ribose moiety at the 
“loop”.40,60,61 As a consequence, multiple organic and inorganic drugs, 
radiopharmaceuticals and diagnostic agents or fluorescence markers have been 
conjugated to these two sites (Figure 5).
61-66
  
 
 
 
Figure 5. Examples of vitamin B12-drug conjugates. 
61-66
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1.6.2.  Antivitamins  
  
Although vitamins are essential nutrients, their effects can be harmful under certain 
clinical conditions. In those cases, the use of antivitamins as “molecules that diminish or 
abolish the action of a vitamin” is desirable.67 Two main approaches for the inhibition 
of vitamin effects can be envisaged: 1) transform the nutrient into a structurally inactive 
species; 2) inhibit its biosynthesis, transport or enzymatic activity.
28
  
As explained in section 1.5., vitamin B12 supports the growth of fast-proliferating tumor 
cells or bacterial infections.
39
 In those cases, a temporary inhibition of B12 enzymatic 
processes would have beneficial antiproliferative effects. A promising approach for the 
impairment of B12-dependent catalytic processes is the synthesis of non-functional 
surrogates of vitamin B12 with higher affinity for those enzymes than the natural 
product. These molecules could be antivitamins B12 and their rational design should take 
into consideration that:  
a) The structure of the antivitamin should resemble that of vitamin B12 as much as 
possible. The antivitamin should compete with B12 for the binding sites of the 
involved transporting proteins and enzymes. Since these biomolecules are 
optimized for hosting the very specific structure of B12, designing an antivitamin 
with a higher affinity for B12 dependent proteins and enzymes is often a big 
problem.  
b) The reactivity within B12 dependent enzymes should be inhibited or modified in 
a way that the targeted enzymatic process is inhibited.   
 
Research in this area has been intense since the 1960s and multiple candidates have 
been synthesized.
28,49,57
 The potential antivitamins B12 include 1) corrin-modified, 2) 
“loop”-modified, 3)  axial ligand-modified and 4) metal-modified B12 derivatives 
(Figure 6). In the studies performed during 1960s-1970s, the antivitamin candidates 
were often evaluated using microbiological assays with Lactibacillus leichmannii, 
Ochromonas malhamensis and Escherichia coli.
49
 Back then, a common indicator for 
the assessment and comparison of the antivitamin activity of different candidates is the 
inhibition index (I.I), defined as required ratio of inhibitor to vitamin needed to reduce 
bacterial growth by 50%. Nowadays, IC50 or specific in vivo studies are often 
employed.
68-70
  According to all these indexes, subtle modifications of the basic Cbl 
framework are tolerated by B12 transporting proteins and/or dependent enzymes. Thus, 
23 
 
the presence of bromide as an electron-withdrawing group at C10 (I.I = 9; Figure 6, top 
left)
49,71, an artificial peptide “loop” (IC50 = 2 M on L. leichmannii; Figure 6, top 
right)
68,72
,  a non-natural ethinyl axial ligand (14% inhibition of tumor growth in mice, 
Figure 6, bottom left)
73
 or a different metal center in the corrin cavity i.e. rhodium       
(I.I = 8, Figure 6, bottom right)
74
 achieve a remarkable competition with B12 cofactors 
and in turn inhibition of cell growth.   
 
 
 
Figure 6. Modified B12 derivatives with antivitamin activity.
49,68,71,73,74
  
 
Another interesting class of antivitamins B12 includes a series of yellow pigments called 
“stable yellow corrinoids”.75 Tested in patients suffering from anemia during the 1960s, 
one of these compounds (pigment I, isolated from Aerobacter aerogenes) showed only 
8% of activity compared to B12.
76
 While the bioactivity and spectroscopic properties of 
these compounds differs from those of vitamin B12 (one broad absorption band at         
450-480 nm instead of the common  and  bands), their exact structure remains a 
mistery.
23
 Nowadays, it is known that “stable yellow corrinoids” are obtained by 
chemical means when Co
II
-corrinoids are reoxidated to Co
III
-corrinoids. The altered 
electronic properties of these yellow corrinoids have their origin in the disruption of the 
24 
 
π-electronic system of the corrin macrocycle (the double bond at C5-C6 is a remarkably 
reactive position).
77-79
  
 
The development of new synthetic procedures for the selective modification of the Cbl 
scaffold will guarantee better access to promising known and new antivitamin B12 
candidates as potential therapeutic agents with new modes of action.  In spite of the 
difficulties lying ahead of us, the need for new drugs with novel modes of action has put 
antivitamins B12 back in the spotlight.
28,57
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1.7.  Metbalamins 
 
Metbalamins are vitamin B12 derivatives containing other metals than cobalt. 
Metbalamins with a modified metal center and an intact corrin ligand are excellent 
antivitamin B12 candidates (as already mentioned in section 1.6.2.)
49,74
, as their structure 
only differs in one single atom compared to Cbl. However, the metal center is the main 
actor in B12 dependent catalytic processes (see section 1.4.).
22
 Thus, the two main 
requisites for the design of an antivitamin are fulfilled: structurally related B12 
derivatives which are catalytically inactive.  
 
Ever since the interest in vitamin B12 chemistry exploded after Hodgkin’s structural 
determination of the molecule,
11
 the extraction and replacement of the metal center 
within this coordination complex has attracted the attention of numerous scientists.
28,57
 
While the idea is simple, the realization of it has been proven an extremely puzzling 
question. Unexpectedly, the synthesis of metbalamins ended up being one of the holy 
grails of bioinorganic chemistry.   
 
1.7.1. Biosynthetic approaches towards metbalamins 
Unidentified cobalt-free corrinoids were first isolated from photosynthetic bacteria in 
1966 by Perlman and Toohey.
80,81
 Following this finding, in 1971 Koppenhagen and 
Pfiffner discovered that the bacterium Chromatium was able to produce -5,6-
(dimethylbenzimidazoyl)hydrogenobamide in the presence of 5,6-
dimethylbenzimidazole.
82
 Thus, Cu
II
, Zn
II
 and Rh
III
 were incorporated to the complete 
corrin scaffold (Figure 7).
82,83
  Additionally, further studies by Koppenhagen on the 
coordination chemistry of the octahedral complex cyanorhodibalamin led to the 
exchange of the  axial ligand, thus affording analogues of organometallic B12 
coenzymes (5’-deoxyadenosylrhodibalamin and methylrhodibalamin).74 The         
metal-modified derivatives with an intact corrin macrocycle preserved the typical ,  
and bands of B12 UV-Vis spectra (i.e. 345, 477 and 503 nm for aquarhodibalamin and 
345, 485 and 514 nm for cyanorhodibalamin) and were tested as antivitamins in 
microbiological assays with L. leichmannii.  Satisfyingly, it was found that the 
descobaltocorrin -5,6-(dimethylbenzimidazoyl)hydrogenobamide and metbalamins 
(Cu, Zn, Rh-containing corrinoids) successfully antagonize vitamin B12 (Figure 7).
49
 
Furthermore, rhodibalamins with different axial ligands were tested on both                   
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L. leichmannii and E. coli, demonstrating that a) the nature of the axial ligands also 
affects their bioactivity and b) the antivitamin activity of a compound is specific for 
each organism.
74
 For example, methylrhodibalamin is the most effective antagonist 
against L. leichmannii (I.I = 8, figure 7) while 5’-deoxyadenosylrhodibalamin is more 
effective as E. Coli inhibitor (I.I = 52, figure 7). 
 
 
 
Figure 7. Antivitamin activity of metbalamins (left) and rhodibalamins with different 
axial ligands (right). 
 
In spite of the promising bioactivity of the studied metbalamins, research on this field 
vanished during the 1980s. Most probably, the loss of interest was related to the tedious 
and extremely low-yielding biosynthetic methods employed for the obtention of 
metbalamins. Only recently metbalamins earned renewed attention as an alternative 
biosynthesis of 5’-deoxyadenosylrhodibalamin was described (Scheme 4).84 The new 
route was established around the construction of plasmids containing cloned amplified 
genes from B12-producing bacteria (Rhodobacter capsulatus SB1003, Brucella 
melitensis 16M, Methanosarcine barkeri and Citrobacter freundii).  
 
 
 
Scheme 4. Biosynthetic production of 5’-deoxyadenosylrhodibalamin.84  
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1.7.2.  Synthetic approaches towards metbalamins 
“No synthetic corrin would as yet exist without recourse to metal templates… 
converting the organic chemists involved in this work to genuine admirers of the depth, 
potentials and wonders of transition metal chemistry.” (A. Eschenmoser)  
 
The demetallation of vitamin B12 by chemical means remains unsolved and represents 
the most fascinating mistery around B12 chemistry.
22
 Renowned chemists have tackled 
this question, yet no efficient method has managed to remove the stunningly stable Co
III 
center from the intact corrin macrocycle. However, some steps towards this ambitious 
goal have been achieved and will be summarized in this section.  
 
In the context of the total synthesis of vitamin B12,
12,14
 the use of metal templates played 
an essential role to arrange the proximity of reaction centers (steric strain), activate 
organic ligands electronically or protect organic sites against alkylation agents.
85
  
Importantly, two key coupling reactions that allowed the formation of the corrin 
macrocycle are completed in the presence of metals: 1) the connection of the pyrrolic 
A/B fragments through a methylene bridge by sulfide contraction utilizes a Zn
II
 center
86
 
and 2) the photochemical formation of a direct C-C bond between A/D fragments is 
completed in high yields (> 95%) when Pd
II
 coordinates the equatorial macrocycle 
(Scheme 5).
85,87
  
 
 
Scheme 5. Ring-closure reactions of artificial Zn
II
 and Pd
II
-containing corrins.
85-87
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Seminal work by Eschenmoser during the 1960s describes the coordination chemistry of 
model artificial corrinoids, showing that different metal centers can be incorporated to 
ring-opened secocorrins.
85
 For example, cyclization of a secocorrinoid containing an 
iminoester on the A-ring and an imine on the B-ring (Scheme 6, left) can only be 
achieved in the presence of a metal template (i.e. Co, Ni or Pd). In that case, a base 
(
t
BuO
-
) catalyzes the deprotonation of a peripheral methylene, rendering the double 
bond on C5-C6 more nucleophilic (Scheme 6, middle) and completing the corrin 
formation (Scheme 6, right).  
 
 
 
Scheme 6. Ni
II
-templated ring closure of an artificial secocorrinoid.
85
  
 
Interestingly, when the metal ions are surrounded by a complete ring-closed corrin 
(Scheme 6, right), demetallation proved to be an extremely challenging task, most likely 
due to the kinetic stabilization offered by the macrocyclic chelation.
85
 While chemical 
procedures to demetallate various porphyrinoid macrocycles are well-established, the 
application of those methods to (model) corrins has led mostly to the destruction of the 
corrin system. Only in 1983, Eschenmoser proposed the first chemical method to 
demetallate a cobalt-containing model corrin compound, based on the use of 1,3-
propanedithiol as a decomplexating agent in the presence of concentrated HCl (Scheme 
7).
88
 However, the model compound lacks all peripheral side chains from  B12. 
 
 
 
Scheme 7. Demetallation of an artificial cobalt-containing corrin.
88
  
29 
 
In the quest of more realistic B12 model compounds, Werthemann implemented the 
synthesis of dicyanocobyrinic acid heptamethylester, (‘cobester’) by acid-catalyzed 
methanolysis of the vitamin (Scheme 8).
89
 In this compound, all amide side chains of 
B12 are replaced by methyl ester groups, rendering the corrinoid hydrophobic and thus 
making it a versatile tool for synthetic investigations of vitamin B12.  
 
 
Scheme 8. ‘Cobester’ synthesis.89  
 
With this model compound of vitamin B12 in hand, its demetallation was attempted 
using Eschenmoser’s conditions (1,3-propanedithiol, HClconc). Unfortunately, cobalt 
could not be extracted from the corrin macrocycle. Curiously, the synthesis led only to 
the unexpected obtention of 5,15-bisnorcobester (Scheme 9, right).
90
 
 
 
 
Scheme 9. Synthesis of 5,15-bisnorcobester. 
90
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Assuming the improbable extraction of cobalt from “complete” ring-closed corrin 
systems, efforts diverted towards ring-opened secocorrinoids. Inhoffen and coworkers 
developed in 1979 a method to cleave the corrin macrocycle of 10-bromocobester 
(Scheme 10, top).
91
 Through ozonolysis, the double bond at positions C5 and C6 was 
replaced by keto and lactam moieties respectively. Later, the reaction conditions were 
optimized by Kräutler and Stepanek, who introduced a photochemical method for the 
synthesis of dioxo and tetraoxocorrinoids.
92,93
 In this method, light-induced singlet 
oxygen (
1
O2
*
) was used to cleave the corrin macrocycle of cobester (Scheme 10, 
bottom).
93,94
 
1
O2
* can attack the delocalized π-electronic system at positions C5-C6 
and/or C14-15 in a spin-allowed reaction, yielding two structural isomers: dicyano-
14,15-dioxocobester and dicyano-5,6-dioxocobester. 
 
 
 
Scheme 10. Synthesis of dioxocobester derivatives by ozonolysis
91
 (top) and 
photooxygenation
92
 (bottom). Only the 5,6-dioxocobester isomers are shown.  
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As it was the case with ring-opened corrin models lacking peripheral side chains 
(Scheme 6, left), the demetallation of ring-opened ‘cobester’ derivatives was feasable. 
Herein, dicyano-10-bromo-5,6-dioxocobester (Scheme 11, top) was demetallated using 
NaSH as decomplexating agent.
91
 Subsequently, different metals (Rh, Pd) were inserted 
in the oxidized metal-free macrocycle.
95
 Unfortunately, all attempts to reconstitute the 
corrin macrocycle with other metals than cobalt failed (Scheme 11, bottom).  
 
 
 
Scheme 11. Synthesis of the dioxopalladibester and dioxorhodibester. 
95
  
 
As it was the case with Eschenmoser’s artificial corrinoids (see Schemes 6 and 7), the 
demetallation and complete corrin reconstitution of ‘cobester’ derivatives was only 
achieved when this hydrophobic compound was lacking a peripheral side-chain. Under 
pyrolytic conditions, a double bond between positions C7-C8 of ‘cobester’ originates, 
eliminating the c-side chain and forming the so-called ‘pyrocobester’(Scheme 12, top 
middle).
96
 After photooxygenolysis, the cobalt center could be extracted from this 
product using P4S10 (Scheme 12, bottom right). Later Ni
II
 was inserted and Inhoffen and 
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coworkers stated that the oxidized nickel-containing corrin macrocycle could be 
reconstituted under McMurry conditions, affording ‘pyronibester’ (Scheme 12, bottom 
left).
97
  
 
 
 
Scheme 12. Synthesis of ‘pyronibester’ from ‘pyrocobester’.97  
 
Although hydrophobic models of corrins lacking the c-side chain and containing nickel 
instead of cobalt were synthesized in the 1980s, the obtention of metbalamins remains 
elusive. Striving to push forward this ambitious goal, the Zelder group started working 
on the complex topic of the chemical (semi)synthesis of metbalamins from vitamin B12.  
Thus, the first chemical demetallation of a complete corrinoid was reported in 2010.
94
 
Concretely, cobalt was removed from the oxidized dicyano-5,6,14,15-
tetraoxocobalamin using ethyleneglycol as decomplexating agent and thus obtaining 
two bicyclic fragments (A/D and B/C) as products of the reaction (Scheme 13).  
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Scheme 13. Synthesis of the bicyclic A/D and B/C corrin fragments from dicyano-
5,6,14,15-tetraoxocobalamin.
94
 
 
Subsequent problems in the reconnection of the two independent fragments led to a 
change in the strategy. During his PhD thesis, Dr. René Oetterli worked on the 
demetallation of dicyano-14,15-dioxocobalamin, establishing a new method to obtain 
metal-free B12 derivatives (Scheme 14): the electrochemical reduction of the kinetically 
inert Co
III 
center to a more labile Co
II
 ion was followed by demetallation of the reduced 
species using an excellent -donor as decomplexating agent (KCN).98  Thus, 14,15-
dioxo-H-balamin was obtained and served as template to coordinate different metal ions 
to the disrupted corrin macrocycle (Ni, Pd, Cu etc).  
34 
 
 
Scheme 14. Synthesis of 14,15-dioxometbalamins.
98
   
 
Unfortunately, the attemps to reconstitute the original corrin macrocycle in 14,15-seco-
corrins were unfruitful. Nevertheless, the commendable progress achieved in the last 
years and the group’s experience in this project provide a solid ground for the goals of 
the present thesis.  
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2. Objective  
 
The goal of this PhD thesis was to establish a chemical route towards metbalamins, 
vitamin B12 derivatives containing different metal centers than cobalt. Since cobalt is 
the main actor in B12-dependent catalytic processes, its replacement gives access to a 
new family of B12 derivatives with modified physicochemical properties. Hence 
metbalamins are excellent candidates of antivitamins B12, molecules that diminish or 
abolish the action of B12-dependent enzymes. Given the involvement of B12 in cell-
growth processes amongst many forms of life, important medicinal applications for 
metbalamins can be envisaged as antibiotics and antiproliferative agents in cancer 
therapy. 
 
 
For decades, the extraction of the cobalt center from the intact corrin macrocycle has 
not been achieved without destruction of the corrin ligand. Therefore, this work aims to 
develop a chemical route towards metbalamins from ring-opened B12 derivatives. 
Herein, the main challenges of this work are to:  
 
- Demetallate ring-opened secocorrinoids. 
- Introduce new metals in the ring-opened corrin cavity. 
- Reconstitute the original corrin macrocycle.  
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3. Results and discussion  
 
3.1. Reconstitution of the corrin macrocycle of B-ring modified 7,8-
seco-corrinoids 
This section describes investigations of B-ring opened B12 derivatives as potential 
precursors for the synthesis of metbalamins. Particularly, it was found that the corrin 
macrocycle of halogen-containing 7,8-seco-corrinoids is efficiently reconstituted under 
reducing conditions. Quantitative conversion was achieved with the one-electron 
reducing agent cobaltocene (CoCp2) and chemoselectivity was obtained by the 
unprecedented use of cyanide as an inorganic protecting group for the metal center 
(Co
III
). In the absence of cyanide, competitive metal (Co
III
) and ligand (corrin) reduction 
processes lead to the formation of several products, including two novel corrinoids with 
an altered delocalized π-electronic system.  
 
Scheme 15. Reductive B-ring reconstitution of 2 and 3 with CoCp2 (top) and NaBH4 
(bottom). 
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3.1.1. Reconstitution of the B-ring using NaBH4 as reducing agent  
Two green 7,8-seco-corrinoids (2 and 3, Scheme 15) with an interrupted corrin 
macrocycle at the B-ring were synthesized in quantitative yields by Dr. René Oetterli in 
our group.
98,99
Interested in the potential utility of 7,8-seco-corrinoids as metbalamin 
precursors, the reactivity of 2 and 3 regarding a) corrin repair and b) metal exchange 
was extensively studied.   
As a starting point, it was investigated if 7,8-seco-corrinoids 2 and 3 could be repaired 
to an intact macrocycle. Previous studies by Kräutler et al. demonstrated that the 
original π-system of a blue 7,8-seco-corrinoid was reconstituted under reducing 
conditions (Scheme 16).
100
  
 
Scheme 16. Ring-closure of a blue 7,8-seco-corrinoid with NaBH4.
100
 
Inspired by this work, the reconstitution of the B-ring of 2 and 3 was attempted using 
the reducing agent NaBH4 (Scheme 15, bottom). The addition of 1.5 equiv of NaBH4 to 
a milimolar aq. sln. of 2 or 3 at 23 ºC led to an immediate colour change from green to 
dark red. UPLC analysis of the reaction mixture after 1 h indicated complete conversion 
of the starting material (Figure 8). From the crude mixture, two compounds (4, 5) were 
isolated by preparative HPLC and fully characterized and a third product (6) was 
identified and its structure was tentatively assigned based on UPLC-MS analysis.  
38 
 
 
Figure 8. UPLC trace (Method 1, see Materials and Methods) of the reaction mixture of 
2 and NaBH4 after 1 h (see Scheme 15, bottom). 
The main fraction (4, Figure 8) contained a red corrinoid with typical values for ,  
and  UV-Vis bands of B12 derivatives with an intact corrin macrocycle (551, 517 and 
360 nm respectively, figure 9). MS analysis of the purified fraction suggested the 
presence of a single product  with m/z = 1372.6 [M+H]
+
. Based on both spectra, the 
formation of Co-cyano-8-hydroxy-cobalamin-c-acid (4, Scheme 15, middle) is 
proposed. Notably, the presence of an axial cyanide ligand in 4 ( ῠ = 2137 cm-1) 
suggests that Co
III
 was not reduced to Co
II
 upon addition of NaBH4 and only a      
ligand-centered reduction (corrin reconstitution) took place for most of the starting 
material. Due to the use of an excess of NaBH4 (1.5 equiv), a small fraction of  the 
green 7,8-seco-corrinoids (2 or 3) was apparently not only reduced at the ligand site but 
also at the metal center. Thus, after reoxidation of this fraction with air,                     
Co-aqua-8-hydroxy-cobalamin-c-acid (4-OH2, m/z = 673.6 [M-H2O]
2+
) was also 
obtained. Indeed, when a larger excess of NaBH4 is employed (5 equiv) 4-OH2 becomes 
the main product of the reaction, being easily converted to 4 by addition of a 
stoichiometric amount of KCN. 
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Figure 9. UV-Vis spectra of 2 (black line, H2O, c = 5.1 x 10
-5
 M) and 4 (red line,                    
H2O, c = 1.6 x 10
-5
 M). 
In order to investigate the mechanism of the reductive ring-closure, the reaction was 
also performed using deuterated sodium borohydride or deuterated solvents (Scheme 
17). Surprisingly, the addition of NaBD4 to 2 in H2O leads to no change in the mass 
spectrum of 4 (m/z = 1372.6, [M+H]
+
), indicating that no hydride from the reducing 
agent is incorporated into the corrin scaffold.  Thus, a tentative radical mechanism in 
which NaBH4 provides an electron to form a ketyl radical at C8 (Y) is proposed. The 
suggested reactive intermediate Y is rapidly coupled to C7 in a C-C forming reaction 
between the radical at C8 and the double bond at C7-C71. If the bromide group is 
eliminated as a Br
.
 radical, a short-lived carbene intermediate at C71 (Z) can be 
originated and rapidly converted to 4 in protic media. Conversely, the use of NaBH4 in 
heavy water (D2O) leads to the formation of a bideuterated ring-closed product ([D2]4, 
m/z = 1374.6, [M-H+2D]
+
), supporting the assumption that two D from the solvent are 
incorporated at C71 in [D2]4. 
40 
 
 
Scheme 17. Proposed mechanism of the radical ring-closure reaction of 2 to 4 with 
tentative intermediates Y and Z.  
While 4 is the main product (33% yield) obtained in the NaBH4-promoted B-ring 
closure reaction described above, several byproducts with different electronic properties 
are formed and can be isolated by HPLC (Figure 8). Most of these fractions are 
complex mixtures of “stable yellow corrinoids”.76-79 It was assumed that the presence of 
these compounds was only related to redox processes occurring at the metal center and 
not a consequence of the reductive B-ring reconstitution. Therefore, these compounds 
were not studied in more detail. However, two minor blue (5) and green (6) colored 
fractions with unusual electronic properties for corrinoids were isolated and identified.   
5 is a by-product isolated in 6% yield in the described reduction of 2 and 3 with NaBH4 
(Scheme 15, middle). In agreement with the measured mass spectrum (m/z = 1225.6 
[M+H]
+
), 
13
C NMR  analysis (figure 10, section 6.3.) confirmed that 5 is                   
Co-cyano-
7
-dehydro-7-decarboxymethyl-8-decarboxyethyl-cobalamin, a corrinoid 
that lacks the b- and c-side chains at the B-ring. Comparison of the 
13
C spectra of  5 and 
vitamin B12 (1)  revealed excellent agreement between the chemical shifts of both 
molecules except for the B-ring signals. Indeed, the C71 ,C72, C81, C82 and C83 
signals of the b- and c- side chains are missing, C7 is now a quaternary carbon              
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( = 150.9 ppm, C7 = 96.7 ppm) and C8 becomes a tertiary carbon ( = 74.2, C8 = 
16.0 ppm). Additionally, C6 and C9 are shifted upfield by 12.4 and and 11.7 ppm 
respectively. These shifts are explained by an increase of the electronic density around 
the B-ring due to the presence of an additional double bond at C7-C8. As a consequence 
of the new double bond, the conjugated π-system of the corrin macrocycle is extended 
and 5 has an intense blue color (max = 622.9 nm, log  = 4.1). 
 
Figure 10. 
13
C NMR spectrum of 5. Quaternary carbons are marked in green (A-, C-, D-
rings and side chains) and blue (B-ring).   
A green by-product (6, Figure 8) was also identified within the reaction mixture of the 
ring-closure reaction with NaBH4 (1.5 equiv). Mass spectrometry studies revealed the 
presence of a mixture of m/z = 1269.6 [M-H2O]
+
 and m/z = 1296.6 [M+H]
+
 that was 
quantitatively converted to m/z = 1296.6 [M+H]
+
  upon addition of an excess of KCN 
(Figure 11). With this data and having characterized 5 as a B12 derivative lacking the b- 
and c- side chains, the structure of the new green compound 6 was tentatively assigned 
assigned as Co-cyano-
7
-dehydro-7-decarboxymethyl-cobalamin. A possible 
mechanism for the conversion of green 7,8-seco-corrinoids 2 and 3 into 6 involves the 
reduction of the ketone at C8 to an alcoholate with NaBH4 (Scheme 18, left) and a 
subsequent [2+2] cycloaddition between the alcoholate moiety and the double bond at 
C7-C71 (Scheme 18, middle). 
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Figure 11. Experimental MS isotopic pattern of 6-OH2 and 6.  
 
 
Scheme 18. Proposed mechanism for the formation of 18.  
5 and 6 represent the first examples of “complete” corrinoids with missing side chains 
reported so far. Until now, such compounds have only been studied using hydrophobic 
models of vitamin B12 (i.e. ‘pyrocobester, see section 1.7.2.).
96
 Recent work by Kräutler 
has described the redox chemistry of such modified corrin derivatives.
101
 Remarkably, 5 
and 6 were obtained at 23 ºC, highlighting that heat is not the only possible driving 
force to form these compounds.  
The transformation of 7,8-seco-corrinoids to 4 was achieved in 33% yields using 
NaBH4 for triggering a ligand-centered reduction. However, the Co
III
 center is partially 
reduced under these conditions leading to the formation of several side-products. 
Aiming to improve chemoselectivity in the reductive B-ring closure and to protect the 
Co
III 
center against reduction, other reducing agents were tested.  
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3.1.2.  Reconstitution of the B-ring using cobaltocene: cyanide as inorganic 
protecting group  
As described in section 3.1.1. (Scheme 17), a plausible mechanism for the corrin 
reconstitution of 7,8-seco-corrinoids 2 and 3 involves the formation of a radical at C8. 
According to this assumption, the main stimulus needed to initiate the reaction is the 
donation of one electron to the secocorrinoids 2 or 3 at their C8 position. Therefore, the 
one-electron reducing agent cobaltocene (CoCp2) was applied to 2 or 3 as an alternative 
to NaBH4.  
When 2 equiv of CoCp2 (E = -0.750 V vs. Ag
+
/AgCl in MeOH)
102
 were added to 2 
under inert atmosphere a metal-centered reduction (Co
III 
to Co
II
) was observed. If the 
reaction mixture was bubbled with air after 30 min of reduction, 2-OH2 (m/z = 
711.72391
 
[M]
2+
, m/zcalc: 711.72340) was obtained (Scheme 19, top). Surprisingly, a 
partial reduction of the corrin ligand was only observered if the reaction mixture was 
stirred for 120 min in the presence of CoCp2, leading to 4-OH2 after reoxidation with air 
(Scheme 19, bottom). The observed reactivity differs notably from the ligand-centered 
reduction of 7,8-seco-corrinoids 2 and 3 when NaBH4 was used (section 3.1.1.). 
 
Scheme 19. Metal-centered reduction of 2 with CoCp2.   
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Aiming for a chemoselective corrin reconstitution between C7 and C8, a protecting 
group for the Co
III
 center at 2 was envisaged. The coordination of a second axial 
cyanide is a straightforward reversible process that lowers the reduction potential of 
Co
III
 by up to 400 mV.
38,103
 Indeed, when CoCp2 is added to 2-CN under the same 
reaction conditions as described above, an immediate colour change from dark green to 
violet was observed (Scheme 20). UPLC-MS analysis revealed quantitative conversion 
to 4-CN (tR = 1.7 min, 1372.5 [M-CN+H]
+
). After deprotecting the Co
III
 center under 
slightly acidic conditions (pH 6), 4 was obtained in quantitative yields. This reaction 
represents the first example in which inorganic cyanide is used as a protecting group in 
natural product synthesis.  
 
Scheme 20. Synthesis of 4-CN from 2-CN. Dotted lines in 2 and 4 indicate                
1
H-
1
H ROESY correlations.  
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3.1.3. Stereochemistry of Co-cyano-8-hydroxy-cobalamin-c-acid (4)  
The orientation of the corrin side chains is fundamental for the biological activity of 
corrinoids.
22,100
 In order to determine the stereochemistry of the c- and d-side chains in 
4, 1D and 2D NMR studies were performed (see section 6.3.). Remarkably, C7A ( = 
1.87 ppm) showed a through-space 
1
H-
1
H ROESY correlation with C4N ( = 6.45 
ppm), demonstrating that the side chains at C7 have the same orientation as in natural 
Cbls (Scheme 20).  
This orientation of the peripheral groups at C7 and C8 was confirmed by the reactivity 
of 4: intramolecular esterification between the carboxylic acid at C72 and the alcohol 
group at C8 was completed overnight in quantitative yields, forming a new product (m/z 
= 1354.6 [M+H]
+
) that contains a c-lactone on the B-ring . For steric reasons, such an 
esterification is only possible if both groups (carboxylic acid at C72 and alcohol at C8) 
are oriented towards the same side of the molecule. The spectra of this c-lactone 
containing compound were compared to those of Co-cyanocobalamin-c-lactone (7), a 
well-known oxidation product of vitamin B12.  Indeed, UPLC coinjections (Figure 12) 
as well as 
1
H and 
13
C NMR studies (Figure 13) revealed that 7 can also be synthesized 
from 7,8-seco-corrinoids 2 and 3. In turn, this means that the peripheral groups at C8 
are also oriented as observed in vitamin B12 and thus Co-cyano-8-hydroxy-cobalamin-
c-acid (4) was formed. 
 
Figure 12. UPLC coinjection of 7 synthesized a) from vitamin B12 (1) and b)  from 
green secocorrinoids (2 or 3).  
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Figure 13. 
1
H NMR spectra of 7 synthesized from B12 (red) or from 2 or 3 (green). 
 
 
 
 
 
 
 
 
 
47 
 
3.1.4.  Ring-closure experiments with rearranged green secocorrinoids  
A rearrangement of the methyl group C7A and the halogen atom at C71 occurs when 2 
or 3 are stirred at 23 ºC in an aq. soln. (Scheme 21), according to crystallographic and 
spectroscopic data (NMR, UV-Vis) collected by Dr. René Oetterli.
98
  
 
Scheme 21. Rearrangement of 2 and 3 to 8 and 9.   
The optimized reaction conditions for the reductive B-ring closure of 7,8-seco-
corrinoids (see section 3.1.1. and 3.1.2.) were also applied to 8 and 9. Thus, when 
NaBH4 was added to 8 or 9 an immediate colour change from green to red showed the 
reconstitution of the corrin macrocycle. Importantly, UPLC-MS analysis after 1 h 
(Figure 14) showed the formation of a single corrinoid with either a cyano (10, m/z = 
687.3 [M+2H]
2+
) or an aqua upper axial ligand (10-OH2, 673.5 [M-H2O+2H]
2+
). 
Addition of stoichiometric amounts of KCN led to the formation of a new product (10) 
in quantitative yields. Contrary to the reactivity of 2 and 3, the reductive ring-closure of 
8 and 9 in the presence of NaBH4 yielded a single product. As expected, 10 was also 
obtained in quantitative yields when CoCp2 was applied to the cyanide-protected 
species 8-CN or 9-CN. However, when a soln. of 10 was stirred overnight at pH 2, 
UPLC-MS studies showed no significant changes in tR or exact mass, demonstrating 
that no intramolecular esterification took place between C72 and the OH group at C8 in 
10. This observation points towards a different orientation of the B-ring peripheral 
groups in 10 compared to 4.  
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Figure 14. UPLC trace (Method 1, see Materials and Methods) of reaction mixture after 
1 h. 
In order to determine a) the orientation of the peripheral groups at the B-ring and b) the 
position of the methyl group C7A (C71A in 8 and 9) after the reductive ring closure, 1D 
and 2D NMR studies were conducted with the new compound (10). According to 
1
H 
NMR analysis, the methyl group corresponding to C7A in 4 ( = 1.87 ppm) is shifted 
upfield in 10 ( = 1.35 ppm,  = 0.52 ppm). Additionally, 1H-13C HMBC analysis of 
10 showed correlations between C7A and C6, C7, C71 and C8, demonstrating that this 
–CH3 is still located on C7 (Scheme 22). Since no other major changes were found in 
the 
1
H or 
13
C spectra of 10 in comparison to 4, it was concluded that the stereocenter at 
the c-side chain has now an unnatural configuration, with the methyl group bound 
directly to C7 but pointing to the upper side of the corrin. This means the methyl group 
C71A at the rearranged 7,8-seco-corrinoids 8 and 9 migrates back to C7 under reducing 
conditions and is oriented to the upper side of the corrin macrocycle (C7A, Scheme 22, 
right). The lack of reactivity of 10 under acidic conditions hints towards a hydroxyl 
group at C8 oriented towards the  face of the corrin. Therefore, this group cannot 
undergo intramolecular esterification with the  oriented carboxylic acid at C72 due to 
steric hindrance. Thus, Co-cyano-8-hydroxy-7-epicobalamin-c-acid (10) originated 
(Scheme 22, right).  
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Scheme 22. Synthesis of 10 from 8 or 9. Dotted lines represent 
1
H-
13
C HMBC 
correlations.  
3.1.5.  Demetallation experiments with 7,8-seco-corrinoids 
 
The reversible procedures to cleave and repair the corrin macrocycle between C7 and 
C8 in quantitative yields represent a straightforward route for the synthesis of modified 
secocorrinoids. Such routes are highly desirable in the context of this thesis since          
1) distortion of the corrin macrocycle is a valid approach to demetallate corrinoids
85,94
 
and 2) it has been demonstrated in section 3.1.2. that the reductive reconstitution of   
7,8-seco-corrinoids is independent of the metal center and could therefore be transferred 
to secocorrinoids containing other metals than cobalt.  
 
In order to specifically reduce the metal center while keeping the corrin ligand intact, 
CoCp2 was used as a reducing agent for the base-on compound 2. As a general 
approach, solns. of 2 were reduced for 20-30 min under inert atmosphere to afford a 
Co
II
-containing 7,8-seco-corrinoid (2
.
, Scheme 23, middle) lacking the upper axial 
cyanide ligand. When UPLC-MS analysis confirmed the formation of the reduced form 
of 2, a decomplexating agent was added (Scheme 23). Reaction conditions for this step 
and products are summarized in Table 1.  
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Scheme 23. General approach for the demetallation trials of 2
.
.  
Conditions   Products  
2) EDTA, 105
 0
C, 3h, 
MeOH  
 
2) EDTA, 0.05% TFA,  
105 
0
C, 3h, MeOH 
 
2) EDTA, 0.05% TFA,  
105 
0
C, 6h, MeOH  
 
2) 80 ºC, 3h, ethylene 
glycol  
Complex mixture 
2) 78 ºC, 1h, H2SO4 
conc 
Complex mixture 
Table 1. Reaction conditions tested and products of the attempted demetallation of 2.  
 
Unfortunately, no metal-free corrinoids were identified and the only products observed 
by UPLC-MS were either starting material or side-products from the metal and ligand 
reduction. Even though the B-ring is opened and cobalt is reduced to the more labile 
Co
II
 state, 2* posesses an extended π-system that heavily protects the metal centre 
against demetallation. On the other hand, it is noteworthy that the presence of some acid 
(0.05 % TFA) at high temperatures (105 ºC) favors the formation of blue and green 
corrinoids 5 and 6. 
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3.1.6.  Stereospecific reconstitution of vitamin B12 
The quantitative synthesis of 7 allowed the stereospecific reconstitution of vitamin B12 
within two steps: 1) a reductive lactone opening with NaBH4 and 2) a primary amide 
formation with NH4Cl and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC
.
HCl) as coupling reagent (Scheme 24).
104
 All in all, a 
stereospecific reconstitution of vitamin B12 from  green 7,8-seco-corrinoids 2 and 3 was 
achieved in four steps.  
 
Scheme 24. Conversion of 7 to B12 (1) in two steps.  
The structures of these two last compounds (11 and 1) were elucidated by X-ray 
diffraction analysis. Single crystals were grown by vapour diffusion of acetone into  11 
or 1 (1 mM). As the crystals were weakly diffracting on a molybdenum source and      
X-ray fluorescence was observed when using copper radiation, both crystals were 
finally measured with the help of a gallium source by Prof. Bernhard Spingler and Dr. 
Markus Neuburger (University of Basel). As anticipated by previous spectroscopic data, 
the orientation of all stereocenters is identical to those observed in naturally occurring 
B12 (Figure 15).  
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Figure 15. Left: overlay of the X-ray structures of 1 (blue) and 11 (normal element 
colours). Right: overlay of 1 (normal element colours) and a reference structure of 
vitamin B12 (red). 
As described in section 3.1.1.; when the ring closure reaction was performed with 
NaBH4 in deuterated solvents, bideuterated [D2]-4 was obtained as main product and 
transformed in [D2]-7 overnight under acidic conditions (pH 2). Following the same 
synthetic route described above in Schemes 17 and 24, bideuterated B12 ([D2]-1)  was 
obtained (m/z = 1357.6 [M-H+2D]
+
). Compared to 1, the 
1
H NMR spectrum of [D2]-1 
differs only in the absence of a duplet at  = 2.2 ppm and a slightly flater multiplet at   
= 2.0 ppm, plausible peaks for the missing CH2 group at C81 (Figure 16). 
 
 
 
 
 
 
Figure 16. Overlapped 
1
H NMR spectra of 1 (green) and [D2]-1  (red). The only 
differences between both spectra are highlighted.  
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In conclusion, a reversible four-step route for the stereospecific reconstitution of 
vitamin B12 (1) from B-ring opened 7,8-seco-corrinoids 2 and 3 was developed (Scheme 
25).
105
 These green secocorrinoids were previously synthesized in a two-step route 
according procedures developed earlier in our group.
98,99
 The whole six-step route from 
1 represents a promising approach for exploring B-ring modified B12 derivatives. The 
ring-closure step of the corrin macrocycle is a potential source of numerous chemical 
modifications of vitamin B12 with modified electronic properties (Scheme 15). 
Furthermore, procedures were optimized until the corrin macrocycle could be disrupted 
to a secocorrinoid and reconstituted in quantitative yields and without the use of time-
consuming purification techniques. These synthetic methods are unprecedented in the 
normally low-yielding vitamin B12 chemistry and could therefore facilitate the 
production of new modified corrinoids for catalytic, sensing and medicinal applications. 
 
Scheme 25. Six-step reversible route for the cleavage and reconstitution of the corrin 
macrocycle of B12.  
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3.2. Synthesis of metbalamins from 5,6-seco-corrinoids 
 
This chapter summarizes efforts to synthesize metbalamins from dicyano-5,6-seco-
corrinoids (Scheme 26). First, dicyano-5,6-dioxocobalamin (13) was obtained from the 
photooxygenation of B12 described in section 1.7.2. (see Scheme 10). Subsequently, 
chemical and electrochemical methods to demetallate 13 were implemented based on 
the extraction of labile Co
II
 ions from the corrin cavity using cyanide as decomplexating 
agent. Next, reconstitution of the corrin macrocycle was partially achieved under 
reductive conditions. Remarkably, both steps (demetallation and corrin reconstitution) 
were later combined in a one-step reaction that led to a metal-free vitamin B12 derivative 
with a single C-C bond at C5-C6 (23). Finally, insertion of Ni
II
, Cu
II
 and Zn
II 
in the 
metal-free corrin cavity of 5,6-diol-H-balamin was achieved under mild conditions, 
leading to the synthesis of novel 5,6-diolmetbalamins (22, 24, 25, 26).  
 
 
 
Scheme 26. Multi-step route for the synthesis of 5,6-diolmetbalamins (M = Ni
II
, Cu
II
, 
Zn
II
). Charges are omitted for clarity. 
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3.2.1. Reactivity of 5,6-seco-corrinoids under reducing conditions: demetallation 
 
As described in section 1.7., the photooxygenation of the corrin macrocycle can be 
applied to B12, obtaining two dioxoisomers: dicyano-14,15-dioxocobalamin (12, 
Scheme 27, top) and dicyano-5,6-dioxocobalamin (13, Scheme 27, bottom). Since 
previous work in the group achieved the demetallation of 12 to form 14,15-dioxo-H-
balamin (14, Scheme 28), it was envisaged to adapt this reaction for 13 and thus build a 
route towards metbalamins using 5,6-dioxocobalamins. Based on previous 
studies
71,99,106
 and experiences described in chapter 1 of this thesis, the “northern” side 
of the corrin macrocycle has an enhanced reactivity for reversible modifications of its 
structure compared to the “southern” side. Therefore, 5,6-dioxocobalamins are potential 
starting materials for the synthesis of metbalamins.  
 
 
 
Scheme 27. Structure and schematic representation of dicyano-14,15-dioxocobalamin 
(12) and dicyano-5,6-dioxocobalamin (13).  
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Scheme 28. Demetallation of dioxocobalamins 12 and 13. Charges are omitted for 
clarity.  
 
Accordingly, the first goal of this project was to develop a reproducible method to 
demetallate 13. Based on earlier experiences with 12 (see section 1.7.2.), the metal 
center was first reduced from the inert Co
III 
to a more labile Co
II
 oxidation state and 
subsequently extracted from the corrin macrocycle by adding a decomplexating agent.
99
 
The electrochemical reduction was optimized adapting voltage, pH, temperature and 
time. The best reaction conditions were found when a voltage of    -0.90 V (vs. 
Ag/AgCl 3M) was applied to an electrolyte soln. (0.1 M TRIS pH 8.1) containing 13 
(0.8 mM) for 2 h at 50 ºC. Subsequently an excess of KCN (100 equiv)  was added to 
the reduced soln. containing intermediate A (Scheme 29) and cobalt was instantly 
removed from the core of the macrocycle, obtaining 5,6-dioxo-H-balamin (15, Scheme 
29, right) in 22% yield, as observed by the rapid color change of the soln. from dark 
brown to pale yellow.  
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Scheme 29. Electrochemical demetallation of 13.  
 
The metal-free compound 15 is a yellow corrinoid with an absorption maximum at     
379 nm (log  = 3.9) at pH 7 (Figure 17). MS analysis of 15 shows a single peak at m/z 
= 1302.63042 [M]
-
 (m/zcalc = 1302.62933) (Figure 17) and its 
1
H NMR  spectrum 
typical for a base-off corrinoid (Figure 18). This data confirms that the extraction of the 
cobalt ion from 13 to form 15 causes no change in the delocalized π-electronic system 
of the secocorrin macrocycle. Surprisingly, 15 is highly stable in soln. at pH 10 (no 
significant change in its structure is found after 1 month according to UPLC-MS 
analysis). However, 15 degrades to undetermined side products after some minutes at 
pH 2, the main one with m/z = 1285.6 [M]
-
.  
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Figure 17. UV-Vis (H2O, c = 4.5 x 10
-5 
M) and HR-MS spectra of 15. 
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Figure 18. 
1
H NMR spectrum of 15.  
 
 
3.2.2. Reactivity of 5,6-seco-corrinoids under reducing conditions: reconstitution 
of the corrin 
 
The reactivity of 5,6-seco-corrinoid 13 was also studied by electrochemical means 
without addition of an excess of KCN as decomplexating agent. As described before 
(section 3.2.1.), when the reduction of 13 was performed at E = -0.90 V for 2 h only the 
Co
III
 center was reduced, while the equatorial ligand remained unaltered according to 
spectroscopic data. However, when a slightly more negative voltage (E =   -1.00 V vs 
Ag/AgCl 3M) was applied for a longer reaction time (> 2.5 h), additional reduction of 
the secocorrin ligand took place (Scheme 30). 16 equiv of KCN were subsequently 
added and HPLC purification under slightly acidic conditions (pH 5) yielded a lemon-
yellow product with a broad band at 455 nm (log = 3.8, Figure 19).  The main band 
was shifted bathochromically by 18 nm (max = 473 nm, Figure 19) upon addition of an 
excess of KCN (100 equiv), indicating the coordination of a second axial cyanide 
ligand. These absorption values are typical for cobalt-containing “stable yellow 
corrinoids” with an altered π-electronic system at the equatorial macrocycle due to the 
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presence of a single bond between C5-C6.
107
 This assumption was also supported by 
UPLC-MS analysis (m/z = 1387.6 [M]
-
), indicating the formation of aquacyano-5,6-
diolcobalamin (16, Scheme 30). A plausible mechanism for the C-C bond formation at 
the “northern” face of the corrin ligand involves the reduction of the two keto moieties 
at C5 and C6 to ketyl radicals (intermediate B, Scheme 30) and a subsequent coupling 
of both radicals. Unfortunately, no reproducible demetallation of 16 was achieved under 
reducing conditions, even after the addition of a large excess of KCN (> 100 equiv).  
 
 
 
Scheme 30. Reductive ring closure of 13 to form 16.   
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Figure 19. UV-Vis spectrum of 16 (black line) and 16-CN (red line) (H2O,                     
c = 2.5 x 10
-5
 M). 
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3.2.3.  A base-on 5,6-dioxocobalamin obtained by remetallation of 5,6-dioxo-H-
balamin (15) 
 
 
15 was stirred at 23 ºC under slightly basic conditions (H2O, 0.1 M TRIS pH 8.1) in the 
presence of CoSO4
.
7H2O (5 equiv, Scheme 31, top). An immediate colour change from 
yellow to dark orange was observed and after 1 h, UPLC-MS analysis showed complete 
conversion to a cobalt-containing corrinoid with  tR= 3.5 min and m/z = 1360.6          
[M-OH2]
+ 
(Method 2, see Materials and Methods). 
1
H NMR analysis of the crude 
mixture confirmed the formation of a single product with peaks corresponding to the 
Dmbz base (C2N, C4N and C7N) appearing at  = 7.50, 7.43 and 7.39 ppm (Figure 20, 
top). The presence of the most downfield chemical shifts between 7 and 8 ppm is 
typical for base-on corrinoids.
108
 According to this spectroscopic data, hydroxo-5,6-
dioxocobalamin (17, Scheme 31) was obtained.   
 
In order to compare the behavior of metal-free dioxoisomers 15 and 14 towards 
metallation, CoSO4
.
7H2O was also added to 14 under the same conditions described 
above (Scheme 31, bottom). In this case, the base-off corrinoid aquahydroxo-14,15-
dioxocobalamin (18) was obtained according to 
1
H NMR analysis (a Dmbz peak 
appears at  = 9.9 ppm, Figure 20, bottom). This fact indicates a different chemical 
behavior of 14 and 15 upon cobalt insertion. Likely, when the cleavage occurs at a site 
spatially close to the f-side chain (C14-C15) unfavorable steric interactions hinder the 
coordination of the “loop” to the CoIII center. As a result, only in the “upper” oxidized  
corrinoid 17 the Dmbz base is able to coordinate a Co
II
 center through the lower axial 
position of the octahedral complex forming a corrinoid with a base-on configuration. 
Importantly, access to base-on corrinoids is an important requirement for transporting 
B12 surrogates with modified catalytic activity into cells (see section 1.3.).
22,25,68
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Scheme 31. Synthesis of base-on 17 and base-off 18. 
 
 
 
Figure 20. 
1
H NMR of base-on 17 (top) vs 
1
H NMR of base-off 18 (bottom).  
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3.2.4.  Synthesis of dioxometbalamins  
 
Having observed the straight forward incorporation of Co
II
 into 15, the same method 
was tested with Ni
II
. Satisfyingly, quantitative conversion to 5,6-dioxonibalamin (19) 
was observed within 1 h (Scheme 32), as confirmed by a batochromic shift of the main 
UV-Vis band to from 379 to 447 nm (log = 3.8) and by HR-MS analysis (m/z = 
680.78633, m/zcalc = 680.78543 [M+2H]
2+
). 
1
H NMR analysis proved that 19 is a 
diamagnetic complex (Figure 21), which in turn means a Ni
II
 complex with a       
square-planar d
8
 configuration was formed. As expected for this geometry and in 
contrast to 17, 19 is a base-off compound (Dmbz= 8.36, 7.48 and 7.43 ppm). These 
results highlight that the corrin cavity of 15 is a suitable macrocyclic ligand for the 
incorporation of other metal ions than cobalt. Remarkably, quantitative conversion of 15 
to Ni
II
-containing 19 was completed using the same reaction conditions (time, 
temperature) as for the synthesis of Co
III
-containing 17. Compound 19 is stable under 
acidic (pH 2), neutral (pH 7) and basic conditions (pH 10). However, upon addition of 
an excess of KCN (100 equiv), 19 is partially demetallated over 30 min, as monitored 
by UV-Vis spectroscopy (Figure 22). Demetallation of 19 to 15 is quantitative after 48 h 
in the presence of KCN (pH 10), as observed by UPLC-MS (tR = 2.5 min,  m/z = 1302.6 
[M]
-
 , Method 2, see Materials and Methods).  
 
 
 
Scheme 32. Synthesis of 19. 
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Figure 21. 
1
H NMR spectrum of 19. 
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Figure 22. UV-Vis spectrum of 19 without KCN (black line) and with KCN  (30 min, 
pH 10, red line; 48 h, pH 10, blue line).  
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After demonstrating that 15 is a suitable macrocyclic ligand for other metals than cobalt, 
5,6-dioxozincbalamin (20) and 5,6-dioxocubalamin (21) were synthesized analogously 
(Scheme 33). 20 is a Zn
II
-containg yellow compound (max = 434 nm) with m/z = 
1368.57403 [M+H]
+
 (m/zcalc = 1368.57303) obtained in base-off configuration 
according to 
1
H NMR analysis (Dmbz = 8.73, 7.56, 7.37 ppm, Figure 23). While Ni
II
-
containing 19 could only be demetallated upon addition of an excess of KCN, Zn
II
 in 20 
can be extracted from the corrin either with KCN (100 equiv) or in soln. at pH 2. The 
demetallation of 20 was indicated by hypsochromic shifts (Figure 22) in the UV-Vis 
spectrum.  The coordination of Cu
II
 to form 5,6-dioxocubalamin (21) was observed by a 
batochromic shift in the UV-Vis spectrum (max = 447 nm) but the paramagnetic nature 
of this complex hindered further structural studies by NMR.  
 
 
 
 
Scheme 33. Synthesis of 20 and 21.  
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Figure 23. 
1
H NMR spectrum of 20. 
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3.2.5. Reactivity of 5,6-dioxonibalamin (19) under reducing conditions: 
demetallation and corrin reconstitution 
 
The presence of a Ni
II
 ion allows 19 to resist harsh reaction conditions and provides a 
square planar geometry within the complex. It was envisaged that this geometry would 
allow the reconnection of positions C5 and C6 at the secocorrin. To achieve this goal, 
electrochemical reducing conditions (E = -1.00 V, 3h, see section 3.2.2.) were applied to 
19 (Scheme 34). Two main observations were made:  
1) The metal ion is resistant to demetallation under reducing conditions. When a 
voltage of -1.00 V is applied to 19, the soln. gradually gets a darker orange 
color. It is assumed that Ni
II
 can be reversibly reduced to Ni
I
.  
2) The ketone at C5 and the lactam at C6 in nickel-containing 19 are coupled 
under reducing conditions forming 5,6-diolnibalamin (22, m/z = 682.4 
[M+2H]
2+
), an analogous reaction to the formation of aquacyano-5,6-
diolcobalamin (16). Concretely, three isomers of 22 were found in the reaction 
mixture (tR = 2.4 min, 3.1 min and 3.5 min) according to UPLC-MS analysis 
(Figure 24, Method 2, see Materials and Methods), most likely due to the 
different possible orientations of the diol at C5-C6. As described in section 
3.2.2., a pinacol-type reaction of C5 and C6 undergoing a radical C-C bond 
formation is envisaged (intermediate C, Scheme 34, middle). 
 
 
 
Scheme 34. Electrochemical synthesis of 22.  
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Figure 24. UPLC trace (Method 2, see Materials and Methods) of the crude mixture (see 
Scheme 34).  
 
When an excess of KCN (100 equiv) was added to the reduced Ni
I
-containing corrinoid, 
an immediate colour change from orange to yellow was observed (Scheme 35).     
UPLC-MS analysis revealed that out of the three nickel-containing isomers, the two 
most polar were quantitatively demetallated (Figure 25). This observation supports that 
labile Ni
I
-corrinoids originate in this reaction, since such a fast demetallation is not 
observed with Ni
II
-containing 19 (section 3.2.4.). Thus, a ring-closed metal-free 
corrinoid (5,6-diol-H-balamin, 23, m/z = 1304.6 [M]
-
) was instantly synthesized. The 
metal-free isomers were isolated by preparative HPLC and analyzed by 
1
H NMR, 
observing identical spectra for both compounds (Figure 26). With this data in hand, it is 
highly likely that the only difference between both isomers is the stereochemistry at C6. 
 
 
 
Scheme 35. Electrosynthesis of 23.  
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Figure 25. UPLC trace (Method 2, see Materials and Methods) of the crude mixture (see 
Scheme 35). 
 
 
 
 
 
Figure 26. 
1
H NMR spectrum of the first (tR = 3.0 min)  and second (tR = 3.2 min) 
isomers of 23. 
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In summary, the experiments described in sections 3.2.1. to 3.2.5. propose a 4-step route 
towards a ring-closed metal-free template of vitamin B12. This route includes the 
following steps: a) photochemical cleavage of the corrin macrocycle, b) demetallation 
of an electrochemically reduced 5,6-dioxocobalamin, c) remetallation with Ni
II 
to a 
square-planar 5,6-dioxonibalamin and d) simultaneous C-C bond formation and 
demetallation to obtain the final product 23 (Scheme 36).  
 
 
 
Scheme 36. 4-step route for the synthesis of 23 from vitamin B12.  
 
Even though this route achieves a reproducible synthesis of 23, different isomers are 
obtained according to UPLC-MS analysis of the reaction mixture. Aiming for a 
stereospecific route involving less synthetic steps, further optimizations were pursued.  
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3.2.6.  CoCp2-mediated one-step synthesis of 5,6-diol-H-balamin from 5,6-
dioxocobalamins   
 
Seeking further developments in the synthesis of metal-free templates of vitamin B12, a 
one-step demetallation and corrin reconstitution reaction starting from 13 to obtain 23 
was envisaged. The prerequisites for such a simultaneous reaction are a) a metal 
reduction to labilize the cobalt center and b) a carbonyl reduction to complete a pinacol-
type reaction. The latter step consists of a C-C bond formation similar to the one 
described in section 3.1. of this work. Therefore, experiments with the one-electron 
reducing agent CoCp2 were also performed with 13. 
 
The addition of CoCp2 (5 equiv) to 13 caused an immediate color change of the soln. 
from blood-orange to dark red. After only 2 min, the addition of an excess of KCN (107 
equiv) led to 15 (Scheme 37, path A). When a larger excess of CoCp2 (11 equiv) was 
added to 13 in three portions over 20 min, not only the metal but also the corrin ligand 
was reduced at positions C5 and C6 (Scheme 37, path B). Thus, the main product 
obtained after the addition of cyanide was 23 (m/z = 1304.6 [M]
-
, max = 383 nm, log  = 
4.0). In this case, the reaction was stereospecific and only one isomer (tR = 2.7 min) of 
the metal-free compound was obtained in 23% yields. 
1
H NMR analysis of this isomer 
was compared to the spectrum of one of the isomers of 23 synthesized by 
electrochemical reduction (see section 3.2.5.). The main difference in the spectrum is 
the change in the chemical shift of the methyl group at C51 ( = 0.38 ppm, Figure 27), 
indicating a different orientation of C51 and therefore suggesting that the stereospecific 
synthesis yields a new isomer with different stereochemistry at C5. Subsequently, the 
1
H NMR spectra of 5,6-diol-H-balamin (23) and 5,6-dioxo-H-balamin (15) were also 
compared: the two spectra are indeed very similar, showing only noticeable shifts for 
the methyl groups at C51 and C151, as expected for the different electronic 
environments of both compounds at the bridging meso positions of the corrin 
macrocycle (Figure 28).  
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Scheme 37. Synthesis of 23 with CoCp2 following a two-step (Path A + C) or a one-step 
(Path B) procedure.  
 
 
 
Figure 27. 
1
H NMR spectra of 23 synthesized by chemical (top) or electrochemical 
(bottom) reduction. Peaks corresponding to C51 are highlighted. 
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Figure 28. 
1
H NMR spectra of 23 and 15. Peaks corresponding to C51 and C151 are 
highlighted. 
 
Having observed a metal-centered reduction in the one-step synthesis of 23 from 13, 
experiments were conducted to determine whether the ligand reduction is dependent on 
the metal center. Consequently an excess of CoCp2 (11 equiv) was added to the      
metal-free compound 15 in 3 portions (Scheme 37, Path C). After 1 h, UPLC-MS 
control experiments showed the formation of one single isomer of 23 (tR = 2.7 min). 
Additionally, when this reaction was performed in the presence of an excess of the 
radical scavenger TEMPO (30 equiv), only starting material was found by UPLC-MS 
analysis of the mixture. These experiments demonstrate that the ring closure follows a 
pinacol-type radical mechanism, independent of the presence or absence of the metal 
center within the corrin cavity.  
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3.2.7. A base-on 5,6-diolcobalamin (24) obtained by remetallation of 5,6-diol-H-
balamin (23) 
 
 
Knowing that 15 can incorporate Co
III
 in its core and coordinate Dmbz through the 
lower axial position, analogous experiments were performed with 23. Indeed, when 23 
was stirred at 23 ºC in the presence of CoSO4
.
7H2O under slightly basic conditions 
(H2O, 0.1 M TRIS, pH 8.1), the base-on derivative Co-hydroxo-5,6-diolcobalamin (24) 
was rapidly formed (around 90 min for full conversion of 23 to 24), as shown by MS 
spectrometry (m/z =  1362.6  [M-OH]
+
) and 
1
H NMR analysis of the crude mixture 
(C4N = 7.54 ppm, C7N = 7.32 ppm, C2N = 7.10 ppm, Figure 29). 
 
 
 
Figure 29. 
1
H NMR spectrum of 24. 
 
In order to fully elucidate the structure of 24 and as an indirect way to gain additional 
insights into the structure of metal-free 5,6-diol-H-balamin (23) and other possible 
diolmetbalamins, thorough  2D NMR studies were performed (see section 6.3.). The 
main conclusions of these studies are:  
- A C-C bond is present between C5 and C6: 1H-13C HMBC show correlations of 
the methyl group at C51 with both C4 and C6.  
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- The compound possesses a base-on configuration with Dmbz being almost 
perpendicularly oriented to the C51-C151 axis of the molecule and only slightly 
tilted towards the A-ring: 
1
H-
1
H ROESY shows several Dmbz signals 
correlating with various peaks belonging to the corrin macrocycle. Thus, C4N 
correlates with all the lower oriented peripheral groups of the “northern” A-ring 
(C1A, C2A, C31). Additionally, C2N has a through-space correlation with the 
southern methyl group at C151. 
- C51 is strongly shifted downfield according to 13C NMR analysis ( = 47.2 ppm, 
+28.9 ppm compared to 1-OH) due to the presence of an –OH group at C5. In 
addition, C51 shows 
1
H-
1
H ROESY through space correlations with the methyl 
group C2A, demonstrating that this –CH3 is oriented to the lower side of the 
corrin macrocycle.  
 
3.2.8.   Synthesis of diolmetbalamins  
 
Having determined the structure of 24 and its stereochemistry at C5, other metals were 
incorporated in the metal-free corrin cavity of 23. The same method used for the 
metallation of 5,6-dioxo-H-balamin (15) was applied for 5,6-diol-H-balamin (23). The 
partial corrin reconstitution at C5-C6 had no remarkable effect on the ability of 23 to 
coordinate other metals than cobalt. Thus, when 23 was stirred for 90 min at 23 ºC in 
the presence of NiSO4
.
7H2O, quantitative conversion to 5,6-diolnibalamin (22, Scheme 
38) was observed by UV-Vis spectroscopy (max = 437 nm, log  = 3.8)  and HR-MS 
spectrometry (1360.56121 [M-H]
-
, m/zcalc = 1360.56468). UPLC analysis revealed that 
only one isomer was synthesized (tR = 3.1 min) with square-planar geometry and base-
off configuration according to 
1
H NMR analysis (Dmbz = 8.34, 7.45, 7.39 ppm, Figure 
30). 
 
 
 
Scheme 38. Synthesis of 22.  
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Figure 30. 
1
H NMR spectrum of 22. 
 
Analogously, 5,6-diol-zincbalamin (25) was synthesized by adding ZnSO4
.
7H2O to a 
stirred soln. of 23 at 23 ºC (Scheme 39), as confirmed by UV-Vis spectroscopy        
(max = 438 nm, log  = 3.9) and HR-MS spectrometry (m/z = 1368.57403 [M+H]
+
, 
m/zcalc = 1368.57303). 
1
H NMR analysis shows the most downfield singlet signal at 
ppm and the most upfield triplet at ppm (Figure 31), ambiguous 
chemical shifts with values between those of base-off 5,6-diolnibalamin (22, 
and 1.00ppm, Figure 30) and base-on hydroxo-5,6-diolcobalamin 
(24,and 0.46 ppm, Figure 29). Additionally, these values differ significantly 
from those of 5,6-dioxozincbalamin (20, and 1.00 ppm, Figure 23) and the 
pattern for the Dmbz UV-Vis bands of 25 differs from those of base-off diol compounds 
like 23 (Figure 32). Subsequently and knowing that the coordination of the Dmbz base 
in vitamin B12 is a pH dependent equilibrium, UV-Vis spectra of 25 were recorded at 
different pH values. At neutral conditions the Dmbz bands appear at 283 and 289 nm. 
No significant changes in the shape or intensity of these bands were observed when the 
compound was dissolved in a strongly basic (pH 12) soln. When a soln. of 25 was 
acidified (pH 1), the Zn
II
 ion left the macrocycle leading to 23 as observed for the zinc-
containing dioxocompound 20. As UV-Vis measurements could not determine the 
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configuration of 25, 
1
H-
1
H ROESY analysis was done under neutral conditions. Indeed 
the spectrum revealed through-space correlations between two peripheral methyl groups 
and Dmbz signals, pointing towards a base-on configuration of this compound (see 
section 3.2.7. and 6.3.). Further NMR and/or crystallographic studies will be needed to 
confirm the formation of a base-on diolmetbalamin.  
 
 
 
Scheme 39. Synthesis of 25.  
 
 
 
 
Figure 31. 
1
H NMR spectrum of 25. 
 
In the presence of CuSO4
.
5H2O, 23 was converted to 5,6-diolcubalamin (26, Scheme 
40) as detected by UV-Vis spectroscopy (max = 439 nm, log  = 3.9) and HR-MS 
spectrometry (m/z = 1365.55327 [M-H]
- 
, m/zcalc = 1365.55327). Like the                  
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Cu
II
-containing dioxoderivative 21, 26 is a paramagnetic complex and thus NMR 
studies could not be efficiently conducted.   
 
 
 
 
Scheme 40. Synthesis of 26.  
 
 
The synthesized diolmetbalamins (22, 25, 26) were obtained in quantitative yields and 
the coordination of Ni
II
, Zn
II
 and Cu
II
 was completed under the same reaction conditions 
as for the synthesis of cobalt-containing 24. The main difference between 24 and 
diolmetbalamins 22, 25 and 26 lies in the lability of the latter compounds within the 
corrin macrocycle. Thus, when a strong σ–donor like KCN (100 equiv) was added to a 
soln. of 22, 25 or 26; the three diolmetalamins were transformed into 23 (Figure 32), as 
observed for the dioxometbalamins described in section 3.2.4. 
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Figure 32. Left: UV-Vis spectrum of 25 without KCN (red line, H2O, c = 3.1 x 10
-5
 M) 
and with KCN (100 equiv, black line). Right: UV-Vis spectrum of 26 without KCN (red 
line, H2O, c = 7 x 10
-5
 M) and with KCN (100 equiv, black line).    
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In summary, sections 3.2.6. to 3.2.8. describe a 2-step route for the synthesis of the 
metal-free B12 template 5,6-dioxo-H-balamin (23). The key point of the route is a one-
step demetallation and corrin reconstitution at positions C5 and C6 using the one-
electron reducing agent CoCp2 (11 equiv). Advantageously, this reaction yields only 
one isomer of 23 (23%) as main product. The structure of metal-free 23 was indirectly 
determined by introducing cobalt in the corrin cavity, affording hydroxo-5,6-
diolcobalamin (24). 1D and 2D NMR studies demonstrated the stereochemistry at C5 
(methyl group is oriented to the lower side of the corrin) and showed that 24 posesses a 
base-on configuration. Therefore 24 is a good candidate for biological applications, 
since it could be transported in its base-on configuration but its modified electronic 
properties would change its reactivity within cells.
22,28
 Aiming to extend the portfolio of 
potential candidates for B12 surrogates with modified enzymatic reactivity, other metals 
(Ni, Zn, Cu) were complexed with 23 in quantitative yields.  However, the coordination 
of these metal ions was completely reversible upon addition of KCN and/or acids. 
Seeking to further stabilize other metal centers than cobalt within the corrin macrocycle, 
subsequent efforts were focused on the complete repair of the delocalized π-electronic 
system of the corrin.  
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3.3. Attemps of dioxo and diol elimination 
 
In this section, endeavors to reconstitute the intact delocalized π-electronic system of 
the corrin macrocycle from “northern” face modified B12 derivatives (5,6-seco-
corrinoids) are presented. The main strategy consisted on the reductive repair of 5,6-
dioxo and 5,6-diol B12 derivatives containing either cobalt or nickel as metal centers 
(Scheme 41). Experiments included the use of a) classic reductive procedures in B12 
chemistry (i.e. reductions with Zn/AcOH); b) methods implemented in this work (i.e. 
CoCp2); and c) classic organic reactions for the formation of C-C and C=C bonds from 
diketones and diols (i.e. Mc Murry, Wolff-Kischner, SmI2). Since many of the 
aforementioned reactions are often solvent-dependent, “incomplete” hydrophobic 
models of 5,6-seco-cobalamins and 5,6-seco-nibalamins were synthesized and screened 
for developing new corrin reconstitution reactions. Results highlight the inertness of the 
so-called “stable yellow corrinoids” with an interrupted electronic system at C5-C6 
towards corrin repair. Although alternative methods for demetallating and forming a 
single C-C bond at positions C5 and C6 were found, a full repair of the corrin 
macrocycle was not achieved.  
 
 
 
Scheme 41. Envisaged reconstitution of 5,6-seco-corrinoids containing Co
III
 or Ni
II
. 
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3.3.1.  Hydrophobic analogues of dioxo and diolmetbalamins  
 
Due to the solvent dependency of some of the C-C and C=C bond forming reactions that 
will be described in section 3.3., the synthesis of hydrophobic B12 derivatives was 
envisaged. One of the main hydrophobic B12 models available is ‘cobester’ (27-CN, 
Scheme 42, see section 1.7.2.).
89
 Photooxygenolysis of 27-CN (Scheme 42, see section 
1.7.2.) led to secocorrins dicyano-14,15-dioxocobester (dicyano-14,15-dioxocobyrinic 
acid heptamethyl ester, 28) and dicyano-5,6-dioxocobester (dicyano-5,6-dioxocobyrinic 
acid heptamethyl ester, 29).
92,109
 
 
 
 
Scheme 42. Synthesis of 28 and 29. 
 
Aiming to extend the library of available hydrophobic Cbls to B12 derivatives containing 
other metals than cobalt, modifications of Werthemann’s procedures to synthesize 
‘cobester’ were applied to dioxo and diolB12 derivatives with other metals than cobalt. 
Within the synthesized metbalamins, those containing Ni
II
 as metal center are the most 
stable derivatives under acidic conditions (see section 3.2.). Therefore, hydrophobic 
models of Ni
II
-containing B12 derivatives were envisaged.  
 
The first studies were conducted with the “southern” modified 14,15-dioxonibalamin 
(30).
98
 The methanolysis of 30 at 80 ºC under acidic conditions led to the replacement 
of the amide side chains by methyl ester groups (Scheme 43). Optimal conversion was 
found after 120 h, with 14,15-dioxonibyrinic acid heptamethyl ester (14,15-
dioxonibester, 31, m/z = 1067.5 6 [M+H]
+
)  being the main product according to UPLC-
MS analysis. According to this spectrum, two main byproducts were identified in the 
crude mixture: 14,15-dioxonibyrinic acid pentamethyl ester (m/z = 1039.5 [M+H]
+
)  
and 14,15-dioxonibyrinic acid hexamethyl ester (m/z = 1053.5 [M+H]
+
). Compound 31 
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was subsequently isolated in 57% yield by flash chromatography (tR = 3.6 min). 
Contrary to “complete” NiII dioxocorrinoids (19, 30), 1H NMR analysis of 31 showed 
broad unresolved peaks that point towards a paramagnetic species. Thus, it was 
assumed that the replacement of all side chains affected the planarity of the secocorrin. 
These observations are in agreement with the geometry of synthetic Ni
II
 corrinoids 
lacking all peripheral side chains, as determined by X-ray crystallography.
110
   
 
 
 
Scheme 43. Synthesis of 31. 
 
Having established the optimal temperature, pH, and reaction time for the synthesis of 
31, these conditions were transferred to the “northern” modified and more reactive 
isomer 5,6-dioxonibester (32, Scheme 44). The reaction progressed in a similar way as 
for the “southern” oxidized derivative 31 and after 120 h, 5,6-dioxonibyrinic acid 
heptamethyl ester (5,6-dioxonibester, 32, m/z = 1067.5 6 [M+H]
+
) was identified as the 
main product of the crude mixture. Again, small fractions of 5,6-dioxonibyrinic acid 
pentamethyl ester (m/z = 1039.5 [M+H]
+
)  and 5,6-dioxonibyrinic acid hexamethyl ester 
(m/z = 1053.5 [M+H]
+
) were found. Isolation of 32 from these side products proved to 
be a demanding task and for our synthetic purposes (synthesis of nibalamins with an 
intact corrin macrocycle) fractions containing small amounts of penta and 
hexasubstituted dioxonibesters were employed.  
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Scheme 44. Synthesis of 32.  
 
The described reaction conditions were also transferred to 5,6-diolnibalamin (22, 
Scheme 44). After 120 h, 5,6-diolnibyric acid heptamethyl ester (5,6-diolnibester, 33, 
m/z = 1069.5 [M+H]
+
) was the main product of the crude mixture, finding also 5,6-
diolnibyric acid hexamethyl ester (m/z = 1055.5, [M+H]
+
) and 5,6-diolnibyric acid 
pentamethyl ester (m/z = 1041.5, [M+H]
+
) as side products. Attemps to purify 33 by 
flash chromatography or preparative HPLC failed and the crude mixture was further 
used for synthetic studies.  
 
 
 
Scheme 45. Synthesis of 33.  
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The synthesis of dioxo and diolnibester derivatives with high temperatures (80 ºC), long 
reaction times (5 days) and under acidic conditions (pH < 1) demonstrated that metal 
ions greatly stabilize the corrin macrocycle. Under milder conditions (pH 2, rt, 
overnight), the metal-free 5,6-dioxo-H-balamin (15) degrades as described in section 
3.2.1. When Ni
II
 is present in the corrin cavity, the equatorial macrocycle remains intact 
under the harsh reaction conditions described above and only the amide side chains are 
slowly replaced by methyl ester groups. With hydrophobic Cbl and nibalamin 
derivatives in hand, endeavors were focused on reconstituting the original π-electronic 
system of the corrin macrocycle.  
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3.3.2.  Attemps to reconstitute the corrin macrocycle of 5,6-seco-cobalamins and 
5,6-seco-nibalamins   
 
a) Reduction with Zn/AcOH  
 
Gossauer and coworkers have extensively studied the structure and reactivity of 
hydrophobic “stable yellow corrinoids”.77-79,107 Concretely, their work led to the 
reductive reconstitution of ‘cobester’ (27-CN) from a yellow ‘cobester’ derivative with 
a corrin macrocycle containing a single bond at C5-C6, a hydroxy group at C5 and a 
hydrogen substituent at C6 (34, Scheme 46, left).
77
 They proposed a reductive ring 
reconstitution in which cobalt plays a fundamental role. Indeed, a metal-centered 
reduction to obtain Co
I
 is completed in the presence of Zn/AcOH. The subsequent 
reoxidation of Co
I
 to Co
III
 pushes two electrons into the A/B methylene bridge, 
achieving the formation of a double bond at positions C5-C6 and thus restoring the 
original delocalized π-electronic system of the corrin macrocycle.  Inspired by that 
work, Zn was added to a soln. of aquacyano-5,6-diolcobalamin (16, Scheme 46, right) 
in acetic acid under a N2(g) atmosphere. However, only complex mixtures were 
observed by UPLC-MS, most likely due to the presence of a hydroxy group at C6 
instead of a hydrogen. 
 
 
 
Scheme 46. Left: reconstitution of 27-CN from 34.  Right:  unsuccessful reconstitution 
of 16 under the same reaction conditions.  
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b) McMurry approach   
 
The use of low-valent titanium reagents for coupling carbonyl or diol functionalities 
into olefins (Scheme 47) has been widely used in organic synthesis during 
decades.
111,112
 Despite the versatility of this reaction and its numerous applications, 
McMurry couplings are highly solvent-dependent and not always reproducible. Within 
our Cbl framework, one of the main synthetic constraints is the choice of solvent: 
vitamin B12 is only soluble in polar solvents like H2O and alcohols of short chain 
(methanol, ethanol). To overcome this limitation, McMurry experiments were 
conducted either in aprotic polar solvents (DMF) or mixtures of apolar solvents 
(Py:dioxane 1:1) that partially dissolve B12 derivatives at high temperatures.  
Alternatively, test reactions were performed with hydrophobic derivatives of B12 
(cobester and nibester derivatives described in section 3.3.1.) that are soluble in solvents 
typically employed for McMurry reactions (i.e. THF).  
 
 
 
Scheme 47. General mechanism for McMurry couplings.   
 
Knowing that the harsh reaction conditions normally required for McMurry couplings 
could affect the corrin macrocycle, preliminary studies were conducted with vitamin 
B12. When 1 was added to a mixture containing low-valent Ti at 100 ºC in either DMF 
or pyridine:dioxane (1:1) for 45 min, a metal-centered reduction of the Co
III
 ion was 
observed but the corrin macrocycle remained intact. Thus, aquacobalamin (1-OH2) was 
obtained as the main product after reoxidation of the crude with air according to MS 
analysis (m/z = 664.9 [M-OH2]
2+
, Scheme 48, top). If the same reaction conditions were 
applied for 90 min, the corrin macrocycle still remained unaltered but the “loop” was 
partially cleaved, leading to mixtures of 1-OH2 and diaquacobinamide (OH2-Cbi) after 
reoxidation (Scheme 48, bottom).  
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Scheme 48. Reactivity of 1 under McMurry conditions. 
 
Once the stability of the corrin macrocycle under McMurry conditions was evaluated, 
the reaction was applied to 5,6-seco-cobalamins. As described in section 3.1. and 3.2., 
the “northern” face of the corrin macrocycle displays an enhanced reactivity towards 
reconstitution. However, when dicyano-5,6-dioxocobalamin (13) or aquacyano-5,6-
diolcobalamin (16) were treated with low-valent Ti in DMF or dioxane:pyridine (1:1),  
the reactivity of the equatorial macrocycle led to complete destruction of the corrin after 
90 min, according to UPLC-MS measurements.  Analogous attempts with 5,6-
diolnibalamin (25) using shorter reaction times (45 min) yielded similar results (Scheme 
49).  
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Scheme 49. Treatment of 13, 16 and 22 and 33 under McMurry conditions. Charges are 
omitted for simplicity.  
 
Taking into account the solvent dependency of the attempted McMurry ring closure, 
preliminary studies were conducted with a hydrophobic derivative of vitamin B12 
containing Ni
II
 as a metal ion: 5,6-diolnibester (33). UV-Vis spectroscopy indicated that 
no changes took place in the corrin macrocycle even after 6 h, with a main band at 433 
nm that remained unaltered throughout the reaction. Indeed, MS analysis showed no 
significant differences between the starting material and the crude mixture.       
 
In summary, the use of McMurry conditions with B12 derivatives leads exclusively to 
reduction of the metal center but leaves the (seco)corrin macrocycle unaltered. 
Additionally, when harsh reaction conditions typical of this method are applied the 
equatorial ligand is eventually destroyed.  
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c) Combined CoCp2 and McMurry approach 
 
Inspired by the effectiveness of CoCp2 to form C-C bonds within 7,8- and 5,6-seco-
corrins (as described in sections 3.1.2. and 3.2.6.), the formation of a double bond 
between C5-C6 in a one-step reaction was attemped by combining CoCp2 with low-
valent Ti. It was envisaged that a) addition of CoCp2 would connect C5 and C6 by a 
single C-C bond and b) low-valent Ti would provide the necessary reducing conditions 
to eliminate the diol moiety at C5-C6 (Scheme 50).  
 
 
 
Scheme 50. General approach for the combined use of CoCp2 and low-valent Ti.  
 
Control experiments were performed with vitamin B12 (1). CoCp2 (6 equiv) was added 
to a soln. of 1 in MeOH under inert atmosphere at 23 ºC. After 30 min, TiCl4 (11 equiv) 
was added to the reduced mixture and temperature was set at 80 ºC for 45 min. UPLC-
MS analysis revealed that this method is harmless for the intact corrin macrocycle, 
triggering only a quantitative metal-centered reduction to 1-OH2 (m/z = 664.9           
[M-OH2]
2+
). Therefore, the same reaction conditions were applied to dicyano-5,6-
dioxocobalamin (13). Surprisingly, 5,6-diol-H-balamin (23) was the main product 
obtained in the reaction as indicated by UPLC-MS (m/z = 1304.6 [M]
-
), even if no KCN 
was added to the reaction mixture as decomplexating agent (Scheme 51). CoCp2 reacted 
as expected reducing Co
III
 to Co
II
 and forming a C-C bond between C5 and C6. On the 
other hand, the addition of TiCl4 did not lead to the desired diol elimination but 
achieved the removal of the reduced cobalt center.  
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Scheme 51. Synthesis of 23 from 13 using CoCp2 and TiCl4.  
 
With this unexpected reactivity and assuming solvents play an important role in low-
valent Ti-mediated couplings, experiments were conducted with hydrophobic cobester 
derivatives in THF. As expected, control experiments with ‘cobester’ (27-CN) 
confirmed the stability of the intact corrin macrocycle under such reaction conditions. 
Again, the only reactivity observed was a partial reduction of the Co
III
 center to form 
diaquacobester (27-OH2, Scheme 52, top). In this case, the reduction of 27-CN to         
27-OH2 was not quantitative most likely due to the presence of additional axial cyanide 
that lowers the reduction potential of the Co
III
 center (see section 3.1.2.). When dicyano-
5,6-dioxocobester (29) was treated analogously, the only remarkable change is also a 
partial metal-centered reduction to yield diaqua-5,6-dioxocobester (29-OH2, Scheme 
52, bottom). In this case, no demetallation of 29 was observed.  
 
 
Scheme 52. Reactivity of 27-CN and 29-CN under the described reduction conditions.   
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d)  SmI2 
 
Since the discovery of SmI2 by Kagan in the 1970s, extensive synthetic applications of 
this reducing agent have been developed.
113,114
 This versatile reagent can complete one 
and two-electron reduction processes and was therefore considered as a suitable 
candidate for performing reductive ring-closing experiments. Additionally, several of 
these SmI2-mediated reactions were performed in advantageous solvent systems for our 
Cbl derivatives, like mixtures of H2O:THF.
114
   
 
Preliminary studies showed that the addition of SmI2 (0.1 M in THF) to a soln. of 1 in 
THF:H2O (5:1) was able to reduce the Co
III
 center while leaving the corrin macrocycle 
unaltered. Consequently, SmI2 is also a convenient reducing agent for synthesizing 1-
OH2. When SmI2 (4.2 equiv) was applied to dicyano-5,6-dioxocobalamin (13) under the 
same reaction conditions, a specific metal-centered reduction was found (Scheme 53). 
The addition of an excess of KCN (11 equiv) to the reduced soln. after different reaction 
times (30 to 90 min) led to 5,6-dioxo-H-balamin (15, Scheme 53, Figure 33).  
 
 
 
Scheme 53. Synthesis of 15 using SmI2.  
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Figure 33. UPLC trace (Method 2, see Materials and Methods) of the reaction crude 
(see Scheme 53).  
 
Observing a metal-centered reactivity, the feasibility of SmI2 as reducing agent for the 
corrin ligand at positions C5 and C6 was tested. For this purpose, 12 equiv of SmI2 were 
added stepwise in three portions over 15 min to a soln. of 13 under inert conditions 
(analogous conditions as in the ring reconstitution with CoCp2 described in section 
3.2.6.).  Unfortunately, no further reactivity of the corrin macrocycle was observed and 
15 remained the main product of the reaction when an excess of KCN was added to the 
reduced reaction mixture.  
 
The reducing agent was tested in a purely organic solvent (THF) with hydrophobic 5,6-
dioxonibalamin (32) and in the presence of LiCl as Lewis acid to increase the reducing 
power of SmI2.
115
 Under these conditions, the addition of SmI2 (9 equiv) to 32 achieves 
the pinacol coupling of the carbonyl moieties at C5 and C6 to form 5,6-diolnibalamin 
(33) in 5 h as observed by MS analysis (m/z = 1069.5 [M+H]
+
). As it was the case in 
previous experiments (see section 3.2.), no further reactivity than the formation of 33 
was found. 
 
All in all, SmI2 proved to be a useful reducing agent for metal-centered reductions and 
the formation of single C-C bonds. This reactivity is in line with that of CoCp2 (see 
sections 3.1. and 3.2.) but does not allow to complete any further step towards the 
synthesis of metbalamins.  
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e) Wolff-Kischner 
 
The Wolff-Kischner reduction was considered as a possible way to close the ring in 5,6-
seco-corrinoids.
116,117
 For this purpose, it was envisaged to first convert the keto moiety 
at C5 into a hydrazine and then evict an N2 group forming a carbene at C5. This reactive 
intermediate would then reconnect C5 and C6, due to the spatial proximity and the 
preorganization of both atoms.  
 
Attempts to form a hydrazone at C5 or C15 of 12 or 13 with p-toluensulfonyl hydrazide 
showed negliglible conversion of the starting material, most likely due to steric 
hindrance. Therefore, the less bulky acetohydrazide was employed. The reaction was 
tested on the “southern” oxidized corrinoid 12, obtaining the best results using a slightly 
acidic aqueous solvent system (pH 5.2) and refluxing the reaction mixture for 4 h. 
Under such conditions, aquacyano-14-oxo-15-acetohydrazonecobalamin (34, m/z = 
1441.5 [M-H]
-
, Scheme 54) was obtained as main product in the crude mixture 
according to UPLC-MS analysis. Attaching acetohydrazone to 12 caused an expansion 
of the π-delocalized system around the D-ring. The additional electrons at 34 affected 
its UV-Vis spectrum, finding a main band (max = 472 nm, log  = 4.0) accompanied by 
a prominent shoulder (max = 530 nm, log  = 3.9). The presence of a hydrazone was 
further confirmed by 
13
C NMR: 64 signals were found for this product (two more than 
in the starting material 12) that correspond to a new quaternary and a new primary 
carbon from the acetohydrazone moiety (figure 34).  
 
 
 
Scheme 54. Synthesis of 34. Delocalized electrons at the D-ring of 12 and 34 are 
marked in red.  
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Figure 34. 
13
C NMR spectrum of 34.  
 
The optimized reaction conditions were transferred to the “northern” oxidized corrin 
macrocycle 13.  Due to the enhanced reactivity of the upper part of the corrin 
macrocycle, quantitative conversion to aquacyano-5-acetohydrazone-6-oxocobalamin 
(35, m/z = 1441.5 [M-H]
-
) was achieved within 30 min according to UPLC-MS analysis 
(Scheme 55). 
 
 
 
Scheme 55. Synthesis of 35. 
 
From the numerous procedures that have been developed during the last decades to 
form a carbene from a hydrazone via liberation of N2, those with mild conditions and 
compatible solvents were tried on 35 (Scheme 56). Cram’s modification of the 
reaction
118
 with potassium terbutoxide in DMSO at 25 ºC was explored but no color 
change was observed in the soln. after 72 h (max = 458 nm). Inspired by Caglioti’s 
work,
119
 a hydride donor (NaBH4) was added to a soln. of 35 under inert atmosphere 
and at 23 ºC. Reduction of the Co
III
 center to Co
II
 was observed by MS as the axial 
cyanide was lost forming 35-OH2 (m/z = 1416 [M-OH2]
-
) but no ligand reactivity was 
found. Encouraged by previous successful experiences on corrin modifications with 
CoCp2 (see sections 3.1. and 3.2.), this one-electron donor was also applied to 35 under 
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inert atmosphere and 23 ºC. However, similar results as with NaBH4 were obtained in 
this case. As observed for 5,6-seco-cobalamins the addition of an excess of KCN after 2 
min of reduction of 35 allowed the identification of the metal-free compound               
5-acetohydrazone-6-oxo-H-balamin (36) by UPLC-MS.   
 
 
Scheme 56. Reactivity of 35 under basic and reducing conditions.  
 
Remarkably, the synthesized hydrazone at C5 is a stable species that resists strong basic 
and reductive conditions and renders the “northern” side of the corrin macrocycle inert 
towards ring reconstitution reactions. The presence of an 8 delocalized π-electronic 
system between the D-ring and the hydrazone moiety might enhances the stability of 34 
and 35, rendering them inert towards carbene formation and hindering the second step 
of the Wolff-Kischner reaction.  
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3.4. Microbiological activity of B12 derivatives  
One of the main goals of this work is the synthesis of B12 antagonists (antivitamins B12) 
to inhibit B12 dependent enzymatic processes. In order to achieve this inhibition, either 
the transport of B12 into cells or the uptake of B12 into the corresponding enzymes must 
be impeded. Consequently, the ideal antivitamin B12 must have high affinity towards 
B12 transporting proteins, ideally in the range of the binding affinities for the natural 
product. Considering the structural complexity of this nutrient and the specificity of B12 
transporting proteins and B12 dependent enzymes, subtle modifications of the  Cbl 
framework were envisaged for accessing antivitamins B12.   
The biological activity of several antivitamin B12 candidates was evaluated with a 
microbiological assay using L. Leichmanii. This gram-positive bacterium is an 
internationally approved organism to assess the biological activity of  vitamin B12 and 
modified B12 surrogates.
49,120
 Indeed, the enzyme ribonucleotide reductase (RNR) in     
L. Leichmanii depends on cofactor B12 (Figure 35).
68
 Thus, when a structurally related 
but catalytically inactive antivitamin B12 is able to compete with B12 for the 
corresponding binding pockets of RNR, the cellular growth of this organism is 
disrupted. Since L. Leichmanii grows forming long opaque filaments in its medium, the 
growth rate of this bacterium can be easily monitored by spectrophotometry ( = 680 
nm).  
 
 
 
Figure 35. B12-dependent enzymatic conversion of ribonucleotides to 
deoxyribonucleotides in L. Leichmannii. 
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3.4.1. Biological evaluation of B-ring modified vitamin B12 derivatives 
 
As described in section 3.1., the reconstitution of B12 (1) from a green 7,8-seco-
corrinoid (2) in 4 steps was implemented. In order to assess the consequences of 
structural modifications of Cbls on their bioactivity and searching for new antivitamins 
B12, competitive assays between B12 and 4, 7 and 11 were performed. In these studies, a 
1000-fold excess of the antivitamin candidates was added  to a bacterial medium 
containing 0.1 nM B12.  
 
As observed in Figure 36, competitive assays between B12 (1) and 4 or 7 demonstrate 
that both B12 derivatives are potent antagonists of the nutrient and can inhibit the growth 
of L. Leichmannii by 50% at 100
 
nM range. In turn this means 4 and 7 may compete 
with 1 for the transporting proteins or for the enzyme, most likely due to their structural 
similarity to the original B12 cofactor (both the corrin macrocycle and the 
stereochemistry of all side chains are identical to those of B12). Indeed, it has been 
found that 4 and 7 diminish the expected catalytic activity from cofactor B12.   
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Figure 36.  Growth of L. Leichmannii at 37 ºC (n = 3) in the presence of 1 and 4 (top), 1 
and 7 (middle) as well as 1 and 11 (bottom).  
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3.4.2. Biological evaluation of reconstituted vitamin B12  
 
Having observed by X-ray crystallography that the final compound of the route is intact 
vitamin B12 (1, see section 3.1.6.), the microbiological assay with L. Leichmannii was 
performed to prove that the biological activity of 1 remains intact independently of its 
origin (bacterial or chemical production).  Concretely, a calibration curve with different 
concentrations of reconstituted B12 in bacterial media was elaborated (Figure 37). An 
increasing growth was found with concentrations from 0.05 nM to 1 nM, confirming 
that reconstituted B12 is an active nutrient for L. Leichmannii. As expected, the bacterial 
growth was identical when the same concentration of microbiologically produced B12 or 
chemically reconstituted B12 was added to two independent L. Leichmannii containing 
media.  
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Figure 37. Growth of L. Leichmannii at 37 ºC (n = 3) with different concentrations of 
reconstituted B12 (0.05, 0.1, 1 nM) and microbially produced B12 (1 nM) .  
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4. Conclusions and outlook   
 
The aim of this work was to establish chemical procedures for the synthesis of 
metbalamins starting from ring-opened secocorrinoids. To obtain metbalamins, it was 
envisaged to 1) demetallate, 2) remetallate and 3) reconstitute the corrin macrocycle of 
different ring-opened B12 derivatives. Herein, two complementary routes towards this 
goal are presented. 
 
1) The 7,8-seco-corrin approach  
The stereospecific reconstitution of vitamin B12 from artificial green 7,8-seco-corrinoids 
was completed in four steps. The key step of this route consists of a quantitative, fast 
and stereospecific ring closure reaction (Scheme 57). For completing this C-C bond 
formation reaction, CoCp2 was introduced as a new reducing reagent and cyanide was 
used as inorganic protecting group to achieve a ligand-centered reduction. Even though 
no demetallation of 7,8-seco-corrinoids was achieved, this route represents the first 
reversible synthesis of B-ring opened B12 derivatives. Importantly, two route 
intermediates are antivitamins B12, as shown by microbiological assays with L. 
Leichmannii. 
 
 
 
Scheme 57. Four-step synthesis of vitamin B12 from a 7,8-seco-corrinoid.  
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2) The 5,6-seco-corrin approach  
The synthesis of metal-modified B12 derivatives was achieved in three steps. The crucial 
reaction in this project is the one-step demetallation and ring closure of dicyano-5,6-
dioxocobalamin (Scheme 58, left). In this unprecedented method, CoCp2 was used as 
metal and ligand reducing agent and KCN was employed for the extraction of cobalt. 
With 5,6-diol-H-balamin in hand, Ni
II
, Zn
II
 and Cu
II 
 were incorporated to the corrin 
cavity obtaining diolmetbalamins. These are a new family of compounds that only differ 
from B12 in its metal center and the presence of a diol moiety instead of a double bond 
at positions C5 and C6. 
 
 
 
Scheme 58. Three-step synthesis of 5,6-diolmetbalamins.  
 
In summary, two routes towards the synthesis of metbalamins from secocorrinoids are 
presented. In both approaches, the corrin macrocycle was reconstituted under reducing 
conditions using CoCp2 as electron donor. However, the different electronic properties 
of 7,8- and 5,6-seco-corrinoids led to completely opposite results when cyanide was 
introduced. Indeed, while this ligand acted as a protecting group for the cobalt center in 
7,8-seco-corrinoids, it behaved as a decomplexating agent for 5,6-seco-corrinoids and 
hence allowed the synthesis of 5,6-diol-metbalamins.      
 
These results pose two major challenges to complete a chemical route towards 
metbalamins: 1) eliminate the diol moiety of 5,6-diolmetbalamins and 2) demetallate 
7,8-seco-corrinoids. 
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5. List of compounds  
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6. Experimental  
 
6.1.  Materials and Methods  
 
Materials: Chemicals were of reagent grade quality or better, obtained from 
commercial suppliers and used without further purification. Vitamin B12 was a generous 
gift from DSM Nutritional products AG (Basel/Switzerland) and Prof. B. Jaun (retired 
ETH Zurich). All solvents were of reagent, analytical, HPLC or LC-MS grade 
respectively and obtained from commercial suppliers. Bidistilled water was used in all 
reactions. Millipore water was used in UPLC measurements.   
 
 
UPLC: UPLC-MS spectra were recorded on an Acquity Waters system equipped with a 
PDA detector and an autosampler using an ACQUITY UPLC BEH C18 Gravity 1.7 μm 
(2.1 mm × 50 mm) reverse phase column. The UPLC system was connected to a Bruker 
Daltonics HCT ESI-MS spectrometer. A total volume of 1 μL of a sample soln. was 
analysed. All solvents used were of LC-MS grade.  
 
- Method 1: A gradient (0 min 5% A, 0.5-2 min 30% A, 2-4 min 100% A, 4-5 min 
100% A) of acetonitrile (solvent A) versus an aq. soln. of 0.1% HCOOH 
(solvent B) was applied using a flow rate of 0.3 mL/min. 
- Method 2: A gradient (0 min 14% A, 0.5-4 min 20% B, 4-4.1 min 100% B, 4.1-
5 min 100%A) of acetonitrile (solvent A) versus an aq. soln. of 0.1% HCOOH 
(solvent B) was applied using a flow rate of 0.3 mL/min. 
 
Preparative HPLC: Separations were conducted on a VWR LaPrep system equipped 
with a PDA detector and Nucleosil C18 250/21 or Nucleosil C18 250/40 columns from 
Macherey-Nagel.  
 
- Method 3: A gradient (0 min 25% C, 0.5-30 min 60% C, 30-30.1 min 100% C, 
30.1-40 min 100% C) of MeOH (solvent C) versus an aq. soln. of 0.1% 
CF3COOH (solvent D) was applied using a flow rate of 16 mL/min. 
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- Method 4: A gradient (0 min 25% C, 0.5-30 min 60% C, 30-30.1 min 100% C, 
30.1-40 min 100% C) of MeOH (solvent C) versus an aq. soln. of 0.1% 
CH3COOH (pH 5, solvent E) was applied using a flow rate of 16 mL/min. 
- Method 5: A gradient (0 min 20% B, 0.5-30 min 26% B, 30-30.1 min 100% B, 
30.1-40 min 100% B) of CH3CN (solvent B) versus an aq. soln. of 0.1% 
CH3COOH (pH 5, solvent E) was applied using a flow rate of 18 mL/min. 
- Method 6: A gradient (0 min 20% B, 0.5-40 min 30% B, 40-40.1 min 100% B, 
40.1-50 min 100% B) of CH3CN (solvent B) versus an aq. soln. of 0.1% 
CH3COOH (pH 5, solvent E) was applied using a flow rate of 18 mL/min. 
- Method 7: CH3CN (19%; solvent A) versus an aq. soln. of 0.1% CF3COOH 
(solvent D) was applied for the iscratic elution using a flow rate of 40 mL/min.  
 
ESI-MS: Spectra were recorded on a Bruker Daltonics HTC ESI-MS operated in the 
positive or negative mode. Injection rate 3 L/min. Nebulizer P =10 psi, dry gas flow 
rate 5 L/min, gas T = 350 ºC. All solvents used were of LCMS grade. 
 
HR-ESI-MS: Spectra were recorded on a Bruker maXis QTOF-MS instrument (Bruker 
Daltonics GmbH, Bremen, Germany). The samples were dissolved in MeOH and 
analyzed via continuous flow injection at 3 µL/min. The mass spectrometer was 
operated either in positive or negative ion mode with a capillary voltage of 4 kV, an 
endplate offset of –500 V, nebulizer pressure of 5.8 psig, and a drying gas flow rate of 4 
L/min at 180°C. The instrument was calibrated with a sodium formate soln. (500µl 
H2O: 500µl iPrOH: 20µl HCOOH: 20µl 0.1M NaOHaq). The resolution was optimized 
at 30.000 FWHM in the active focus mode. The accuracy was better than 2 ppm in a 
mass range between m/z 118 and 1600. 
Spectroscopy: UV-Vis spectra were recorded on a Varian Cary 50 using quartz cells 
with a path length of 1 cm. Citation of λmax (log ε) in nm. 
1
H- and 
13
C-NMR as well as 
2D-NMR spectra were recorded on a 500 MHz Oxford NMR AS 500 using a QNP 
probehead and MestReNova 6.0.2 as evaluation tool. All spectra were recorded in D2O 
at 300 K and TSP was used as a reference for all 
13
C-NMR experiments.  
Electrochemistry: Electrosynthesis was performed in a 50 mL five-necked round 
bottom flask containing three electrodes: a Pt-net (working electrode), a Pt wire 
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(counterelectrode) and an Ag/AgCl (3M) reference electrode. The electrodes were 
connected to AMEL Potentiostat Mod. 549 and compounds were dissolved in an 
electrolyte soln. (0.1 M TRIS in H2O, pH 8.1).  
Solid Phase Extraction: Chromafix C18ec columns were applied for solid phase 
extraction (SPE). The compounds were dissolved in water, transferred to the adsorbent, 
washed with water and eluted with MeOH. 
Bacterial growth tests: B12 dependent Lactobacillus leichmannii was purchased (as 
strain DSMZ 20355, ATCC 7830) from the German Collection of Microorganisms and 
Cell Cultures (Braunschweig, Germany). For maintenance, stock cultures Lactobacillus 
were routinely grown overnight in Difco Microinoculum broth at 30 °C. The medium 
was centrifuged after 24 h (3 min x 5000 rpm), the supernatant was removed and the 
pellet was washed three times with sterile 0.9 % NaCl. Vitamin B12 Assay Medium 
(#82897; Fluka, Buchs, Switzerland) was prepared in 8 mL screw cap test tubes 
according to the supplier’s instructions and sterilized (15 min at 121 °C). Dilutions of 
B12 were added to the medium using sterile filters (0.22 µm) followed by the addition of 
a 50 µL inoculum. All growth experiments were always performed in triplicates at       
37 °C. Growth was monitored spectrophotometrically at 680 nm at time intervals of 2-3 
h. 
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6.2.  Experimental procedures  
 
Cyanocobalamin (1): 11 (11 mg, 8 mol, 1 
equiv) was dissolved in NH4Cl (4M; 4 mL) and 
EDC.HCl (150 mg, 780 mol, 10 equiv) was 
added. The mixture was stirred overnight at 23 ºC, 
purified with solid phase extraction and then with 
preparative HPLC (Method 3). Lyophilization 
afforded 1 (2.3 mg, 2 mol, 21%) as a red 
powder.   
 
UV-Vis (H2O, c = 1.3 x 10
-5 M)  /nm (log) = 
279 (4.4), 306 (4.3), 321 (4.1), 361 (4.5), 411 
(4.0), 512 (4.0), 522 (4.1). ESI-MS (H2O) m/z = 1355.6 [M+H]
+, 678.6 [M+2H]2+ 
(m/zcalc: 1355.6). HR-ESI-MS (H2O)  m/z= 678.29106  [M+2H]
2+ (m/zcalc: 678.29098) 
UPLC (Method 1)   tR = 1.7 min.  
1H-NMR (D2O, 500 MHz) /ppm  = 7.29 (s, 1H), 
7.10 (s, 1H), 6.52 (s, 1H), 6.36 (d, J = 3.2 Hz, 1H), 6.09 (s, 1H), 4.28 (m, 2H), 4.20 (m, 
1H), 4.07 (m, 2H), 3.92 (m, 1H), 3.76 (dd, J = 12.9, 3.9 Hz, 1H), 3.59 (d, J = 14.7 Hz, 
1H), 3.41 (dd, J = 11.4, 5.3 Hz, 1H), 2.97-0.99 (m, 40H), 2.59 (s, 3H), 2.55 (s, 3H), 2.27 
(s, 6H), 1.88 (s, 3H), 1.46 (s, 3H), 1.41 (s, 3H), 1.40 (s, 3H), 1.27 (d, J = 6.3 Hz, 3H), 
1.21 (s, 3H), 0.46 (s, 3H). 13C-NMR (D2O, 126 MHz) /ppm  = 182.8, 181.6, 180.9, 
180.6, 179.8, 179.6, 178.5, 178.4, 177.8, 177.5, 176.3, 168.8, 168.0, 144.5, 139.4, 
137.9, 135.8, 132.7, 119.2, 114.2, 110.3, 106.8, 97.7, 89.8, 87.8, 84.9, 77.7, 75.7, 75.7, 
71.5, 63.1, 61.9, 59.0, 58.4, 56.4, 54.2, 50.9, 50.0, 48.0, 45.6, 45.5, 41.7, 37.6, 37.3, 
35.3, 34.9, 34.3, 34.2, 34.0, 30.8, 28.7, 28.7, 22.7, 22.6, 22.2, 22.1, 22.0, 21.9, 19.5, 
18.5, 18.1, 17.9. 
 
Co-cyano-71-bromo-7,8-seco-cobalamin (2): synthesized according to literature 
procedures.98  
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Co-cyano-71-chloro-7,8-seco-cobalamin (3): synthesized according to literature 
procedures.98  
 
Co-cyano-8-hydroxy-cobalamin-c-acid (4): 
Method a: 7,8-seco-corrinoid 2 (38 mg, 26 
mol, 1 equiv) was dissolved in ddH2O (2 mL) 
and NaBH4 (1.5 mg, 39mol, 1.5 equiv) was 
added to the stirred soln. An immediate colour 
change from green to dark red was observed. 
The mixture was stirred for 45 min and then 
purified by solid phase extraction and 
preparative HPLC (Method 4). 4 was obtained as 
a red powder (12 mg, 9mol, 33%) after 
lyophilization.  
 
Method b: 7,8-seco-corrinoid 2 (20 mg, 14 mol, 1 equiv) and KCN (11 mg, 170 mol, 
12 equiv) were dissolved in MeOH (4 mL). The mixture was stirred for 30 min. 
Subsequently, the dark green soln. was purged with N2(g) for 15 min and CoCp2 (10 mg, 
53 mol, 4 equiv) was added in a nitrogen atmosphere. The mixture turned immediately 
violet. Quantitative conversion to Co-dicyano-8-hydroxy-cobalamin-c-acid (4-CN) 
was observed within 5 min according to MS measurements (m/z = 1380.6 [M]-). The pH 
of the soln. was adjusted to 6 with an aq. soln. of CH3COOH (2 M) and stirred at     23 
ºC for 1 h until the soln. turned red. Solvents were removed under reduced pressure. The 
red product 4 was dissolved in ddH2O and purified with solid phase extraction. The 
solvent was evaporated and 4 was isolated in good yields (16 mg, 12 mol, 86%) after 
lyophilization.  
Note: When TEMPO (4 equiv) was added to the mixture immediately before the 
addition of CoCp2, no colour change was observed and UPLC-MS analysis yielded a 
single peak at tR = 2.2 min and m/z = 1450.4 [M+H]
+, corresponding to the starting 
material (2).  
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UV-Vis (H2O, c = 1.6 x 10
-5
 M)  / nm (log) = 278 (4.3), 306 (4.1), 360 (4.5), 410 
(3.9), 517 (4.0), 552 (4.0). UPLC (Method 1) tR = 1.7  min. ESI-MS (H2O) m/z = 
1372.5 [M+H]
+ 
(m/zcalc: 1372.6). HR-ESI-MS m/z= 686.78065 [M+2H]
2+ 
(m/zcalc: 
687.78279). 
1
H NMR (500 MHz, D2O) δ/ppm = 7.27 (s, 1H), 7.10 (s, 1H), 6.45 (s, 1H), 
6.35 (d, J = 3.2 Hz, 1H), 6.16 (s, 1H), 4.30 (dd, J = 10.4, 6.5 Hz, 3H), 4.08 (m, 4H), 
3.95 (dd, J = 12.7, 2.3 Hz, 1H), 3.77 (dt, J = 12.4, 6.3 Hz, 2H), 3.62 (m, 2H), 3.36 (d, J 
= 6.6 Hz, 1H), 2.96-1.10 (m, 35 H), 2.58 (s, 3H), 2.56 (s, 3H), 2.25 (s, 3H), 2.23 (s, 3H), 
1.86 (s, 3H), 1.50 (s, 3H), 1.41 (s, 3H), 1.38 (s, 3H), 1.26 (s, 3H), 1.21 (s, 3H), 0.59 (dd, 
J = 21.7, 9.6 Hz, 1H), 0.42 (s, 3H). 
13
C NMR (126 MHz, D2O) δ/ppm = 182.8, 181.8 , 
181.7, 180.9 , 180.5, 180.2, 179.4, 178.5, 178.4, 177.5, 176.7, 168.7, 166.4, 144.4, 
139.5, 138.0, 135.9, 132.6, 119.0, 114.2, 109.4, 107.3, 95.4, 89.8, 88.4, 87.9, 84.7, 77.6, 
75.7, 75.6, 71.5, 63.0, 62.0, 59.4, 57.4, 56.5, 51.1, 49.9, 48.0, 45.9, 45.5, 41.7, 37.6, 
37.3, 36.1 , 35.3, 35.0, 34.2, 33.9, 31.7, 30.8, 28.8, 22.6, 22.1, 22.0, 21.8, 21.7, 20.0, 
19.5, 18.6, 17.9. 
 
 
Co-cyano-
7
-dehydro-7-decarboxymethyl-8-decarboxyethyl-cobalamin (5): 7,8-
seco-corrinoid 2 (20 mg, 14 mol, 1 equiv) was dissolved in ddH2O (2 mL) and NaBH4 
(0.8 mg, 21mol, 1.5 equiv) was added to the stirred 
soln. at 23 ºC. An immediate color change from green 
to dark red was observed. The mixture was stirred for 
45 min and then purified by solid phase extraction and 
preparative HPLC (Method 3), yielding 5 as a blue 
powder (1 mg, 1mol, 6%) after lyophilization. Note: 
The main product in this reaction was 4 (33%) and 6 
was also obtained as a side-product.    
 
UV-Vis (H2O,  c = 2.5 x 10
-5
 M)  / nm (log) = 278 
(4.4), 359 (4.4), 432 (3.9), 623 (4.1). UPLC (Method 1) 
tR = 2.6  min. ESI-MS (H2O) m/z = 1225.6 [M+H]
+ 
(m/zcalc: 1225.5). HR-ESI-MS m/z 
= 613.25401 [M+2H]
2+ 
(m/zcalc: 613.25387). 
1
H NMR (500 MHz, D2O) δ/ppm = 7.06 
(s, 1H), 6.99 (s, 1H), 6.44 (s, 1H), 6.28 (s, 1H), 5.87 (s, 1H), 4.70 (td, J = 8.8, 4.3 Hz, 
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1H), 4.31 (d, J = 8.5 Hz, 1H), 4.26 (d, J = 3.4 Hz, 1H), 4.16 (d, J = 6.3 Hz, 1H), 4.09 (d, 
J = 10.9 Hz, 2H), 3.96 (d, J = 11.1 Hz, 1H), 3.77 (dd, J = 12.9, 4.4 Hz, 1H), 3.65 (d, J = 
14.4 Hz, 1H), 3.48 (d, J = 10.3 Hz, 1H), 2.94-1.71 (m, 19H), 2.72 (s, 6H), 2.68 (s, 3H), 
2.28 (s, 3H), 1.92 (s, 3H), 1.50 (s, 3H), 1.42 (s, 3H), 1.35 (s, 3H), 1.28 (d, J = 6.3 Hz, 
3H), 1.20 (s, 3H), 0.42 (s, 3H). 
13
C NMR (126 MHz, D2O) δ/ppm = 182.0, 181.1, 
181.1, 180.9, 180.5, 178.4, 178.4, 177.5, 169.2, 164.7, 155.7, 150.9, 144.2, 139.2, 
137.1, 135.8, 132.4, 118.5, 116.3, 113.9, 108.3, 95.5, 89.7, 89.1, 84.9, 78.7, 75.9, 75.5, 
74.5, 71.5, 64.3, 63.4, 63.3, 62.0, 59.2, 56.7, 51.4, 50.3, 48.2, 44.7, 41.7, 37.6, 37.1, 
35.8, 35.2, 34.2, 33.9, 30.9, 28.3, 23.6, 22.6, 22.3, 21.8, 19.3, 19.0, 18.8, 18.1, 14.8. 
 
 
Co-cyanocobalamin-c-lactone (7): 7,8-seco-
corrinoid 2 (20 mg, 14 mol, 1 equiv) and KCN 
(11 mg, 170 mol, 12 equiv) were dissolved in 
MeOH (4 mL). The mixture was stirred for 30 
min. Subsequently, the dark green soln. was 
purged with N2(g) for 15 min and CoCp2 (10 mg, 
53 mol, 4 equiv) was added in a nitrogen 
atmosphere. The mixture turned immediately 
violet. Quantitative conversion to Co-dicyano-
8-hydroxy-cobalamin-c-acid (4-CN) was 
observed within 5 min according to MS 
measurements (m/z = 1380.6 [M]-). The pH was 
adjusted to 3 with an aq. soln. of CH3COOH (2 M) and stirred at 23 ºC and solvents 
were removed under reduced pressure. The crude was stirred overnight in an aq. soln. of 
CF3COOH (0.1%, 3 mL), affording quantitative conversion to 7. The red soln. was 
desalted with solid phase extraction. The solvents were removed under reduced pressure 
yielding 7 in good yields (16 mg, 12 mol, 85%).  
Alternatively, 7 was also synthesized according to literature procedures121 in 91% yields 
starting from 1 and used as reference. 
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UV-Vis (H2O, 1.8 x 10
-5 M):  / nm (log 278 (4.3), 305 (4.2), 359 (4.5), 409 (3.9), 
522 (4.0), 551 (4.0). UPLC (Method 1) tR = 2.0 min. ESI-MS (H2O): m/z = 1354.6 
[M+H]+, 677.9 [M+2H]2+ (m/zcalc: 1354.5). HR-ESI-MS (H2O): m/z = 677.77521 
[M+2H]2+ (m/zcalc: 677.77516). 
1H NMR (D2O, 500 MHz) /ppm  =  7.32 (s, 1H), 7.12 
(s, 1H), 6.44 (s, 1H), 6.37 (d, J = 3.2 Hz, 1H), 6.09 (s, 1H), 4.29 (m, 2H), 4.20 (dd, J = 
8.9, 1.9 Hz, 1H), 4.09 (m, 2H), 3.93 (dd, J = 12.9, 2.4 Hz, 1H), 3.75 (dd, J = 12.9, 4.0 
Hz, 1H), 3.61 (d, J = 14.4 Hz, 1H), 3.38 (d, J = 9.8 Hz, 1H), 3.31 – 3.26 (m, 1H), 3.00 – 
2.92 (m, 2H), 2.85-1.15 (m, 35H), 2.61 (s, 3H), 2.57 (s, 3H), 2.29 (s, 3H), 2.27 (s, 3H), 
1.93 (s, 3H), 1.49 (s, 3H), 1.42 (s, 3H), 1.38 (s, 3H), 1.26 (d, J = 6.3 Hz, 3H), 1.17 (s, 
3H), 0.50 (s, 3H). 13C NMR  (D2O, 126 MHz): /ppm = 183.0, 182.5, 182.2, 180.8, 
180.5, 179.1, 178.8, 178.5, 178.4, 177.4, 169.8, 168.6,165.1, 144.7, 139.7, 138.1, 136.1, 
132.9, 118.2, 114.7, 109.7, 108.6, 98.1, 94.6, 90.0, 88.00, 84.9, 78.4, 75.9, 75.7, 75.1, 
71.6, 63.2, 62.1, 59.3, 56.5, 55.1, 51.7, 50.1, 45.5, 44.3, 41.8, 37.7, 37.2, 35.3, 35.1, 
34.2, 33.6, 32.0, 31.6, 30.7, 28.8, 22.8, 22.3, 22.1, 21.9, 21.8, 21.8, 19.5, 19.1, 18.8, 
18.0. 
 
 
Co-7-bromo-71-methyl-7,8-seco-cobalamin (8): synthesized according to literature 
procedures.
98
  
 
 
Co-7-chloro-71-methyl-7,8-seco-cobalamin (9): synthesized according to literature 
procedures.
98
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 Co-cyano-8-hydroxy-cobalamin-epi-c-acid (10): 
Method a: Rearranged 7,8-seco-corrinoid 898 (13 
mg, 9 mol, 1 equiv) was dissolved in ddH2O (2 
mL) and NaBH4 (1.5 mg, 39mol, 4 equiv) was 
added to the stirred soln. at 23 ºC. An immediate 
color change from green to dark red was 
observed. After 1 h, an aq. soln. of CF3COOH 
(0.1%, 2 mL) was added and the mixture was 
stirred overnight at 23 ºC. The product was 
desalted by solid phase extraction and 10 was 
obtained as a red powder (11 mg, 8 mol, 89 %) 
after lyophilization.  
 
Method b: Rearranged 7,8-seco-corrinoid 898 (14 mg, 10 mol, 1 equiv) and KCN (16 
mg, 244 mol, 24 equiv) were dissolved in MeOH (3 mL). The mixture was stirred for 
30 min. Subsequently, the dark green soln. was purged with N2(g) for 15 min and CoCp2 
(8 mg, 42 mol, 4 equiv) was added in a nitrogen atmosphere. The mixture turned violet 
within seconds. Quantitative conversion to Co-dicyano-8-hydroxy-7-epicobalamin-
c-acid (10-CN) was observed within 5 min according to MS measurements. The pH of 
the soln. was adjusted to 3 with an aq. soln. of CF3COOH (0.5%) and stirred at 23 ºC 
overnight. Solvents were removed under reduced pressure. The red product 10 was 
dissolved in ddH2O and purified with solid phase extraction. The solvent was 
evaporated and 10 was isolated in good yields (12 mg, 9 mol, 89 %) after 
lyophilization.  
 
UV-Vis (H2O, 1.8 x 10
-5 M):  / nm 
(log  UPLC (Method 
1)  tR = 1.9 min. ESI-MS (H2O) m/z = 1372.6 [M+H]
+ (m/zcalc: 1372.6). 
1H NMR (D2O, 
500 MHz) /ppm  =  7.27 (s, 1H), 7.08 (s, 1H), 6.42 (s, 1H), 6.35 (d, J = 2.9 Hz, 1H), 
6.01 (s, 1H), 4.30 (dd, J = 10.3, 6.5 Hz, 3H), 4.17 (d, J = 7.2 Hz, 1H), 4.07 (t, J = 9.0 
Hz, 3H), 3.92 (m, 2H), 3.77 (dd, J = 12.7, 3.4 Hz, 2H), 3.63 (m, 3H), 3.35 (d, J = 8.0 
Hz, 2H), 3.18 (m, 2H), 2.96 (dd, J = 14.3, 9.5 Hz, 2H), 2.77-1.13 (m, 15H), 2.58 (s, 3H), 
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2.56 (s, 3H), 2.25 (s, 6H), 1.48 (s, 3H), 1.40 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H), 1.25 (s, 
3H), 1.20 (s, 3H), 0.43 (s, 3H). 13C NMR  (D2O, 126 MHz): /ppm = 182.8, 182.1, 
181.6, 180.7, 180.3, 179.9, 179.4, 178.3, 178.2, 177.4, 174.5, 168.5, 166.9, 144.2, 
139.3, 137.8, 135.7, 132.5, 118.8, 114.1, 109.2, 107.1, 94.7, 89.6, 87.7, 86.9, 84.5, 77.5, 
75.5, 75.4, 71.3, 62.9, 61.7, 59.0, 57.4, 56.2, 50.9, 49.7, 47.8, 45.3, 43.8, 41.6, 37.3, 
37.1, 35.8, 35.1, 34.8, 34.0, 33.8, 31.5, 30.6, 28.8, 22.4, 21.9, 21.8, 21.7, 21.5, 21.1, 
19.3, 18.6, 18.3, 17.7. 
 
 
Co-cyanocobalamin-c-monocarboxylic acid 
(11): 7 (16 mg, 12 mol, 1 equiv) was dissolved 
in ddH2O (2 mL). NaBH4 (1.4 mg, 38 mol, 3 
equiv) was added and the red soln. was stirred for 
20 min at 23 ºC. Afterwards a second portion of 
NaBH4 (1.4 mg, 38 mol, 3 equiv) was added and 
the resulting mixture was stirred for further 20 
min at 23 ºC. The product was subsequently 
purified with solid-phase extraction. The solvent 
was evaporated under reduced pressure and 11 
was isolated by preparative HPLC (Method 3), 
affording 11 (6.5 mg, 5 mol, 42%) as a red 
powder after lyophilization.  
Alternatively, 11 was synthesized from 1 according to literature procedures in two steps 
and 44% yields. This compound was used as a reference.104  
 
UV-Vis (H2O, c = 1.8 x 10
-5 M):  /nm (log 279 (4.3), 305 (4.1), 323 (4.1), 361 
(4.5), 410 (3.9), 516 (4.0), 551 (4.0). UPLC (Method 1) tR = 1.8 min. ESI-MS (H2O) 
m/z = 1356.5 [M+H]+, 678.9 [M+2H]2+ (m/zcalc : 1356.6). HR-ESI-MS (H2O): m/z = 
678.78326 [M+2H]2+ (m/zcalc = 678.78299). 
1H-NMR (D2O, 500 MHz) /ppm = 7.29 
(s, 1H), 7.10 (s, 1H), 6.51 (s, 1H), 6.36 (s, 1H), 6.09 (s, 1H), 4.29 (s, 3H), 4.12 (m, 3H), 
4.08 (d, J = 12.1 Hz, 3H), 3.93 (d, J = 12.1 Hz, 2H), 3.77 (m, 2H), 3.62 (d, J = 14.0 Hz, 
2H), 3.48 (dd, J = 10.9, 5.0 Hz, 2H), 3.34 (d, J = 10.0 Hz, 2H), 2.97 (dd, J = 14.2, 9.3 
Hz, 2H), 2.80-0.99 (m, 28 H)  2.58 (s, 3H), 2.56 (s, 3H), 2.27 (s, 6H), 1.87 (s, 3H), 1.46 
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(s, 3H), 1.42 (s, 3H), 1.39 (s, 3H), 1.26 (d, J = 6.1 Hz, 3H), 1.19 (s, 3H), 0.46 (s, 3H). 
13C-NMR  (D2O, 126 MHz) /ppm  =  182.8, 181.7, 181.0, 180.6, 179.9, 179.8, 178.6, 
178.5, 177.6, 177.3, 176.4, 168.8, 168.4, 144.7, 139.6, 137.9, 135.9, 132.8, 120.5, 
119.3, 118.1, 114.3, 109.9, 106.9, 97.6, 89.9, 87.9, 84.8, 77.8, 75.9, 75.8, 71.7, 63.2, 
62.0, 59.3, 57.9, 56.5, 53.5, 50.9, 50.0, 45.6, 44.6, 41.8, 37.7, 37.4, 35.4, 35.1, 34.5, 
34.3, 34.1  30.9, 28.9, 22.7, 22.2, 22.1, 22.0, 21.9, 21.9, 19.6, 18.7, 18.2, 18.0. 
 
Dicyano-14,15-dioxocobalamin (12): synthesized according to literature procedures.
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 Dicyano-5,6-dioxocobalamin (13): The 
photooxigenation of B12 was performed with 
modifications based on the procedure described by 
Kräutler and Stepánek.
93,94
 Vitamin B12 (240 mg, 
177 mol, 1 equiv), KCN (14 mg, 215 mol, 1.2 
equiv) and the photosensitizer MB (7 mg, 22 mol, 
0.1 equiv) were dissolved in O2(g)-saturated 
CH3OD (8 mL). The mixture was irradiated with a 
250 W halogen lamp and bubbled with O2(g) (1 
bubble per second) for 8 h. The solvent was 
subsequently removed under reduced pressure and 
the crude was purified by preparative HPLC 
(Method 7), obtaining dicyano-5,6-dioxocobalamin (66 mg, 47 mol, 27%) as a blood-
orange powder after lyophilization.   
 
UV-Vis (H2O, c = 4.5 x 10
-5 
M):  /nm 
(logshUPLC (Method 2)  tR = 
2.3 min. ESI-MS  (H2O) m/z = 1412.6 [M]
-
, (m/zcalc: 1412.6). 
1
H-NMR (D2O, 500 
MHz) /ppm = 8.41 (s, 1H), 7.57 (s, 1H), 7.49 (s, 1H), 6.44 (d, J = 4.7 Hz, 1H), 5.87 (s, 
1H), 4.86 (dt, J = 7.7, 5.3 Hz, 2H), 4.62 (d, J = 3.0 Hz, 1H), 4.43(dd, J = 10.9, 5.8 Hz, 
1H), 3.95 (dd, J = 12.6, 2.5 Hz, 1H), 3.85 (dd, J = 12.7, 4.2 Hz, 1H), 3.77 (d, J = 10.2 
Hz, 1H), 3.72 (dd, J = 6.7, 4.0 Hz, 1H), 3.46 (dd, J = 14.3, 3.3 Hz, 1H), 3.33 (dd, J = 
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14.1, 5.6 Hz, 1H), 3.12 (dd, J = 7.7, 3.4 Hz, 1H), 2.98 (m, 2H), 2.71-1.12 (m, 40H)  2.42 
(s, 3H), 2.40 (s, 3H), 2.12 (s, 3H), 1.71 (s, 3H), 1.33 (s, 6H), 1.30 (d, J = 6.3 Hz, 3H), 
1.21 (s, 3H), 1.16 (s, 3H), 0.91 (s, 3H).  
13
C NMR (D2O, 126 MHz) /ppm =  201.0, 
191.9, 190.1, 186.4, 181.1, 181.0, 180.8, 180.3, 178.7, 178.2, 177.7, 177.6, 163.7, 
145.4, 143.2, 136.3, 135.3, 134.5, 121.6, 120.3, 118.0, 114.0, 90.3, 88.5, 86.1, 77.6, 
77.0, 75.0, 74.9, 73.9, 63.8, 62.0, 61.7, 56.4, 51.8, 51.00, 49.6, 47.6,  44.6, 44.2, 44.2, 
42.5, 42.5, 37.1, 36.6, 35.9, 35.2, 34.6, 34.4, 29.5, 28.7, 26.8, 24.7, 22.6, 22.2, 22.0, 
21.5, 21.3, 20.6, 20.2, 19.1, 17.7. 
 
14,15-dioxo-H-balamin (14): synthesized according to literature procedures.
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5,6-dioxo-H-balamin (15): 
Method a, electrosynthesis: 13 (40 mg, 28 mol, 
1 equiv) was dissolved in ddH2O (0.1 M TRIS in 
H2O, pH 8.1, 35 mL), which was added to the 
electrochemical reactor (see Materials and 
Methods). The soln. was purged with N2(g) for 15 
min. A reducing potential (E = -0.9V vs. Ag/AgCl 
3M) was applied at 50 ºC and the soln. turned 
gradually darker. The voltage was turned off after 
2 h and an excess of KCN (200 mg, 3 mmol, 107 
equiv) was immediately added to the brown soln., 
which turned bright orange within 1 min. The crude was stirred at 23
 
ºC for 30 min and 
then purified by solid phase extraction and preparative HPLC (Method 5). 15 (8 mg, 6 
mol, 22%) was obtained as a yellow powder after lyophilization.  
 
Method b, chemical synthesis: 13 (18 mg, 13 mol, 1 equiv) was dissolved in ddH2O 
(0.1 M TRIS in H2O, pH 8.1, 3 mL) and the soln. was purged with N2(g) for 15 min. 
CoCp2 (12 mg, 63 mol, 5 equiv) was added to the blood orange soln. in a nitrogen 
atmosphere and the soln. turned brown within seconds. After 2 min an excess of KCN 
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(93 mg, 1.4 mmol, 107 equiv) was added at once. The soln. turned dark yellow within 1 
min and was stirred in the presence of cyanide for 30 min. The crude was subsequently 
purified with solid phase extraction and preparative HPLC (Method 5), thus affording 
15 (3.5 mg, 3 mol, 27%) as a yellow powder after lyophilization. 
 
UV-Vis (H2O, c = 4.5 x 10
-5 
M):  /nm (log 280 (4.0), 289 (4.0), 379 (3.9). UPLC 
(Method 2) tR = 2.5 min. ESI-MS (H2O) m/z = 1302.7 [M]
-
, (m/zcalc : 1302.6). HR-ESI-
MS (H2O) m/z= 1302.63042 [M]
-
 (m/zcalc: 1302.62933). 
1
H-NMR (D2O, 500 MHz) 
/ppm = 8.40 (s, 1H), 7.53 (s, 1H), 7.44 (s, 1H), 6.43 (d, J = 4.5 Hz, 1H), 5.42 (s, 1H), 
4.58 (dd, J = 8.2, 4.1 Hz, 2H), 4.44 (m, 2H), 4.29 (d, J = 3.7 Hz, 1H), 3.95 (dd, J = 12.6, 
2.9 Hz, 2H), 3.84 (dd, J = 12.6, 4.2 Hz, 2H), 3.44 (m, 3H), 3.27 (dd, J = 14.1, 3.3 Hz, 
1H), 3.12 (dd, J = 8.4, 4.9 Hz, 1H), 3.08 (d, J = 12.9 Hz, 1H), 2.77-1.45 (m, 33H), 2.45 
(s, 3H), 2.37 (s, 3H), 2.35 (s, 3H), 1.70 (s, 3H), 1.41 (s, 3H), 1.27 (s, 3H), 1.26 (s, 3H), 
1.25 (s, 3H), 1.15 (s, 3H), 1.03 (s, 3H), 0.98 (s, 3H), 0.72 (s, 3H). 
13
C-NMR  (D2O, 126 
MHz) /ppm  =  206.3, 192.9, 186.3, 182.4, 182.0, 181.8, 181.4, 181.1, 180.4, 180.1, 
179.3, 177.8, 172.5, 154.0, 145.3, 142.9, 136.3, 135.4, 134.5, 121.6, 118.9, 113.9, 91.8, 
88.5, 86.7, 86.2, 84.2, 77.0, 75.1, 75.0, 73.9, 63.8, 59.9, 57.8, 52.9, 51.9, 51.8, 51.5, 
50.3, 48.3, 44.4, 44.2, 43.0, 41.9, 38.2, 37.6, 36.2, 35.8, 34.2, 30.6, 30.4, 29.0, 25.9, 
24.3, 22.6, 22.2, 22.0, 21.4, 21.3, 20.7, 20.0, 19.6. 
 
 
Aquacyano-5,6-diolcobalamin (16): 13 (42 mg, 
29 mol, 1 equiv) was dissolved in ddH2O (0.1 M 
TRIS in H2O, pH 8.1, 35 mL) and was 
subsequently added to an electrochemical reactor 
(see Materials and Methods). The soln. was purged 
with N2(g) for 15 minutes. A reducing potential   
(E = -1.0 V vs. Ag/AgCl 3M) was applied at 50 ºC 
and the soln. turned gradually darker. The voltage 
was stopped after 4 h and an excess of KCN (30 
mg, 461 mol, 16 equiv) was immediately added to 
the brown soln., which turned blood-orange within 
2 min. The crude was stirred at 23
 
ºC for 5 min and then purified by solid phase 
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extraction and preparative HPLC (Method 5). 16 (8 mg, 6 mol, 22%) was obtained as 
a yellow powder after lyophilization.  
 
UV-Vis (H2O, c = 7.3 x 10
-5 
M):  /nm (log 
 UPLC (Method 2) tR = 3.0 min. ESI-MS 
(H2O) m/z = 1387.7 [M]
-
,(m/zcalc : 1387.6). HR-ESI-MS (H2O) m/z = 695.29359  
[M+2H]
2+
 (m/zcalc: 695.29372).  
1
H-NMR (D2O, 500 MHz) /ppm =  9.25 (s, 1H), 7.70 
(s, 1H), 7.66 (s, 1H), 6.62 (d, J = 5.3 Hz, 1H), 6.06 (s, 1H), 4.31 (m, 2H), 4.02 (d, J = 
8.7 Hz, 1H), 3.93 (d, J = 10.1 Hz, 2H), 3.83 (dd, J = 12.6, 3.9 Hz, 2H), 3.45 (s, 1H), 
3.37 (m, 2H), 3.28 (d, J = 4.6 Hz, 3H), 2.98 (d, J = 17.6 Hz, 1H), 2.91 (s, 1H), 2.79-1.05 
(m, 23H), 2.46 (s, 3H), 2.35 (s, 3H), 1.51 (s, 3H), 1.47 (s, 3H), 1.39 (s, 3H), 1.27 (s, 
3H), 1.23 (s, 3H), 1.21 (d, J = 3.1 Hz, 3H), 1.21 (s, 3H), 1.11 (s, 3H).  
 
 
 
Co-hydroxo-5,6-dioxocobalamin (17): 15 (4 
mg , 3 mol, 1 equiv) was dissolved in ddH2O 
(0.1 M TRIS, pH 8.1, 3 mL) and CoSO4
.
7H2O (4 
mg, 14 mol, 5 equiv) was added at 23 ºC. The 
mixture was stirred for 1 h and purified with solid 
phase extraction. 17 was obtained as an orange 
powder (3.3 mg, 2.4 mol, 79%) after 
lyophilization.  
 
 
UV-Vis (H2O, c = 1.0 x 10
-5
 M):  /nm (log 
280 (4.4), 463 (4.0). UPLC (Method 2) tR = 3.5 min. ESI-MS  (H2O) m/z = 1360 [M-
OH2]
+
, 681.0 [M-OH2]
2+ 
(m/zcalc : 1360.6). 
1
H-NMR (D2O, 500 MHz) /ppm = 7.49 (s, 
1H), 7.42 (s, 1H), 7.37 (s, 1H), 6.42 (d, J = 2.9 Hz, 1H), 5.68 (s, 1H), 4.44 – 4.42 (m, 
1H), 4.18 (d, J = 8.3 Hz, 1H), 4.09 (d, J = 9.8 Hz, 1H), 3.90 (d, J = 12.8 Hz, 1H), 3.77 
(dd, J = 12.9, 4.0 Hz, 1H), 3.50 (s, 1H), 3.21 (s, 2H), 2.85-0.89 (m, 27H),  2.46 (s, 3H), 
2.40 (s, 3H), 2.32 (s, 6H), 1.41 (s, 3H), 1.36 (s, 3H), 1.26 (s, 3H), 1.23 (s, 3H), 1.20 (d, J 
= 6.4 Hz, 3H), 1.11 (s, 3H), 1.04 (s, 3H).
13
C-NMR  (D2O, 126 MHz) /ppm  = 210.0, 
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198.0, 184.4, 182.3, 181.7, 181.5, 181.0, 180.3, 179.7, 178.8, 177.9, 177.9, 177.8, 
167.6, 146.3, 145.6, 141.7, 137.7, 135.4, 133.6, 123.6, 114.3, 109.3, 98.1, 91.8, 89.9, 
84.9, 81.5, 76.2, 75.8, 75.7, 72.3, 63.4, 61.1, 57.1, 55.5, 52.8, 50.9, 50.9, 50.6, 47.6, 
46.4, 45.2, 42.9, 37.6, 37.0, 34.6, 34.5, 33.9, 33.7, 33.5, 30.5, 28.8, 24.9, 22.6, 22.3, 
21.9, 21.6, 20.2, 18.9, 18.7, 18.5, 16.5. 
 
 
Dihydroxo-14-15-dioxocobalamin (18): synthesized according to literature 
procedures.
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5,6-dioxonibalamin (19): 15 (8 mg , 6 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 3 mL) and NiSO4
.
6H2O (9 mg, 34 mol, 6 
equiv) was added at 23 ºC. The mixture was 
stirred for 1 h and purified with solid phase 
extraction. 19 was obtained as an orange powder 
(7 mg, 5 mol, 84%) after lyophilization.  
 
UV-Vis (H2O, c = 2.5 x 10
-5 
M):  /nm (log 
279 (4.3), 289 (4.3), 448 (4.0). UPLC (Method 
2)   tR = 2.6 min. ESI-MS  (H2O) m/z = 1360.6 
[M+H]
+
, 681.0 [M+2H]
2+
 (m/zcalc for 
C62H88N13NiO16P :1360.6). HR-ESI-MS (H2O): m/z = 680.78633 [M+2H]
2+
 (m/zcalc for 
C62H90N13NiO16P: 680.78543), 691.77731 [M+Na]
2+
 (m/zcalc for C62H89N13NaNiO16P: 
691.77640), 702.76837 [M+2Na]
2+
. 
1
H-NMR (D2O, 500 MHz) /ppm = 8.36 (s, 1H), 
7.48 (s, 1H), 7.43 (s, 1H), 6.49 (d, J = 5.3 Hz, 1H), 6.12 (s, 1H), 4.35 (d, J = 15.0 Hz, 
1H), 3.92 (dd, J = 12.4, 2.7 Hz, 1H), 3.85 (dd, J = 12.5, 4.1 Hz, 1H), 3.67 (s, 4H), 3.29 
(d, J = 3.6 Hz, 1H), 3.26 (d, J = 3.5 Hz, 1H), 3.23 (s, 2H), 3.14 – 3.10 (m, 1H), 3.05 (d, J 
= 11.8 Hz, 1H), 2.98 (s, 2H), 2.82 – 2.74 (m, 1H), 2.65-1.00 (m, 22 H), 2.37 (s, 3H), 
2.22 (s, 3H), 2.20 (s, 3H), 2.18 (s, 3H), 1.47 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H), 1.13 (s, 
3H), 1.11 (d, J = 6.4 Hz, 3H), 0.93 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) /ppm  = 201.4, 
194.6, 185.6, 185.1, 180.9, 180.6, 178.7, 178.5, 178.0, 177.8, 177.7, 176.8, 165.8, 
144.7, 143.5, 135.0, 134.6,134.5, 134.4, 121.5, 114.0, 110.5, 97.8, 89.6, 88.5, 78.6, 78.0, 
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75.5, 75.1, 64.5, 64.4, 64.3, 62.2, 59.7, 55.3, 52.7, 51.8, 51.7, 50.6, 49.0, 47.0, 46.3, 
43.3, 43.1, 36.9, 35.9, 35.8, 34.4, 34.2, 32.5, 29.7, 27.2, 25.3, 23.3, 22.9, 22.4, 22.2, 
21.1, 21.0, 20.9, 18.9, 17.1. 
 
 
5,6-dioxozincbalamin (20): 15 (3 mg , 2 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 2 mL) and ZnSO4
.
5H2O (3.5 mg, 12 mol, 6 
equiv) was added at 23 ºC. The mixture was 
stirred for 3 h and purified with solid phase 
extraction. 20 was obtained as a yellow powder 
(2.5 mg, 1.8 mol, 90%) after lyophilization. 
 
UV-Vis (H2O, c = 1.2 x 10
-5 
M):  /nm 
(log. ESI-MS (H2O) m/z 
= 1365.6 [M+H]
+
 (m/zcalc for C62H89O16N13PZn = 
1365.6 [M+H]
+
). 
1
H-NMR (D2O, 500 MHz) 
/ppm = 8.73 (s, 1H), 7.56 (s, 1H), 7.37 (s, 1H), 6.54 (d, J = 3.3 Hz, 1H), 5.67 (s, 1H), 
4.45 (d, J = 6.7 Hz, 1H), 4.21 (s, 1H), 4.03 (d, J = 12.7 Hz, 1H), 3.85 (dd, J = 12.3, 6.0 
Hz, 2H), 3.77 (d, J = 14.3 Hz, 1H), 3.28 (t, J = 6.9 Hz, 1H), 3.10-1.05 (m, 31 H), 2.49 
(s, 3H), 2.47 (s, 3H), 2.26 (s, 3H), 1.62 (s, 3H), 1.56 (s, 3H), 1.42 (s, 2H), 1.41 (s, 3H), 
1.39 (s, 3H), 1.11 (s, 3H), 1.10 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) /ppm  = 199.7, 
196.9, 192.3, 184.7, 182.1, 181.0, 180.9, 180.7, 180.67, 179.2, 178.9, 178.0, 176.9, 
170.2, 146.5, 138.6, 138.2, 137.0, 134.7, 120.4, 114.0, 111.3, 95.4, 87.0, 86.5, 84.4, 
76.3, 75.5, 75.0, 73.4, 65.4, 63.9, 63.7, 57.4, 55.4, 54.0, 51.6, 51.2, 48.7, 46.8, 45.0, 
42.2, 37.7, 36.9, 36.9, 36.9, 36.6, 35.5, 31.8, 30.0, 28.9, 26.1, 24.5, 23.1, 22.5, 22.3, 
21.9, 20.9, 20.7, 19.7, 18.9, 17.7. 
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5,6-dioxocubalamin (21): 15 (2 mg , 1.5 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 2 mL) and CuSO4
.
5H2O (2 mg, 8 mol, 5 
equiv) was added at 23 ºC. The mixture was 
stirred for 3 h and purified with solid phase 
extraction. 21 (1.5 mg, 1.1 mol, 72%) was 
obtained as an orange powder after lyophilization.  
 
UV-Vis (H2O, c = 4.2 x 10
-5 
M):  /nm (log 
290 (4.3), 301 (4.2), 447 (4.1). UPLC (Method 2)  
tR = 3.0 min. ESI-MS (H2O) m/z = 1365.6 
[M+H]
+
 (m/zcalc : 1365.6).  HR-ESI-MS (H2O): 
m/z = 683.28191 [M+2H]
2+
 (m/zcalc: 683.28256). 
 
 
5,6-diolnibalamin (22):  
Method a: 19 (6 mg, 4 mol, 1 equiv) was 
dissolved in ddH2O (0.1 M TRIS, pH 8.1, 30 mL) 
that was subsequently added to an electrochemical 
reactor (see materials and methods). The soln. was 
purged with N2(g) for 15 min. A reducing 
potential (E = -1.0 V vs. Ag/AgCl 3M) was 
applied at 50 ºC and the soln. turned gradually 
darker. The voltage was swichted off after 4 h and 
the crude was stirred at 23 ºC for 30 min in the 
presence of air. The crude mixture was then 
purified by solid phase extraction and preparative HPLC (Method 6), obtaining 3 
isomers of 19 as orange powders after lyophilization.  
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Method b: 23 (2.5 mg, 1.8 mol, 1 equiv) was 
dissolved in ddH2O (0.1 M TRIS, pH 8.1, 2 mL) 
and an excess of NiSO4
.
7H2O (17 mg, 60 mol, 
33 equiv) was added. The mixture was stirred 
for 90 min at 23 ºC and the product was purified 
using solid phase extraction. 22 (2 mg, 1.5 
mol, 83%) was obtained as an orange powder.  
 
 
Analytical data referred to the isomer obtained 
by Method b. UV-Vis (H2O, c = 3.2 x 10
-5 
M):   
 /nm (log 280 (4.0), 290 (4.0), 437 (3.8). 
UPLC (Method 2)  tR = 3.1 min. ESI-MS  (H2O) m/z = 1360.5 [M-H]
-
, 1398.5 [M+Cl]
- 
(m/zcalc : 1360.6  [M-H]
-
 1398.5 [M+Cl]
-
).  HR-ESI-MS (H2O): m/z = 1360.56121 [M-
H]
-
 (m/zcalc: 1360.56468). 
1
H-NMR (D2O, 500 MHz) /ppm =  8.34 (s, 1H), 7.45 (s, 
1H), 7.39 (s, 1H), 6.45 (s, 1H), 6.02 (s, 1H), 4.93 (s, 1H), 4.86 (s, 2H), 4.36 (s, 2H), 
4.06 (d, J = 9.5 Hz, 1H), 3.89 (d, J = 10.8 Hz, 2H), 3.82 (d, J = 9.4 Hz, 2H), 3.29 (m, 
3H), 3.16 (d, J = 13.8 Hz, 1H), 3.05 (s, 1H), 2.86 (d, J = 17.3 Hz, 1H), 2.70-0.86 (m, 36 
H), 2.68 (s, 3H), 2.48 (s, 3H), 2.16 (s, 3H), 2.14 (s, 3H), 1.68 (s, 3H), 1.40 (s, 3H), 1.22 
(s, 3H), 1.10 (d, J = 5.9 Hz, 3H), 1.05 (s, 6H), 1.00 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) 
/ppm  = 202.2, 188.7, 186.3, 180.8, 180.7, 180.6, 179.6, 178.5, 177.9, 177.9, 177.8, 
176.8, 165.4, 144.8, 143.5, 139.0, 135.3, 134.7, 121.5, 114.0, 110.8, 97.3, 89.0, 88.4, 
81.3, 79.1, 78.5, 75.5, 75.4, 74.6, 73.1, 64.4, 63.6, 62.4, 55.2, 51.8, 50.6, 46.5, 46.5, 
45.6, 43.3, 43.1, 36.9, 36.0, 35.6, 35.1, 35.0, 34.1, 32.3, 29.2, 28.2, 25.0, 23.3, 23.2, 
22.4, 21.9, 21.1, 21.0, 19.2, 19.1, 18.9, 17.6. 
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5,6-diol-H-balamin (23): 
Method a (from 19): 19 (8 mg, 6 mol, 1 equiv) 
was dissolved in ddH2O (0.1 M TRIS, pH 8.1, 30 
mL) that was subsequently added to an 
electrochemical reactor (see materials and 
methods). The soln. was purged with N2(g) for 15 
min. A reducing potential (E = -1.0 V vs. 
Ag/AgCl 3M) was applied at 50 ºC and the bright 
yellow soln. turned gradually darker. The voltage 
was stopped after 4 h and an excess of KCN (26 
mg, 400 mol, 100 equiv) was added. The 
mixture was stirred for 30 min at 23 ºC in the 
presence of air. The product was purified by solid 
phase extraction and preparative HPLC (Method 6), obtaining 3 isomers of 19 as orange 
powders after lyophilization.  
 
Method b (from 13): 13 (57 mg, 40 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 7 mL) and the soln. was purged with N2 (g) 
for 15 min. CoCp2 (83 mg, 439 mol, 11 equiv) 
was added under a nitrogen atmosphere in three 
portions over 15 min at 23 ºC. The reduced 
mixture was stirred for other 5 min and then an 
excess of KCN (200 mg, 3 mmol, 107 equiv) was 
added at once. The soln. turned brighter within 1 
min and was further stirred for 30 min. The crude 
was subsequently purified with solid phase 
extraction and preparative HPLC (Method 5), 
thus affording 23 (12 mg, 9 mol, 23%) as a yellow powder after lyophilization. 
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Method c (from 15): 15 (8 mg, 6 mol 1 equiv) was dissolved in ddH2O (0.1 M TRIS, 
pH 8.1, 7 mL), and the mixture was purged with N2(g) for 15 min. CoCp2 (14 mg, 74 
mol, 12 equiv) was added to the yellow soln. in three portions over 1 h in a N2(g) 
atmosphere at 23 ºC. The mixture was stirred at 23 ºC for additional 30 min. CoCp2 was 
filtered off and the crude mixture was purified using solid phase extraction and 
preparative HPLC (Method 5). 23 (1.6 mg, 1.2 mol, 20%) was afforded as a yellow 
powder after lyophilization.  
Note: When TEMPO (30 equiv) was added to a soln. of 15 in ddH2O (0.1 M TRIS, pH 
8.1):MeOH (2:1, 3 mL) before adding CoCp2, UPLC-MS analysis yielded a single peak 
at tR = 2.6 min and m/z = 1302.6 [M]
-
, corresponding to the starting material 15.  
 
Analytical data refered to the isomer synthesized by Methods b and c. UV-Vis (H2O,     
c = 7.7 x 10
-5 
M):  /nm (log 279 (4.1), 288.0 (4.0), 383.0 (4.0).  UPLC (Method 2)   
tR = 2.7 min. ESI-MS  (H2O) m/z = 1304.6 [M]
-
,(m/zcalc : 1304.6). HR-ESI-MS (H2O)  
m/z= 1304.63348  [M]
-
 (m/zcalc: 1304.64498). 
1
H-NMR (D2O, 500 MHz) /ppm  8.41 
(s, 1H), 7.53 (s, 1H), 7.45 (s, 1H), 6.43 (d, J = 4.9 Hz, 1H), 5.43 (s, 1H), 4.57 (d, J = 3.2 
Hz, 1H), 4.41 (m, 2H), 4.08 (d, J = 4.2 Hz, 1H), 3.92 (dd, J = 12.5, 2.6 Hz, 1H), 3.81 
(dd, J = 12.6, 4.2 Hz, 1H), 3.56 (d, J = 7.5 Hz, 1H), 3.33 (m, 3H), 3.11 (dd, J = 8.2, 5.0 
Hz, 1H), 2.85-1.00 (m, 35H), 2.86 (d, J = 13.7 Hz, 1H), 2.71 (d, J = 16.3 Hz, 1H), 2.65 
(d, J = 5.9 Hz, 3H), 2.57 (m, 2H), 2.37 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H), 1.91 (s, 3H), 
1.27 (s, 3H), 1.26 (s, 3H), 1.12 (s, 3H), 1.11 (s, 3H), 1.06 (s, 6H), 0.78 (s, 3H).
13
C-
NMR  (D2O, 126 MHz) /ppm  =  193.8, 184.9, 182.2, 182.1, 181.9, 181.2, 181.1, 
180.6, 179.5, 177.8, 145.5, 143.1, 136.3, 135.3, 134.7, 121.7, 119.6, 113.8, 91.3, 88.2, 
86.6, 85.3, 84.3, 77.1, 77.1, 75.2, 75.1, 73.8, 73.8, 72.9, 72.6, 63.9, 59.5, 52.8, 51.6, 
51.3, 50.6, 48.3, 47.7, 47.5, 44.8, 44.5, 44.4, 41.2, 38.4, 37.3, 36.2, 35.8, 34.3, 31.1, 
30.7, 29.2, 29.1, 26.1, 24.0, 22.6, 22.2, 22.1, 21.5, 20.8, 19.8, 19.7. 
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Co-hydroxo-5,6-diolcobalamin (24): 23 (12 mg, 
9 mol, 1 equiv) was dissolved in ddH2O (0.1 M 
TRIS, pH 8.1, 3 mL) and the soln. was purged 
with N2(g) for 15 min. CoSO4
.
7H2O (20 mg, 71 
mol, 8 equiv) was added to the yellow soln. in a 
nitrogen atmosphere and in the absence of light. 
The mixture was stirred for 90 min at 23 ºC and 
purified with solid phase extraction. 24 (11 mg, 8 
mol, 88%) was obtained as an orange powder.  
 
UV-Vis (H2O, c = 6.6 x 10
-5 
M):  /nm 
(log UPLC (Method 2) tR = 3.7 min. ESI-
MS (H2O) m/z = 1362.5 [M-OH]
+
 (m/zcalc : 1362.6). HR-ESI-MS (H2O) m/z = 
682.29026 [M-OH+2H]
2+
 (m/zcalc : 682.29218). 
1
H-NMR (D2O, 500 MHz) /ppm = 
7.54 (s, 1H), 7.32 (s, 1H), 7.10 (s, 1H), 6.36 (d, J = 2.9 Hz, 1H), 5.87 (s, 1H), 4.30 (dd, J 
= 10.5, 6.8 Hz, 2H), 4.17 (d, J = 10.7 Hz, 1H), 4.07 (m, 1H), 3.92 (d, J = 10.9 Hz, 2H), 
3.75 (dd, J = 12.8, 3.5 Hz, 2H), 3.58 (d, J = 14.3 Hz, 2H), 3.41 (d, J = 10.5 Hz, 1H), 
3.25 (m, 1H), 3.03 (dd, J = 11.7, 3.3 Hz, 2H), 2.89 (dd, J = 14.3, 9.6 Hz, 2H), 2.60 (s, 
3H), 2.41 (s, 3H), 2.36 (s, 3H), 2.28 (s, 3H), 1.51 (s, 3H), 1.44 (s, 3H), 1.37 (s, 3H), 
1.35 (s, 3H), 1.27 (s, 3H), 1.22 (s, 3H), 0.46 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) /ppm  
= 202.2, 186.5, 182.5, 182.4, 182.3, 180.9, 180.1, 179.0, 178.5, 177.7, 177.4, 168.3, 
160.8, 146.1, 140.8, 138.3, 136.9, 132.8, 121.3, 119.7, 114.8, 108.9, 97.5, 90.4, 85.2, 
85.1, 81.5, 77.8, 75.8, 75.5, 71.6, 63.4, 63.2, 62.6, 61.8, 55.8, 53.5, 52.2, 52.0, 51.3, 
48.1, 47.2, 46.6, 46.0, 42.0, 37.7, 37.5, 35.5, 34.8, 34.7, 34.5, 33.8, 30.6, 30.2, 29.0, 
22.9, 22.1, 22.0, 21.7, 19.5, 19.0, 16.6. 
 
 
 
 
 
 
 
 
 
126 
 
5,6-diolzincbalamin (25): 23 (11 mg, 8 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 3 mL)  and an excess of ZnSO4
.
7H2O (25 mg, 
87 mol. 11 equiv) was added in the absence of 
light. The mixture was stirred for 90 min at 23 ºC 
and the product was purified using solid phase 
extraction. 25 (10 mg, 8 mol, 87%) was obtained 
as a yellow powder.  
 
 
UV-Vis (H2O, c = 3.1 x 10
-5 
M):  /nm (log  
283 (4.1), 289 (4.1), 438 (3.9). UPLC (Method 2)   tR = 3.6 min. ESI-MS  (H2O) m/z =  
1368.6 [M+H]
+
. HR-ESI-MS (H2O) m/z =  1368.57403 [M+H]
+ 
 (m/zcalc : 1368.57303). 
1
H-NMR (D2O, 500 MHz) /ppm =  8.17 (s, 1H), 7.59 (s, 1H), 7.37 (s, 1H), 6.47 (d, J = 
2.7 Hz, 1H), 5.39 (s, 1H), 4.45 (d, J = 3.3 Hz, 1H), 4.35 (dd, J = 14.7, 6.5 Hz, 1H), 4.23 
(d, J = 7.2 Hz, 2H), 3.99 (d, J = 12.8 Hz, 2H), 3.73(m, 3H), 3.58 (d, J = 14.3 Hz, 1H), 
3.21 (m, 1H), 2.99 (m, 1H), 2.94 (m, 1H), 2.66-0.95 (m, 24 H), 2.56 (s, 1H), 2.37 (s, 
3H), 2.30 (s, 3H), 2.27 (s, 3H), 1.26 (s, 3H), 1.25 (s, 3H), 1.19 (s, 3H), 1.13 (s, 3H), 
1.10 (s, 3H), 1.07 (s, 3H), 0.72 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) /ppm  = 198.5, 
192.8, 184.4, 183.3, 181.9, 181.4, 181.1, 180.9, 179.9, 178.6, 177.8, 177.8, 170.6, 
145.5, 140.3, 137.6, 136.6, 133.0, 120.4, 113.7, 110.9, 93.1, 89.2, 84.8, 76.9, 76.1, 75.5, 
74.0, 73.4, 72.0, 64.7, 63.6, 56.6, 53.3, 52.7, 51.3, 50.0, 48.6, 48.2, 44.9, 44.8, 42.0, 
37.1, 36.1, 36.0, 35.5, 35.2, 32.4, 29.4, 29.1, 26.8, 26.1, 22.3, 22.3, 21.9, 21.8, 21.8, 
21.7, 21.5, 20.2, 18.8, 18.6.   
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5,6-diolcubalamin (26): 23 (1 mg, 0.7 mol, 1 
equiv) was dissolved in ddH2O (0.1 M TRIS, pH 
8.1, 2 mL)  and an excess of CuSO4
.
5H2O (10  
mg, 40 mol, 57 equiv) was added. The mixture 
was stirred for 90 min at 23 ºC and the product 
was purified using solid phase extraction. 26 (1 
mg, 0.7 mol, 96%) was obtained as an orange 
powder.  
 
UV-Vis (H2O, c = 7.4 x 10
-5 
M):  /nm (log 
287 (4.1), 295 (4.1), 439 (3.9). UPLC (Method 2) 
tR = 3.6 min. ESI-MS (H2O) m/z = 1365.6 [M-H]
-
 (m/zcalc = 1365.6). HR-ESI-MS 
(H2O) m/z = 1365.55327 [M-H]
- 
  (m/zcalc : 1365.55893 [M-H]
-
).  
 
 
Dicyanocobyrinic acid heptamethyl ester  (‘cobester’, 27-CN): synthesized 
according to literature procedures.
89
 
 
 
Dicyano-14,15-dioxo-cobyrinic acid heptamethyl ester  (14,15-dioxocobester, 28): 
synthesized according to literature procedures.
92
 
 
 
Dicyano-5,6-dioxo-cobyrinic acid heptamethyl ester  (5,6-dioxocobester, 29): 
synthesized according to literature procedures.
92
 
 
 
14,15-dioxonibalamin (30): synthesized according to literature procedures.
98
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14,15-dioxonibyrinic acid heptamethyl 
ester (14,15-dioxonibester, 31): 14,15-
dioxonibalamin  (30, 18 mg, 13 mol, 1 
equiv) was dissolved in MeOH (10 mL) 
and the soln. was purged with N2(g) for 
15 min. The flask was cooled to 0 ºC and 
H2SO4 (250 L, 98%) was added. The 
acidic soln. was then refluxed at 85 ºC 
under inert atmosphere for 120 h, after 
which the crude was cooled to 23 ºC and diluted with ddH2O (30 mL). The product was 
subsequently extracted with CH2Cl2 (3x20 mL), the organic phase was washed with 
brine (2x20 mL), dried with Na2SO4 and and the solvent was removed under reduced 
pressure. The product was isolated by flash chromatography (CH2Cl2:MeOH 98:2 to 
90:10) and 14,15-dioxonibester (8 mg, 7.5 mol, 57%) was obtained as an orange 
powder after lyophilization.  
 
UV-Vis (H2O, c = 6.2 x 10
-5 M):  /nm (log 359 (3.3), 452 (3.6). UPLC (Method 1)   
tR = 3.6 min. ESI-MS (H2O:MeOH 1:1) m/z = 1067.6 [M+H]
+ (m/zcalc = 1067.4). HR-
ESI-MS (MeOH) m/z = 1067.43762 [M+H]
+ 
(m/zcalc : 1067.43700 [M+H]
+
). 
 
 
 
5,6-dioxonibyrinic acid heptamethyl 
ester (5,6-dioxonibester, 32): 5,6-
dioxonibalamin  (19, 5 mg, 4 mol, 1 
equiv) was dissolved in MeOH (3 mL) 
and the soln. was purged with N2(g) for 
15 min. The flask was cooled to 0 ºC and 
H2SO4 (65 L, 98%) was added. The 
acidic soln. was then refluxed at 85 ºC 
under inert atmosphere for 120 h, after 
which the crude was cooled to 23 ºC and diluted with ddH2O (10 mL). The product was 
subsequently extracted with CH2Cl2 (3x10 mL), the organic phase was washed with 
brine (2x10 mL) and dried with Na2SO4. The solvent was removed under reduced 
pressure. The crude was used for synthetic purposes without further purification.  
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5,6-diolnibyrinic acid heptamethyl 
ester (5,6-diolnibester, 33): 5,6-
diolnibalamin  (22, 5 mg, 4 mol, 1 
equiv) was dissolved in MeOH (4 mL) 
and the soln. was purged with N2(g) for 
15 min. The flask was cooled to 0 ºC and 
H2SO4 (65 L, 98%) was added. The 
acidic soln. was then refluxed at 85 ºC 
under inert atmosphere for 120 h, after 
which the crude was cooled to 23 ºC and diluted with ddH2O (10 mL). The product was 
subsequently extracted with CH2Cl2 (3x10 mL), the organic phase was washed with 
brine (2x10 mL) and dried with Na2SO4. The solvent was removed under reduced 
pressure. The crude was used for synthetic purposes without further purification.  
 
 
 
Aquacyano-14-oxo-15-acetohydrazonecobalamin (34): 12 (50 mg, 35 mol, 1 equiv) 
was dissolved in ddH2O (0.1 % CH3COOH, pH 
5.2) and the soln. was purged with N2(g) for 15 
min. Acetohydrazide (40 mg, 540 mol, 15 equiv) 
was added to the stirred soln. under a nitrogen 
atmosphere and the mixture was heated to 110 ºC. 
After 4 h the crude was cooled to 23 ºC and 
desalted by solid phase extraction. The product 
was purified by preparative HPLC (Method 5) 
and 36 (7.5 mg, 5 mol, 15%) was obtained as a 
blood-orange powder after lyophilization.   
 
 
UV-Vis (H2O, c = 2.3 x 10
-5 
M):  /nm (log 280 (4.5), 288 (4.4), 321 (4.2), 472 
(4.0), 530ish (3.9). UPLC (Method 2) tR = 2.2 min. ESI-MS  (H2O) m/z = 1441.5  [M-
H2O+H]
+ 
 (m/zcalc = 1441.6). 
1
H-NMR (D2O; 500 MHz) /ppm = 8.13 (s, 1H), 7.32 (s, 
1H), 7.23 (s, 1H), 6.16 (d, J = 2.9 Hz, 1H), 5.44 (s, 1H), 4.46 (m, 2H), 4.36 (d, J = 3.3 
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Hz, 1H), 4.15 (t, J = 4.9 Hz, 1H), 3.65 (m, 1H), 3.57 (t, J = 8.5 Hz, 1H), 3.14 (m, 1H), 
3.02 (m, 1H), 2.89 (m, 1H), 2.55-1.89 (m, 28 H) 2.16 (s, 6H), 2.05 (s, 3H), 2.00 (s, 3H), 
1.74 (s, 3H), 1.44 (s, 3H), 1.14 (s, 3H), 1.08 (s, 3H), 1.05 (d, J = 6.2 Hz, 3H), 1.01 (s, 
3H), 0.99 (s, 3H), 0.28 (s, 3H). 
13
C-NMR  (D2O, 126 MHz) /ppm  = 191.6, 183.5, 
183.4, 181.8, 181.3, 180.9, 180.5, 179.1, 179.0, 178.2, 178.0, 178.0, 171.8, 165.7, 
147.3, 145.2, 143.2, 136.3, 135.4, 134.5, 121.7, 114.0, 112.9, 97.8, 89.7, 88.7, 86.9, 
83.2, 77.4, 75.0, 74.2, 63.9, 61.8, 59.1, 58.5, 54.0, 53.5, 49.8, 47.9, 47.7, 47.0, 45.3, 
42.6, 38.4, 37.4, 36.5, 35.6, 35.5, 33.9, 28.5, 28.0, 27.3, 27.2, 25.5, 25.2, 23.9, 22.7, 
22.3, 22.1, 21.1, 21.6, 20.4, 18.8, 18.1. 
 
 
Aquacyano-5-acetohydrazone-6-oxocobalamin (35): 13 (5 mg, 4 mol, 1 equiv) was 
dissolved in ddH2O (0.1 % CH3COOH, pH 5.2) 
and the soln. was purged with N2(g) for 15 min. 
Acetohydrazide (4 mg, 54 mol, 15 equiv) was 
added to the stirred soln. under a nitrogen 
atmosphere and the mixture was heated to 110 ºC. 
After 30 min the crude was cooled to 23 ºC and 
desalted by solid phase extraction. The product 
was identified by UPLC-MS (m/z = 1441.5 [M-
H2O+H]
+
) and used for synthetic purposes without 
further purification.  
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 Aquacyano-5-acetohydrazone-6-oxo-H-balamin 
(36): 35 (2 mg, 1 mol, 1 equiv) was dissolved in 
MeOH and the soln. was purged with N2(g) for 15 
min. CoCp2 (1.5 mg, 8 mol, 8 equiv) was added 
to the soln. in a nitrogen atmosphere and the soln. 
turned brown within seconds. After 2 min an 
excess of KCN (6.5 mg, 0.1 mmol, 100 equiv) was 
added at once. The product was identified by 
UPLC-MS (m/z = 1358.6 [M-H]
-
). 
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6.3.  NMR data 
 
 
Co-cyano-8-hydroxy-cobalamin-c-acid (4): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Atom numbering of 4.  
 
 
133 
 
 
 
Figure 39. 
1
H NMR spectrum of 4.  
 
 
 
 
 
Figure 40. 
13
C NMR spectrum of 4. 
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Figure 41. 
1
H-
1
H COSY spectrum of 4. 
 
 
 
 
Figure 42. 
1
H-
1
H ROESY spectrum of 4. 
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Figure 43. 
1
H-
13
C HSQC spectrum of 4. 
 
 
 
 
 
Figure 44. 
1
H-
13
C HMBC spectrum of 4. 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Comparison of NMR chemical shift values for 1-4. Assignments by 
1
H NMR, 
13
C NMR, 
1
H-
1
H COSY, 
1
H-
1
H ROESY, 
1
H-
13
C HSQC and 
1
H-
13
C HMBC. 
 
 
1H 
/ppm 
1 4  
C1 - - - - - - 
C1A 0.43 0.42 -0.01 
C2 - - - - - - 
C2A 1.39 1.41 +0.02 
C21 2.39 2.34 -0.05 
C22 - - - - - - 
C3 4.17 4.08 -0.09 
C31 1.96 2.00 +0.04 
C32 2.48/2.54 2.50  
C33 - - - - - - 
C4 - - - - - - 
C5 - - - - - - 
C51 2.52 2.56 +0.04 
C6 - - - - - - 
C7 - - - - - - 
C7A 1.85 1.87 +0.02 
C71 2.17/2.56 2.01/2.65 -0.16/+0.09 
C72 - - - - - - 
C8 3.46 - - - - 
C81 1.02/2.00 1.33/2.02 +0.31/+0.02 
C82 1.00/1.83 0.59/2.02 -0.41/+0.19 
C83 - - - - - - 
C9 - - - - - - 
C10 6.06 6.16 +0.10 
C11 - - - - - - 
C12 - - - - - - 
C12A 1.43 1.50 +0.07 
C12B 1.17 1.20 +0.03 
C13 3.32 3.37 +0.05 
C131 1.95/2.02 2.02  
C132 2.61 2.60 -0.01 
C133 - - - - - - 
C14 - - - - - - 
C15 - - - - - - 
C151 2.55 2.58 +0.03 
C16 - - - - - - 
C17 - - - - - - 
C17B 1.37 1.38 +0.01 
C171 1.81/2.63 1.82/2.61 +0.01/-0.02 
C172 2.09/2.52 2.02/---  
C173 - - - - - - 
C175 2.94/3.59 2.95/3.62 +0.01/+0.03 
C176 4.28 4.31 +0.03 
C177 1.24 1.26 +0.02 
C18 2.75 2.96 +0.21 
C181 2.66/2.74 2.67/2.76 +0.01/+0.02 
C182 - - - - - - 
C19 4.07 4.08 +0.01 
C1R 6.33 6.36 +0.03 
C2R 4.26 4.08/4.30  
C3R 4.71 4.72 +0.01 
C4R 4.04 4.08 +0.04 
C5R 3.73/3.91 3.76/3.95 +0.03/+0.04 
C2N 7.06 7.11 +0.05 
C4N 6.49 6.45 -0.04 
C5N - - - - - - 
C6N - - - - - - 
C7N 7.26 7.27 +0.01 
C8N - - - - - - 
C9N - - - - - - 
C10N 2.24 2.24 0.00 
C11N 2.24 2.26 +0.02 
13C 
/ppm 
1 4  
C1 87.9 87.8 -0.1 
C1A 21.9 22.6 +0.7 
C2 50.1 49.9 -0.2 
C2A 19.3 19.9 +0.6 
C21 45.3 45.4 +0.1 
C22 178.6 178.5 -0.1 
C3 58.8 59.3 +0.5 
C31 28.5 28.8 +0.3 
C32 37.5 37.5  0.0  
C33 180.7 180.6 -2 
C4 182.8 182.7 -0.1 
C5 110.3 109.3 -1.0 
C51 18 18.5 +0.5 
C6 168.1 166.3 -1.8 
C7 54.2 57.4 +3.2 
C7A 21.5 21.7 +0.2 
C71 45.5 45.9 +0.4 
C72 177.9 181.8 +3.9 
C8 58.2 88.4 +30.2 
C81 28.5 36.1 +7.6 
C82 34.2 31.7 -2.5 
C83 180.5 180.4 -0.1 
C9 176.4 176.7 +0.3 
C10 97.5 95.3 -2.2 
C11 179.7 179.4 -0.3 
C12 50.9 51.0 +0.1 
C12A 21.7 21.8 +0.1 
C12B 33.8 34.0 +0.2 
C13 56.2 56.5 +0.3 
C131 30.8 30.6 -0.2 
C132 37.2 37.2 0.0 
C133 181 180.9 -0.1 
C14 168.8 168.6 -0.2 
C15 106.9 107.2 +0.3 
C151 17.8 17.9 +0.1 
C16 181.7 181.7 0.0 
C17 62.0 61.9 -0.1 
C17B 18.4 19.5 +1.1 
C171 34.8 34.9 +0.1 
C172 35 35.3 +0.3 
C173 177.5 177.5 0.0 
C175 47.9 48.0 +0.1 
C176 75.5 75.5 0.0 
C177 21.6 22.1 +0.5 
C18 41.5 41.6 +0.1 
C181 34 34.2 +0.2 
C182 178.5 178.4 -0.1 
C19 77.5 77.4 -0.1 
C1R 89.5 89.7 +0.2 
C2R 71.4 71.5 +0.1 
C3R 75.6 75.7 +0.1 
C4R 84.6 84.7 +0.1 
C5R 62.9 63.0 +0.1 
C2N 144.3 144.3 0.0 
C4N 119.0 119.0 0.0 
C5N 135.8 135.7 -0.1 
C6N 137.9 137.9 0.0 
C7N 114.0 114.1 +0.1 
C8N 132.8 132.6 -0.2 
C9N 139.5 139.4 -0.1 
C10N 22.1 21.9 -0.2 
C11N 22.1 21.9 -0.2 
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Figure 45.
 1
H-
1
H ROESY correlations within 4.    
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Co-cyano-
7
-dehydro-7-decarboxymethyl-8-decarboxyethyl-cobalamin (5): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Atom numbering of 5.  
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Figure 47. 
1
H NMR spectrum of 5.  
 
 
 
 
Figure 48. 
13
C NMR spectrum of 5. 
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Table 3. Comparison of 
13
C NMR chemical shifts of 1 and 5 (tentatively assigned).  
Co-cyano-8-hydroxy-cobalamin-epi-c-acid (10). 
13
C 
/ppm
1 5  
C1 87.9 89.1 +1.2 
C1A 21.9 22.6 +0.7 
C2 50.1 50.3 +0.2 
C2A 19.3 18.8 -0.5 
C21 45.3 44.7 -0.6 
C22 178.6 178.4 -0.2 
C3 58.8 59.2 +0.4 
C31 28.5 28.3 -0.2 
C32 37.5 37.6 +0.1 
C33 180.7 180.9 +0.2 
C4 182.8 182.0 -0.8 
C5 110.3 113.9 +3.6 
C51 18.0 14.8 -3.2 
C6 168.1 155.7 -12.4 
C7 54.2 150.9 +96.7 
C7A 21.5 23.6 +2.1 
C71 45.5 -- -- 
C72 177.9 -- -- 
C8 58.2 74.5 +16 
C81 28.5 -- -- 
C82 34.2 -- -- 
C83 180.5 -- -- 
C9 176.4 164.7 -11.7 
C10 97.5 95.5 -2.0 
C11 179.7 180.5 +0.8 
C12 50.9 51.3 +0.4 
C12A 21.7 22.3 +0.6 
C12B 33.8 33.9 -0.1 
C13 56.2 56.7 +0.5 
C131 30.8 30.9 +0.1 
C132 37.2 37.1 -0.1 
C133 181.0 181.1 +0.1 
C14 168.8 169.2 +0.4 
C15 106.9 108.3 +1.4 
C151 17.8 18.1 +0.3 
C16 181.7 181.1 -0.6 
C17 62.0 62.0 0.0 
C17B 18.4 19.0 +0.6 
C171 34.8 35.2 +0.4 
C172 35.0 35.8 +0.8 
C173 177.5 177.5 0.0 
C175 47.9 48.2 +0.3 
C176 75.5 75.5 0.0 
C177 21.6 19.3 -2.3 
C18 41.5 41.7 +0.2 
C181 34.0 34.2 +0.2 
C182 178.5 178.4 -0.1 
C19 77.5 78.7 +1.2 
C1R 89.5 89.7 -0.2 
C2R 71.4 71.5 +0.1 
C3R 75.6 75.9 +0.3 
C4R 84.6 84.9 +0.3 
C5R 62.9 64.3 +1.4 
C2N 144.3 144.2 -0.1 
C4N 119.0 118.5 -0.5 
C5N 135.8 135.8 0.0 
C6N 137.9 137.1 -0.8 
C7N 114.0 116.3 +2.2 
C8N 132.8 132.4 -0.4 
C9N 139.5 139.2 -0.3 
C10N 22.1 21.8 -0.3 
C11N 22.1 21.8 -0.3 
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Figure 49. Atom numbering of 10.  
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Figure 50. 
1
H NMR spectrum of 10.  
 
 
 
Figure 51. 
13
C NMR spectrum of 10.  
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Figure 52. 
1
H-
13
C HSQC spectrum of 10. 
 
 
 
 
 
Figure 53. 
1
H-
13
C HMBC spectrum of 10. 
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Table 4. Chemical shifts of 
1
H and 
13
C NMR spectra of 1, 4 and 10. Assignments by 
1
H 
NMR, 
13
C NMR, 
1
H-
13
C HSQC and 
1
H-
13
C HMBC. 
  
1
H 
/ppm
8-OH-epi-c-
acid-
CNCbl100 
10 4 
C1 - -  - - 
C1A 0.41 0.43 0.42 
C2 - -  - - 
C2A 1.39 1.40 1.41 
C21 2.34 2.36 2.34 
C22 - - - - - - 
C3 4.14 4.17 4.08 
C31 2.00 2.02 2.00 
C32 2.49/2.56 2.43 2.50 
C33 - - - - - - 
C4 - - - - - - 
C5 - - - - - - 
C51 2.53 2.46 2.56 
C6 - - - - - - 
C7 - - - - - - 
C7A 1.32 1.26 1.87 
C71 3.16/3.65 3.18/3.70 2.01/2.65 
C72 - - - - - - 
C8 3.41 - - - - 
C81 1.02/2.00 1.16/2.02 1.33/2.02 
C82 1.00/1.83 0.60/2.02 0.59/2.02 
C83 - - - - - - 
C9 - - - - - - 
C10 5.98 6.01 6.16 
C11 - - - - - - 
C12 - - - - - - 
C12A 1.47 1.48 1.50 
C12B 1.18 1.20 1.20 
C13 3.33 3.35 3.37 
C131 1.98/2.06 2.01 2.02 
C132 2.56 2.64 2.60 
C133 - - - - - - 
C14 - - - - - - 
C15 - - - - - - 
C151 2.55 2.58 2.58 
C16 - - - - - - 
C17 - - - - - - 
C17B 1.33 1.38 1.38 
C171 1.81/2.51  1.82/2.61 
C172 2.06/2.60 2.01 2.02 
C173 - - - - - - 
C175 2.93/3.57 2.98/3.63 2.95/3.62 
C176 4.28 4.30 4.31 
C177 1.23 1.26 1.26 
C18 2.75 2.97 2.96 
C181 2.66/2.74 2.64/2.75 2.67/2.76 
C182 - - - - - - 
C19 4.06 4.07 4.08 
C1R 6.33 6.35 6.36 
C2R 4.27 4.07/4.30 4.08/4.30 
C3R 4.71 4.73 4.72 
C4R 4.05 4.07 4.08 
C5R 3.73/3.91 3.77/.3.92 3.76/3.95 
C2N 7.06 7.08 7.11 
C4N 6.39 6.42 6.45 
C5N - - - - - - 
C6N - - - - - - 
C7N 7.25 7.27 7.27 
C8N - - - - - - 
C9N - - - - - - 
C10N 2.22 2.42 2.24 
C11N 2.23 2.37 2.26 
13
C 
/ppm
8-OH-
epi-c-
acid-
CNCbl100 
10 4 
C1 87.4 86.9 87.8 
C1A 21.4 21.5 22.6 
C2 49.2 49.7 49.9 
C2A 19.2 19.3 19.9 
C21 44.8 45.3 45.4 
C22 177.8 178.3 178.5 
C3 58.7 59.0 59.3 
C31 28.2 28.8 28.8 
C32 36.4 37.3 37.5 
C33 180.0 180.3 180.6 
C4 182.4 182.8 182.7 
C5 108.6 109.2 109.3 
C51 18.4 18.6 18.5 
C6 166.2 166.9 166.3 
C7 57.6 57.4 57.4 
C7A 20.9 21.2 21.7 
C71 43.2 43.8 45.9 
C72 177.9 182.1 181.8 
C8 86.3 87.7 88.2 
C81 35.7 35.7 36.1 
C82 31.0 31.5 31.7 
C83 179.6 179.9 180.4 
C9 178.0 174.5 176.7 
C10 94.3 94.7 95.3 
C11 179.4 179.4 179.4 
C12 50.1 50.9 51.0 
C12A 21.3 21.9 21.8 
C12B 33.2 33.8 34.0 
C13 56.0 56.3 56.5 
C131 29.8 30.6 30.6 
C132 36.5 37.1 37.2 
C133 180.2 180.7 180.9 
C14 168.8 168.5 168.6 
C15 106.7 107.1 107.2 
C151 17.5 17.7 17.9 
C16 180.9 181.2 181.7 
C17 61.1 61.7 61.9 
C17B 17.9 18.3 19.5 
C171 34.3 34.8 34.9 
C172 37.7 35.1 35.3 
C173 177.8 177.4 177.5 
C175 47.2 47.8 48.0 
C176 75.0 75.4 75.5 
C177 20.8 21.7 22.1 
C18 41.0 41.6 41.6 
C181 33.4 34.0 34.2 
C182 177.9 178.2 178.4 
C19 77.1 77.5 77.4 
C1R 89.2 89.6 89.7 
C2R 70.9 71.3 71.5 
C3R 74.9 75.5 75.7 
C4R 84.0 84.5 84.7 
C5R 62.5 62.9 63.0 
C2N 143.8 144.2 144.3 
C4N 118.4 118.8 119.0 
C5N 135.1 135.7 135.7 
C6N 137.4 137.8 137.9 
C7N 113.7 114.1 114.1 
C8N 131.8 132.5 132.6 
C9N 138.9 139.3 139.4 
C10N 21.9 22.4 21.9 
C11N 21.7 22.4 21.9 
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Figure 54. 
1
H-
13
C HMBC correlations within 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
Cohydroxo-5,6-diol-cobalamin (24): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. Atom numbering of 24.  
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Figure 56. 
1
H NMR spectrum of 24. 
 
 
 
Figure 57. 
13
C NMR spectrum of 24. 
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Figure 58. 
1
H-
1
H COSY spectrum of 24. 
 
 
 
Figure 59. 
1
H-
1
H ROESY spectrum of 24.  
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Figure 60. 
1
H-
13
C HSQC spectrum of 24.  
 
 
 
 
Figure 61. 
1
H-
13
C HMBC spectrum of 24.  
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Table 5. Chemical shifts of 
1
H and 
13
C NMR spectra of 1-OH and 24. Assignments by 
1
H NMR, 
13
C NMR, 
1
H-
1
H COSY, 
1
H-
1
H ROESY, 
1
H-
13
C HSQC and 
1
H-
13
C HMBC. 
  
1H 
/ppm 
1-OH122  24 
C1 - - - - - - 
C1A 0.45 0.46 +0.01 
C2 - - - - - - 
C2A 1.47 1.35 -0.12 
C21 2.67/2.33 0.92/1.67  
C22 - - - - - - 
C3 3.99 3.25 -0.74 
C31 1.89 0.92 -0.97 
C32 2.59/2.54   
C33 - - - - - - 
C4 - - - - - - 
C5 - - - - - - 
C51 2.57 2.41 -0.16 
C6 - - - - - - 
C7 - - - - - - 
C7A 1.89 1.51 -0.38 
C71 
 
- -  
C72 - - - - - - 
C8 3.43  - - 
C81 2.01 1.67/3.04  
C82 1.83/1.01   
C83 - - - - - - 
C9 - - - - - - 
C10 6.07 5.87 -0.2 
C11 - - - - - - 
C12 - - - - - - 
C12A 1.47 1.44 -0.03 
C12B 1.30 1.37 +0.07 
C13 3.40 3.41 +0.01 
C131 2.09 2.00/2.64  
C132 2.66 2.64 -0.02 
C133 - - - - - - 
C14 - - - - - - 
C15 - - - - - - 
C151 2.64 2.60 -0.04 
C16 - - - - - - 
C17 - - - - - - 
C17B 1.40 1.22 -0.18 
C171 2.88/2.51   
C172 2.17   
C173 - - - - - - 
C175 2.96 2.89/3.60  
C176 3.84/3.63 4.31  
C177 1.26 1.27 +0.01 
C18 
 
  
C181 2.78/2.70 2.89  
C182 - - - - - - 
C19 4.25 4.18 -0.07 
C1R 6.25 6.36 +0.11 
C2R 
 
  
C3R 4.72 4.31 -0.41 
C4R 4.05 4.07 +0.02 
C5R 3.93 3.92 +0.01 
C2N 6.74 7.10 0.36 
C4N 6.50 7.54 +1.04 
C5N - - - - - - 
C6N - - - - - - 
C7N 7.17 7.32 +0.17 
C8N - - - - - - 
C9N - - - - - - 
C10N 2.27 2.36 +0.09 
C11N 2.22 2.28 +0.06 
13C 
/ppm 
1-OH122 24  
C1 88.0 81.5 -6.5 
C1A 22.9 16.6 -6.3 
C2 49.9 52.2 +2.3 
C2A 20.4 19.5 -0.9 
C21 45.8 46.6 +0.8 
C22 179.2 182.6 +3.4 
C3 59.6 52.0 -7.6 
C31 29.3 29.1 -0.2 
C32 38.0 34.7 -3.3 
C33 180.8 180.1 -0.7 
C4 181.9 202.2 +20.3 
C5 109.5 121.3 +11.8 
C51 18.3 47.2 +28.9 
C6 166.8 177.4 +10.6 
C7 53.3 63.2 +9.9 
C7A 23.1 21.6 -1.5 
C71 47.4 46.0 -1.4 
C72 178.2 179.0 -0.8 
C8 59.2 53.5 5.7 
C81 29.1 30.1 +1.0 
C82 35.5 37.5 +2.0 
C83 180.1 160.8 -19.3 
C9 175.8 182.3 +6.5 
C10 96.1 97.5 +1.4 
C11 179.8 186.5 +6.7 
C12 50.4 51.3 +0.9 
C12A 22.7 22.1 -0.6 
C12B 34.6 33.8 -0.8 
C13 56.5 55.8 -0.7 
C131 30.7 30.6 -0.1 
C132 37.8 37.7 -0.1 
C133 181.1 180.9 -0.2 
C14 168.0 168.4 +0.4 
C15 106.3 108.9 +2.6 
C151 18.4 21.7 +3.3 
C16 181.2 182.4 +1.2 
C17 61.4 61.8 +0.4 
C17B 19.6 19.0 -0.6 
C171 35.5 34.5 -1.0 
C172 34.7 35.5 +0.8 
C173 177.8 177.6 -0.2 
C175 48.2 48.1 -0.1 
C176 75.7 75.5 -0.2 
C177 21.9 22.0 +0.1 
C18 42.3 41.9 -0.4 
C181 34.6 34.8 +0.2 
C182 178.8 178.5 -0.3 
C19 77.1 77.8 +0.7 
C1R 89.9 90.4 +0.5 
C2R 71.6 71.6 0.0 
C3R 75.8 75.8 0.0 
C4R 84.9 85.2 +0.3 
C5R 63.2 63.4 +0.2 
C2N 145.0 146.1 +1.1 
C4N 119.6 119.7 +0.1 
C5N 135.7 136.9 +1.2 
C6N 137.9 138.3 +0.4 
C7N 114.1 114.8 +0.7 
C8N 132.4 132.8 +0.4 
C9N 139.6 140.7 +1.1 
C10N 22.7 22.9 +0.2 
C11N 22.1 22.9 +0.8 
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62. Top 
1
H-
13
C HMBC correlations within 24; Bottom 
1
H-
1
H ROESY 
correlations within 24.    
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1H signal  
 
 HMBC  ROESY 
  
 
 
 
   
C4N 
 
 C10N, C8N, C6N  C1A, C2A, C31, C10N 
C7N 
 
 C11N ,C5N, C9N   C11N, C1R, C3R  
C2N 
 
 C8N, C9N  C151, C1R  
C1R 
 
 C2R  C3R, C4R 
C10 
 
 C8, C9, C11, C12  C81, C12A, C12B 
C5R 
 
 C3R  
 C13 
 
 C11, C14  C12B, C151 
C3 
 
 
C2, C21, C22, C31, C32, 
C4  C2A, C51 
C81 
 
 C82, C83  C7A 
C132 
 
 C13, C131, C133  
 C151 
 
 C15, C14, C16  
 C51 
 
 C3, C4, C6  C2A 
C10N 
 
 C4N, C5N, C6N  
 C11N 
 
 C5N, C6N, C7N  
 C7A 
 
 C8  
 C12A 
 
 C11 C12, C12B, C13  
 C12B 
 
 C11 C12, C12A, C13  
 C2A 
 
 C21, C3, C4  
 C177 
 
 C175, C176  
 C1A 
 
 C1, C2  
  
 
Table 6. 
1
H-
13
C HMBC and 
1
H-
1
H ROESY correlations within 24.    
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5,6-diolzincbalalmin (25):  
 
Figure 63. 
1
H NMR spectrum of 5,6-diol-zincbalamin (25).  
 
Figure 64. 
13
C NMR spectrum of 5,6-diol-zincbalamin (25). 
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Figure 65. 
1
H-
1
H ROESY spectrum of 25.  
 
 
Figure 66. 
1
H-
1
H ROESY spectrum of 25 (zoom).  
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Appendix 1: Modified B12 biovectors for the tuneable release of CO
58
 
A series of C10 and B ring modified B12 derivatives were synthesized during this work 
according to procedures developed by Wagner et al and by Dr. René Oetterli in our 
group (Figure 67).
71,98
 This includes mainly halogenated B12 derivatives and/or B12 
derivatives containing a c-lactone on the B-ring. As observed by spectroscopic and 
electrochemical studies, binding electron withdrawing groups (EWG) like halogens to 
the corrin scaffold affects the electronic properties of the complexes and specifically the 
redox potential at the Co
III 
center. 
 
Figure 67. C10 and B-ring modified B12 derivatives synthesized for these studies.  
The liberation of minute amounts of carbon monoxide (CO) under physiological 
conditions has benefitial effects under numerous medical conditions.
123-125 
Based on 
previous work by Zobi et al, it is known that vitamin B12 can be exploited as a biovector 
to deliver carbon monoxide releasing molecules (CORMs) based on a 17 electron 
rhenium (II) complex (Figure 68).
65
 CNCbl and [Et4N]2[Re(CO)2Br4] were connected 
through a cyanide bridge that ensures electronic communication between the metal 
centres of both complexes.  
156 
 
 
Figure 68. Structures of B12-Re
II
-CORMs.  
Aiming to tune the kinetics of CO release, it was envisaged that changes in the 
electronic properties of Co
III
 would affect the electronic environment at the Re
II
 
complex and consequently modify the CO release. Therefore, the modified B12 
compounds were synthesized, characterized and sent to our cooperation partner Prof. 
Fabio Zobi (University of Fribourg, Switzerland), where they were coordinated to the 
CORM cis-[Re(CO)2Br4]
2-
. UV-Vis studies demonstrated that a) aquation of the Re
II
-
core and b) half-life time of  CO release within the Co
III
-CN-Re
II
 complexes were faster 
the higher ECo(III)/Co(I) values were found.  The observed trend may be rationalized 
considering that an electron deficient Co
III
 ion obtains an enhanced -donation from the 
axial cyanide bridge. As a consequence, the 17-electron Re
II
 complex receives weaker 
electronic stabilization from the bridging ligand, rendering it more labile towards ligand 
substitution. 
The anti-platelet effect of these B12-Re-CORMS was evaluated by the group of Prof. 
Chlopicki (Jagiellonian University, Poland), finding that all of them inhibit platelet 
aggregation. All the investigated compounds avoid the formation of platelets at 
milimolar range.  
 
 
 
 
 
157 
 
Appendix 2: Publications  
 
1) Synthesis of a B-Ring Opened 7,8-seco-Vitamin B12 Derivative with Grob 
Fragmentation. R. Oetterli, L. Prieto, B. Spingler, F. Zelder, Org. Lett., 2013, 
15, 4630.  
 
2) Antivitamins for Medicinal Applications. F. Zelder, M. Sonnay, L. Prieto, 
ChemBioChem, 2015, 16, 1264. 
 
3) Inorganic Cyanide as Protecting Group in the Stereospecific Reconstitution of 
Vitamin B12 from an Artificial Green Secocorrinoid. L. Prieto, B. Spingler, F. 
Zelder, Org. Lett, 2016, 18, 5292. 
 
4) Modified Biovectors for the Tuneable Activation of Anti-platelet Carbon 
Monoxide Release. L. Prieto, J. Rossier, K. Derszniak, J. Dybas, R. Oetterli, E. 
Kottelat, S. Chlopicki, F. Zelder, F. Zobi, Chem Commun, 2017, 53, 6840. 
 
5) A CoCp2 Mediated Demetallation/C-C Bond Forming Reaction: Formation of a 
Ni
II
-Containing Vitamin B12 Derivative with a Cofactor-F430-Type π-system 
from a Secocorrin. L. Prieto, R. Otterli, F. Zelder, in preparation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
 
 
159 
 
 
 
 
 
 
160 
 
 
161 
 
 
 
 
 
 
 
162 
 
 
 
 
 
163 
 
 
 
 
 
164 
 
 
 
 
 
165 
 
166 
 
 
 
 
 
167 
 
 
 
 
 
168 
 
 
 
 
 
169 
 
 
 
 
 
170 
 
 
171 
 
 
172 
 
 
173 
 
 
 
174 
 
 
 
175 
 
176 
 
 
 
177 
 
 
 
 
 
178 
 
 
 
 
 
179 
 
 
 
180 
 
 
 
 
 
181 
 
 
 
182 
 
 
 
 
183 
 
 
 
 
 
184 
 
 
 
 
 
 
 
185 
 
Appendix 3: Curriculum vitae 
Personal data 
Name   Lucas Prieto González-Posada 
Nationality  Spanish 
Date of Birth  10.11.1989 
 
Education 
06/2013 – 07/2017 Ph.D. Studies in Chemistry, Department of Chemistry, 
University of Zurich. PD. Dr. Felix Zelder/ Prof. Dr. 
Roger Alberto.   
 
09/2012-05/2013  Master Thesis, Institute of Inorganic Chemistry, 
University of Zurich. PD. Dr. Felix Zelder. 
 
10/2011 – 07/2012 Master studies in Chemistry (Erasmus Exchange 
Program), University of Vienna (Austria). 
 
2007 – 2012                          “Licenciado en Química” (Diplom in Chemistry), 
University of Oviedo, Oviedo, Spain. 
 
 
 
Publications  
1) Synthesis of a B-Ring Opened 7,8-seco-Vitamin B12 Derivative with Grob 
Fragmentation. R. Oetterli, L. Prieto, B. Spingler, F. Zelder, Org. Lett., 2013, 
15, 4630.  
 
2) Antivitamins for Medicinal Applications. F. Zelder, M. Sonnay, L. Prieto, 
ChemBioChem, 2015, 16, 1264. 
 
3) Inorganic Cyanide as Protecting Group in the Stereospecific Reconstitution of 
Vitamin B12 from an Artificial Green Secocorrinoid. L. Prieto, B. Spingler, F. 
Zelder, Org. Lett, 2016, 18, 5292. 
 
4) Modified Biovectors for the Tuneable Activation of Anti-platelet Carbon 
Monoxide Release. L. Prieto, J. Rossier, K. Derszniak, J. Dybas, R. Oetterli, E. 
Kottelat, S. Chlopicki, F. Zelder, F. Zobi, Chem Commun, 2017, 53, 6840. 
 
5) A CoCp2 Mediated Demetallation/C-C Bond Forming Reaction: Formation of a 
Ni
II
-Containing Vitamin B12 Derivative with a Cofactor-F430-Type π-system 
from a Secocorrin. L. Prieto, R. Otterli, F. Zelder, in preparation.  
 
 
 
186 
 
Fellowships 
- Forschungskredit Fellowship 2015, University of Zurich (08/2015-08/2016). 
Funding extension for the project: Metbalamins: a Synthetic Route Towards a 
New Class of Promising Antivitamin B12 candidates. 
 
- Forschungskredit Fellowship 2014, University of Zurich (07/2014-04/2015). 
Funding for the project: Metbalamins: a Synthetic Route Towards a New Class 
of Promising Antivitamin B12 candidates. 
 
Awards  
- CMSZH Travel Award (2017) to attend the “6th Georgian Bay International 
Conference on Bioinorganic Chemistry”, Parry Sound, Canada.  
 
- Best Oral Presentation Award at “Early Researchers Forum” within AsBIC8 
(8
th
 Asian Biological Inorganic Chemistry Conference, 2016), Auckland, New 
Zealand.  
 
- Student Bursary (2016) by the Society of Biological Inorganic Chemistry to 
attend the “8th Asian Biological Inorganic Chemistry Conference”. 
 
- SCS/SCNAT Chemistry Travel Award (2016) to attend the “8th Asian 
Biological Inorganic Chemistry Conference”. 
 
- 2nd Best Poster Presentation Prize at ISBOMC 14 (7th International 
Symposium on Bioorganometallic Chemistry, 2014), Vienna, Austria. 
 
Selected Scientific Contributions 
 
- Modified Vitamin B12 Derivatives for the Tuneable Activation of Anti-platelet 
CO release, Oral Presentation, “6th Georgian Bay International Conference on 
Bioinorganic Chemistry” (CanBIC 6), 05/2017, Parry Sound, Canada. 
 
- A Reversible Route for the Stereospecific Reconstitution of Vitamin B12 Using 
Cyanide as Inorganic Protecting Group, Oral Presentation, Early Researchers 
Symposium at the 8th Asian Biological Inorganic Chemistry, 12/2016, 
Auckland, New Zealand.  
 
- Metal and Ligand Centered Reactivity of Cobalamins. Poster Presentation, 
42nd International Conference on Coordination Chemistry (ICCC 2016), 
07/2016 Brest, France.  
 
- Ring-modified Vitamin B12 Derivatives as Potential B12 Antivitamins. Poster 
Presentation, 7th International Symposium on Bioorganometallic Chemistry 
(ISBOMC14), 07/2014, Vienna, Austria.  
 
 
 
 
187 
 
References 
 
 (1) Whipple, G. H.; Hooper, C.; Robscheit, F. Am. J. Physiol. 1920, 53, 167. 
 (2) Dawson, A.; Evans, H.; Whipple, G. Am. J. Physiol. 1920, 51, 232. 
 (3) Whipple, G.; Hooper, C.; Robscheit, F. Blood 1920, 53. 
 (4) Minot, G. R.; Murphy, W. P. JAMA 1926, 87, 470. 
 (5) Murphy, W. P.; Monroe, R. T.; Fitz, R. JAMA 1927, 88, 1211. 
(6) Rickes, E. L.; Brink, N. G.; Koniuszy, F. R.; Wood, T. R.; Folkers, K. 
Science 1948, 107, 396. 
(7) Brink, N. G.; Wolf, D. E.; Kaczka, E.; Rickes, E. L.; Koniuszy, F. R.; 
Wood, T. R.; Folkers, K. J. Am. Chem. Soc. 1949, 71, 1854. 
 (8) Kaczka, E.; Wolf, D. E.; Folkers, K. J. Am. Chem. Soc. 1949, 71, 1514. 
 (9) Smith, E. L. Brit. Med. J. 1949, 2, 1367. 
 (10) Smith, E. L. J. Pharm. Pharmacol 1949, 1, 500. 
(11) Hodgkin, D. C.; Kamper, J.; Mackay, M.; Pickworth, J.; Trueblood, K. 
N.; White, J. G. Nature 1956, 178, 64. 
 (12) Woodward, R. B. Pure App. Chem. 1973, 33, 145. 
 (13) Eschenmoser, A. Naturwissenschaften 1974, 61, 513. 
 (14) Eschenmoser, A.; Wintner, C. E. Science 1977, 196, 1410. 
(15) Garibaldi, J. A.; Kosuke, I.; Lewis, J. C.; James, M.; U.S. Patent No. 
2576932 A 1951. 
 (16) Wood, T. R.; David, H.; U.S. Patent No.  2595499 A 1952. 
 (17) Friedrich, W.; Bernhauer, K. Angew. Chem. 1953, 65, 627. 
(18) Barker, H.; Weissbach, H.; Smyth, R. Proc. Natl. Acad. Sci. USA 1958, 
44, 1093. 
(19) Buchanan, J.; Elford, H. L.; Loughlin, R.; McDougall, B.; Rosenthal, S. 
Ann. N. Y. Acad. Sci 1964, 112, 756. 
(20) Guest, J.; Friedman, S.; Dilworth, M.; Woods, D. Ann. N. Y. Acad. Sci 
1964, 112, 774. 
(21) Barker, H.; Suzuki, F.; Iodice, A.; Rooze, V. Ann. N. Y. Acad. Sci 1964, 
112, 644. 
 (22) Banerjee, R. Chemistry and Biochemistry of B12; Wiley, 1999. 
(23) Pratt, J. M. Inorganic chemistry of vitamin B12; Academic Press Inc. 
London Ltd., 1972. 
188 
 
(24) Kraatz, H.-B.; Metzler-Nolte, N. Concepts and models in bioinorganic 
chemistry; Wiley-VCh New York, 2006. 
(25) Kräutler, B.; Golding, B. T.; Arigoni, D. Vitamin B12 and B12-Proteins; 
Wiley, 2008. 
 (26) o Proinsias, K.; Giedyk, M.; Gryko, D. Chem. Soc. Rev. 2013, 42, 6605. 
 (27) Bridwell-Rabb, J.; Drennan, C. L. Curr. Opin. Chem. Biol 2017, 37, 63. 
 (28) Zelder, F.; Sonnay, M.; Prieto, L. ChemBioChem 2015, 16, 1264. 
 (29) Zelder, F. Chem. Commun. 2015, 51, 14004. 
 (30) Männel-Croise, C.; Zelder, F. ACS Appl. Mat. Interf. 2012, 4, 725. 
(31) Karczewski, M.; Ociepa, M.; Pluta, K.; ó Proinsias, K.; Gryko, D. Chem. 
Eur. J. 2017, 23, 7024. 
 (32) Giedyk, M.; Goliszewska, K.; Gryko, D. Chem. Soc. Rev. 2015, 44, 3391. 
(33) Kräutler, B. J., B. in Concepts and Models in Bioinorganic Chemistry; 
Kraatz, H. B.; Metzler-Nolte N. , Eds., p. 177-212; Wiley-VCH 
Weinheim, 2006. ; Wiley VCH, Weinheim: 2006. 
(34) Brown, K. L.; Hakimi, J. M.; Nuss, D. M.; Montejano, Y. D.; Jacobsen, 
D. W. Inorg. Chem. 1984, 23, 1463. 
 (35) Gruber, K.; Puffer, B.; Kräutler, B. Chem. Soc. Rev. 2011, 40, 4346. 
(36) Battersby, A. R.; Fookes, C. J. R.; Matcham, G. W. J.; McDonald, E. 
Nature 1980, 285, 17. 
(37) Stich, T. A.; Brooks, A. J.; Buan, N. R.; Brunold, T. C. J. Am. Chem. 
Soc. 2003, 125, 5897. 
 (38) Lexa, D.; Sayeant, J. M.; Zickler, J. J. Am. Chem. Soc. 1980, 102, 2654. 
(39) Zelder, F.; Alberto, R. In The Porphyrin Handbook; Kadish, K. M., 
Smith, K. M., Guilard, R., Eds.; Elsevier Science: San Diego, 2012; Vol. 
25, p 83. 
(40) Wuerges, J.; Garau, G.; Geremia, S.; Fedosov, S. N.; Petersen, T. E.; 
Randaccio, L. Proc. Natl. Acad. Sci. USA 2006, 103, 4386. 
(41) Petrus, A. K.; Fairchild, T. J.; Doyle, R. P. Angew. Chem. Int. Ed. 2009, 
48, 1022. 
(42) Schneider, Z.; Stroinski, A. Comprehensive B12: Chemistry, 
Biochemistry, Nutrition, Ecology, Medicine; Walter de Gruyter, 1987. 
(43) Banerjee, R.; Gherasim, C.; Padovani, D. Curr Opin Chem Biol 2009, 13, 
484. 
189 
 
(44) Jarrett, J. T.; Hoover, D. M.; Ludwig, M. L.; Matthews, R. G. 
Biochemistry 1998, 37, 12649. 
(45) Mancia, F.; Keep, N. H.; Nakagawa, A.; Leadlay, P. F.; McSweeney, S.; 
Rasmussen, B.; Diat, O.; Evans, P. R. Structure 1996, 4, 339. 
(46) Drennan, C.; Huang, S.; Drummond, J.; Matthews, R.; Lidwig, M. 
Science 1994, 266, 1669. 
 (47) Stubbe, J. Science 1994, 266, 1663. 
 (48) Elschenbroich, C. Organometallchemie; Springer-Verlag, 2013. 
(49) Friedrich, W. Vitamin B12 und verwandte Corrinoide; Thieme Stuttgart, 
1975. 
(50) McLean, G. R.; Pathare, P. M.; Wilbur, D. S.; Morgan, A. C.; 
Woodhouse, C. S.; Schrader, J. W.; Ziltener, H. J. Cancer Res. 1997, 57, 
4015. 
(51) Guzzo, M. B.; Nguyen, H. T.; Pham, T. H.; Wyszczelska-Rokiel, M.; 
Jakubowski, H.; Wolff, K. A.; Ogwang, S.; Timpona, J. L.; Gogula, S.; 
Jacobs, M. R. PLoS Pathog 2016, 12, e1005949. 
(52) Andrès, E.; Loukili, N. H.; Noel, E.; Kaltenbach, G.; Abdelgheni, M. B.; 
Perrin, A. E.; Noblet-Dick, M.; Maloisel, F.; Schlienger, J.-L.; Blicklé, J.-
F. CMAJ 2004, 171, 251. 
(53) Hin, H.; Clarke, R.; Sherliker, P.; Atoyebi, W.; Emmens, K.; Birks, J.; 
Schneede, J.; Ueland, P. M.; Nexo, E.; Scott, J. Age and Ageing 2006, 35, 
416. 
(54) Toh, B.-H.; van Driel, I. R.; Gleeson, P. A. New. Engl. J. Med. 1997, 
337, 1441. 
(55) Stryer, L. Biochemistry; 3 ed.; W. H. Freeman and Company: New York, 
1988. 
(56) Pettenuzzo, A.; Pigot, R.; Ronconi, L. Eur. J. Inorg. Chem. 2017, 2017, 
1625. 
 (57) Kräutler, B. Chem. Eur. J. 2015, 21, 11280. 
(58) Prieto, L.; Rossier, J.; Derszniak, K.; Dybas, J.; Oetterli, R. M.; Kottelat, 
E.; Chlopicki, S.; Zelder, F.; Zobi, F. Chem. Commun. 2017, 53, 6840. 
(59) Gupta, Y.; Kohli, D. V.; Jain, S. K. Crit. Rev. Ther. Drug Carrier Syst. 
2008, 25, 347. 
190 
 
(60) Siega, P.; Wuerges, J.; Arena, F.; Gianolio, E.; Fedosov, S. N.; Dreos, R.; 
Geremia, S.; Aime, S.; Randaccio, L. Chem. Eur. J. 2009, 15, 7980. 
(61) Zelenka, K.; Brandl, H.; Spingler, B.; Zelder, F. Dalt. Trans. 2011, 40, 
9665. 
(62) Kunze, S.; Zobi, F.; Kurz, P.; Spingler, B.; Alberto, R. Angew. Chem. Int. 
Ed. 2004, 43, 5025. 
(63) Mundwiler, S.; Spingler, B.; Kurz, P.; Kunze, S.; Alberto, R. Chem. Eur. 
J. 2005, 11, 4089. 
(64) Shell, T. A.; Shell, J. R.; Rodgers, Z. L.; Lawrence, D. S. Angew. Chem. 
Int. Ed. 2014, 53, 875. 
(65) Zobi, F.; Blacque, O.; Jacobs, R. A.; Schaub, M. C.; Bogdanova, A. Y. 
Dalt. Trans. 2012, 41, 370. 
(66) Vortherms, A. R.; Kahkoska, A. R.; Rabideau, A. E.; Zubieta, J.; 
Andersen, L. L.; Madsen, M.; Doyle, R. P. Chem. Commun. 2011, 47, 
9792. 
(67) Somogyi, J. C.; Trautner, K. In Vitamine; Ammon, R., Dirscherl, W., 
Eds.; Georg Thieme: Stuttgart, 1974; Vol. 3, p 10. 
(68) Zhou, K.; Oetterli, R. M.; Brandl, H.; Lyatuu, F. E.; Buckel, W.; Zelder, 
F. ChemBioChem 2012, 13, 2052. 
(69) Mutti, E.; Ruetz, M.; Birn, H.; Kräutler, B.; Nexo, E. PLoS ONE 2013, 8, 
e75312. 
(70) Stabler, S. P.; Brass, E. P.; Marcell, P. D.; Allen, R. H. J. Clin. Invest 
1991, 87, 1422. 
 (71) Wagner, F. Annu. Rev. Biochem 1966, 35, 405. 
 (72) Zelder, F.; Zhou, K.; Sonnay, M. Dalt. Trans. 2013, 42, 854. 
(73) Smith, E. L.; Mervyn, L.; Muggleton, P.; Johnson, A.; Shaw, N. Ann. N. 
Y. Acad. Sci 1964, 112, 565. 
(74) Koppenhagen, V. B.; Elsenhans, B.; Wagner, F.; Pfiffner, J. J. J. Biol. 
Chem. 1974, 249, 6532. 
 (75) Helgeland, K.; Jonsen, J.; Laland, S. Biochem. J. 1961, 81, 260. 
(76) Helgeland, K.; Jonsen, J.; Laland, S.; Lygren, T.; Rømcke, O. Nature 
1963. 
(77) Grüning, B.; Holze, G.; Jenny, T. A.; Nesvadba, P.; Gossauer, A.; Ernst, 
L.; Sheldrick, W. S. Helv. Chim. Acta 1985, 68, 1754. 
191 
 
(78) Grüning, B.; Holze, G.; Gossauer, A.; Ernst, L. Helv. Chim. Acta 1985, 
68, 1771. 
(79) Holxe, G.; Jenny, T. A.; Nesvadba, P.; Gossauer, A.; Ernst, L.; Keller, 
W.; Kratky, C. Helv. Chim. Acta 1991, 74, 1287. 
 (80) Toohey, J. I. In Federation proceedings 1965; Vol. 25, p 1628. 
 (81) Perlman, D.; Toohey, J. Nature 1966. 
 (82) Koppenhagen, V.; Pfiffner, J. J. Biol. Chem. 1971, 246, 3075. 
(83) Koppenhagen, V. B.; Wagner, F.; Pfiffner, J. J. J. Biol. Chem. 1973, 248, 
7999. 
(84) Widner, F. J.; Lawrence, A. D.; Deery, E.; Heldt, D.; Frank, S.; Gruber, 
K.; Wurst, K.; Warren, M. J.; Kräutler, B. Angew. Chem. 2016, 128, 
11451. 
 (85) Eschenmoser, A. Pure App. Chem. 1969, 20, 1. 
 (86) Eschenmoser, A. Q. Rev., Chem. Soc. 1970, 24, 366. 
(87) Yamada, Y.; Wehrli, P.; Miljkovic, D.; Wild, H.-J.; Bühler, N.; Götschi, 
E.; Golding, B.; Löliger, P.; Gleason, J.; Pace, B.; Ellis, L.; Hunkeler, 
W.; Schneider, P.; Fuhrer, W.; Nordmann, R.; Srinivasachar, K.; Keese, 
R.; Müller, K.; Neier, R.; Eschenmoser, A. Helv. Chim. Acta 2015, 98, 
1921. 
(88) Lewis, N. J.; Pfaltz, A.; Eschenmoser, A. Angew. Chem. Int. Ed. 1983, 
22, 735. 
(89) Werthemann, L., PhD Thesis, Untersuchungen an Kobalt (II)-und Kobalt 
(III)-Komplexen des Cobyrinsäure-heptamethylesters, ETH Zurich 1968. 
(90) Lewis, N. J.; Nussberger, R.; Kräutler, B.; Eschenmoser, A. Angew. 
Chem. 1983, 95, 744. 
(91) Hinze, R. P.; Schiebel, H. M.; Laas, H.; Heise, K. P.; Gossauer, A.; 
Inhoffen, H. H.; Ernst, L.; Schulten, H. R. Eur. J. Org. Chem. 1979, 
1979, 811. 
 (92) Kräutler, B. Helv. Chim. Acta 1982, 65, 1941. 
 (93) Kräutler, B.; Stepánek, R. Angew. Chem. Int. Ed. 1985, 24, 62. 
(94) Zelder, F. H.; Buchwalder, C.; Oetterli, R. M.; Alberto, R. Chem. Eur. J. 
2010, 16, 6155. 
(95) Hinze, R. P.; Wullbrandt, D.; Inhoffen, H. H. Eur. J. Org. Chem. 1980, 
1980, 821. 
192 
 
 (96) Ernst, L.; Holze, G.; Inhoffen, H. H. Eur. J. Org. Chem. 1981, 1981, 198. 
 (97) Holze, G.; Inhoffen, H. H. Angew. Chem. 1985, 97, 887. 
(98) Oetterli, R. M., PhD Thesis, A (semi) synthetic Route Towards' Met-
balamins', University of Zurich, 2013. 
(99) Oetterli, R. M.; Prieto, L.; Spingler, B.; Zelder, F. Org. Lett. 2013, 15, 
4630. 
(100) Ruetz, M.; Fedosov, S. N.; Kräutler, B. Angew. Chem. Int. Ed. 2012, 51, 
6780. 
 (101) Kräutler, B. Chem. Eur. J. 2012, 18, 9032. 
(102) Ruiz-Sánchez, P.; König, C.; Ferrari, S.; Alberto, R. J. Biol. Inorg. Chem. 
2011, 16, 33. 
 (103) Sonnay, M.; Fox, T.; Blacque, O.; Zelder, F. Chem. Sci. 2016. 
(104) Brown, K.; Zou, X.; Wu, G.-Z.; Zubkowski, J.; Valente, E. Polyhedron 
1995, 14, 1621. 
(105) Prieto, L.; Neuburger, M.; Spingler, B.; Zelder, F. Org. Lett. 2016, 18, 
5292. 
(106) Fedosov, S. N.; Ruetz, M.; Gruber, K.; Fedosova, N. U.; Kräutler, B. 
Biochemistry 2011, 50, 8090. 
(107) Gossauer, A.; Grüning, B.; Ernst, L.; Becker, W.; Sheldrick, W. S. 
Angew. Chem. Int. Ed. 1977, 16, 481. 
(108) Bax, A.; Marzilli, L. G.; Summers, M. F. J. Am. Chem. Soc. 1987, 109, 
566. 
(109) Prieto, L. M. T., Synthesis of Oxidatively Cleaved 'Incomplete' 
Corrinoids, University of Zurich, 2013. 
 (110) Dobler, M.; Dunitz, J. Helv. Chim. Acta 1971, 54, 90. 
 (111) Fürstner, A.; Bogdanović, B. Angew. Chem. Int. Ed. 1996, 35, 2442. 
 (112) McMurry, J. E. Chem. Rev. 1989, 89, 1513. 
 (113) Girard, P.; Namy, J.; Kagan, H. J. Am. Chem. Soc. 1980, 102, 2693. 
 (114) Kagan, H. B. Tetrahedron 2003, 59, 10351. 
(115) Fuchs, J. R.; Mitchell, M. L.; Shabangi, M.; Flowers, R. A. Tetrahedron 
Lett. 1997, 38, 8157. 
 (116) Kishner, N. J. Russ. Phys. Chem. Soc. 1911, 43, 582. 
 (117) Wolff, L. Chem. Liebigs Ann. Chem 1912, 384, 25. 
 (118) Cram, D. J.; Sahyun, M. R. V. J. Am. Chem. Soc. 1962, 84, 1734. 
193 
 
 (119) Caglioti, L. Tetrahedron 1966, 22, 487. 
 (120) Thompson, H.; Dietrich, L.; Elvehjem, C. J. Biol. Chem. 1950, 184, 175. 
 (121) Bonnett, R. Chem. Rev. 1963, 63, 573. 
 (122) Calafat, A. M.; Marzilli, L. G. J. Am. Chem. Soc. 1993, 115, 9182. 
 (123) Alberto, R.; Motterlini, R. Dalt. Trans. 2007, 1651. 
(124) García‐Gallego, S.; Bernardes, G. J. Angew. Chem. Int. Ed. 2014, 53, 
9712. 
 (125) Motterlini, R.; Otterbein, L. E. Nat. Rev. Drug Discov. 2010, 9, 728. 
 
 
 
 
